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Zusammenfassung 
 
Die Anzahl an Melanomerkrankungen, bei denen sich ein bösartiger Hauttumor aus 
Melanozyten entwickelt, nimmt in entwickelten Ländern stetig zu. Dabei hängt die 
Wahrscheinlichkeit, eine Erkrankung zu überleben, stark davon ab, ob Metastasen gebildet 
werden. Ist dies der Fall, verschlechtern sich die Aussichten und die Langzeit- 
Überlebensrate der Betroffenen dramatisch. Aus diesem Grund besteht ein grosser Bedarf 
an neuen Strategien zur Behandlung metastatischer Melanome. Hauptauslöser für 
Melanomerkrankungen sind ultraviolettes Licht und daraus entstehende Schädigung der 
DNA. In etablierten Melanomen spielt auch die Mikroumgebung des Tumors eine wichtige 
Rolle bei dessen Fortschreiten, denn die Umgebung hilft Tumoren, ihren Bedarf an 
Nährstoffen und Sauerstoff zu decken und unterstützt Metastasierung. Die Mikroumgebung 
weist Keratinozyten, Fibroblasten, Endothelzellen und Immunzellen auf, die alle potentiell am 
Fortschreiten des Tumors beteiligt sind.  Tumor-Stroma Interaktionen führen zu einer 
inflammatorischen Umgebung, die Angiogenese  und Metastasierung fördert. Des Weitern 
setzen die Zellen der Mikroumgebung des Tumors Faktoren frei, die einer spezifischen 
Immunantwort vorbeugen und so den Tumor vor Zerstörung bewahren. Aufgrund ihres 
unkontrollierten Wachstums und erhöhten metabolischen Bedarfs weisen Melanome häufig 
hypoxische und nekrotische Bereiche auf. Aus diesen Arealen werden lösliche Faktoren wie 
Gefahrensignale (“danger signals“) ausgeschüttet, die die Mikroumgebung anregen und 
dazu manipulieren können, die ungünstigen Bedingungen zu beseitigen. 
 
In dieser Doktorarbeit konzentrierten wir uns auf die Untersuchung von zwei Faktoren 
nekrotischer und hypoxischer Tumore, zum einen das potente proinflammatorische Zytokin 
Interleukin (IL)-1β, zum anderen das Alarmin High-Mobility Group Box 1 (HMGB1). 
 
In einem ersten Projekt untersuchten wir, ob Melanomzellen die Fähigkeit zur Sekretion von 
IL-1β besitzen. Dazu bestimmten wir in Melanomzellen die Expression verschiedener 
Komponenten von Inflammasomen, welche intrazelluläre Komplexe zur Detektion von 
Pathogenen oder Zellschädigung sind, die bei Aktivierung proIL-1β zu seiner biologisch 
aktiven Form verarbeiten. Wir konnten zeigen, dass Melanomzellen aufgrund des Fehlens 
eines funktionellen Inflammasoms selbst nicht im Stande sind, aktives IL-1β zu sekretieren. 
Jedoch konnte gezeigt werden, dass nekrotische Melanomzellen in der Lage sind, die 
Freisetzung von IL-1β aus humanen Monozyten und THP-1 Makrophagen zu stimulieren. 
Zusätzlich konnten wir die Anwesenheit eines IL-1β-sekretierenden Makrophagen-Subtyps, 
CD68+ Melanophagen, in humanen Melanomproben nachweisen. 
 
VIII Zusammenfassung 
 
In einem zweiten Projekt wurde mit Hilfe von shRNA und Inhibition eine tumor-fördernde 
Aktivität von HMGB1, welches aus hypoxischen Arealen humaner Melanome und muriner 
B16 Melanome ausgeschleust wird, nachgewiesen.  HMGB1, das wir auch in erhöhter 
Konzentration im Serum von Melanompatienten mit Metastasen gefunden haben, induziert 
die Polarisation von tumor-assoziierten Makrophagen hin zu einem M2 Phänotypen.  
HMGB1 regt die Expression des Chemokinrezeptors CXCR4 auf M2 Makrophagen sowie die 
Sekretion des immunsuppressiven Zytokins IL-10 mittels des HMGB1 Rezeptors Receptor 
for Advanced glycation Endproducts (RAGE) in vitro an.  Durch Verwendung eines 
Antikörpers gegen IL-10 konnte das Wachstum von B16 Melanomen in vivo vermindert 
werden. Bemerkenswerterweise konnten IL-10-produzierende M2 Makrophagen in Biopsien 
von Melanompatienten mit Metastasen nachgewiesen werden.  
  
In Summe tragen unsere Ergebnisse zu einem besseren Verständnis von Tumor-Stroma 
Interaktionen in Melanomen bei. Die wichtigste Errungenschaft dieser Arbeit besteht in der 
Erkenntnis, dass aus Tumoren stammendes HMGB1, welches unter hypoxischen 
Bedingungen in den extrazellulären Raum freigesetzt wird, einen wichtigen Beitrag zur 
Funktion von M2 Makrophagen leistet und das Überleben von Melanomen durch die 
Unterdrückung der Immunabwehr mittels IL-10 unterstützt. Das unterstreicht die wichtige 
Rolle von HMGB1 in der Regulation von M2 Makrophagen und macht HMGB1 zu einem 
potenziellen Angriffsziel von Medikamenten, welche die Funktion von M2 Makrophagen in  
der Mikroumgebung von Melanomen beeinflussen sollen. 
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Summary 
 
The incidence of cutaneous melanoma, a malignancy arising from melanocytes, is constantly 
increasing in developed countries. In its metastatic stage, melanoma is associated with a 
poor prognosis for the patients and low long-term survival rate. For this reason, new 
therapeutic strategies to treat metastatic melanoma are still needed. The development of 
melanoma is known to be mainly caused by ultraviolet light and subsequent DNA damage. 
Once established, the tumor microenvironment also plays a crucial role in cancer 
progression by supporting the needs of tumor cells and promoting metastasis. The 
microenvironment contains keratinocytes, fibroblasts, endothelial cells and immune cells, 
each of these cell types being potentially involved in tumor progression. The tumor-stroma 
interactions result in an inflammatory environment favoring angiogenesis and metastasis. 
Furthermore, the cells of the tumor microenvironment also release factors preventing specific 
immune responses against malignant cells and therefore protect the tumor from destruction. 
Due to uncontrolled growth and increased metabolic need, hypoxia and necrosis are 
frequently observed in solid tumors. Soluble factors including danger signals released from 
these hypoxic and necrotic areas can interact with and manipulate the microenvironment to 
overcome such unfavorable conditions 
 
In this PhD thesis, we focused on the study of two products of necrotic and hypoxic tumors, 
namely the potent pro-inflammatory cytokine Interleukin (IL)-1β and the alarmin High-Mobility 
Group Box 1 (HMGB1).  
 
First, we determined whether melanoma cells have the ability to secrete IL-1β. Therefore we 
assessed in melanoma cells the expression of components of inflammasomes, which are 
intracellular complexes that detect pathogens and cell damage. Once activated, 
inflammasomes process proIL-1β into its bioactive form. We could show that melanoma cells 
themselves are not able to secrete functional IL-1β since they lack a functional 
inflammasome. However, necrotic melanoma cells were able to stimulate the release of IL-1β 
from human monocytes and THP-1 macrophages. In addition, we could confirm the presence 
of a macrophage subtype, CD68+ melanophages, in human melanoma samples, which 
infiltrated the tumor and released IL-1β. 
 
In a second project, using shRNA and inhibition strategies, we could identify tumor-derived 
HMGB1, which is released from hypoxic areas of human metastatic melanoma and murine 
B16 melanoma, to promote tumor progression. HMGB1, which we also found at elevated 
levels in the serum of metastatic melanoma patients, induced the polarization of tumor-
associated macrophages to a tumor-promoting M2 phenotype. HMGB1 induced the 
X Summary 
 
expression of the chemokine receptor CXCR4 on M2 macrophages and the secretion of the 
immuno-suppressive cytokine IL-10 through the HMGB1 receptor Receptor for Advanced 
glycation Endproducts (RAGE) in vitro. Usage of an anti-IL-10 antibody resulted in reduced 
tumor growth of B16 melanoma in vivo. Noteworthy, the presence of IL-10 producing M2 
macrophages could be confirmed in human metastatic melanoma biopsies. 
 
Taken together, these findings contribute to a better understanding of tumor-stroma 
interactions in melanoma. The most important finding of this work is that tumor-derived 
HMGB1 released to the extracellular space from hypoxic tumor areas is an important factor 
driving M2 macrophage action and assisting melanoma survival through the suppression of 
immune responses driven by IL-10, emphasizing the potential of HMGB1 as a possible drug 
target to manipulate M2 functions in the tumor microenvironment of melanoma. 
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1.1. The skin 
1.1.1. Skin structure 
The skin has a central function in controlling interactions of multicellular organisms with their 
environment. It is a bidirectional barrier that on the one hand protects from exogenous 
insults, including chemicals and physical stress like irradiation with UV light, but also against 
invading pathogens. On the other hand, it prevents loss of thermal energy and water. 
Essential additional roles of the skin include thermal regulation, and the production of vitamin 
D. Finally, the skin is our biggest organ of perception. Its structure consists in two distinct 
layers separated by the basement membrane.  
The epidermis is the outer layer and is directly exposed to the environment. It is one of the 
body’s structures that continuously replaces its cellular stock. Keratinocyte proliferation takes 
place in the basal cell layer, whereas keratinocytes of the outer layer of the epidermis do not 
proliferate anymore. During the migration from the inner to the outer epidermal layers, 
keratinocytes undergo terminal differentiation [1, 2] and form the cornified envelope to build 
up a barrier protecting the body against environmental insults. The flat keratin-filled 
keratinocytes termed corneocytes in this layer form a structure known as stratum corneum 
(Figure 1). Beside keratinocytes, the epidermis contains melanocytes, an epidermis-specific 
form of dendritic cells (DCs) termed Langerhans cells, sensory Merkel cells making synapse-
like contacts and T cells [3-5]. 
The dermis is located under the basement membrane and is mainly composed of 
extracellular matrix proteins such as collagen that are produced by fibroblasts. Other cell 
types found in the dermis are macrophages, DCs, mast cells (MCs) and T cells. In contrast to 
the epidermis, the dermis contains blood vessels, sebaceous glands, sweat glands, hair 
follicles, nerve endings and lymphatic vessels [6-8] (Figure 1).  
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Source: Kendall et al., 2013 [9] 
Figure 1. Skin structure and cellular composition 
The skin is made of two main layers, the epidermis and the dermis. The resident cell populations allow for 
maintenance of an efficient barrier against the loss of thermal energy and water, and protection against 
environmental insults such as ultraviolet (UV) radiation and microbial pathogens. The blood and lymph vessels 
assist in the migration of immune cells into and out of the skin, so that the cell population of the skin is constantly 
in a state of flux, in response to the demands of the cutaneous immune responses. 
 
1.1.2. Protective skin functions 
The skin passively protects the body as a physical barrier, but active biological processes 
taking place in this organ also ensure the integrity of the body. Such active processes include 
the continuous interactions of the skin with the microflora colonizing it. Indeed, in non-
pathological conditions, the epidermis is under an equilibrium state with the skin microbiome. 
[10]. This microbiome provides essential assistance in wound healing, defense against 
pathogens and development of the immune system [11-13]. Sebocytes located in sebaceous 
glands in the dermis also contribute to the maintenance of skin homeostasis. Sebocytes 
regulate the degree of skin colonization with anti-microbial peptides such as defensin-1 and 
defensin-2 contained within sebum, and in turn, the microorganisms deliver antibiotic and 
antifungal substances to the skin surface [14-18]. 
A key function in the recognition of pathogens is ensured by keratinocytes, which express a 
variety of receptors, so-called pathogen recognition receptors (PRRs), detecting a broad 
range of pathogen-derived molecules as well as autologous molecules products that signal 
stress and danger usually resulting from cell damage [19]. Such pathogen-associated 
molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) are sensed 
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by PRRs, and result in keratinocyte responses including production of RNases, S100 family 
members and microbiocides like β-defensins and the cathelicidin LL-37 [20-25]. Additionally, 
keratinocytes can upon PRR triggering release chemokines and cytokines such as CXCL9, 
CXCL10, CXCL11, tumor necrosis factor α (TNF-α), IL-1α, IL-1β, IL-6 and IL-18, which either 
directly harm pathogens or attract and instruct immune cells to the site of injury [26-32].  
Due to its broad spectrum of immunological defense mechanisms, the skin under normal 
conditions is able to ensure an efficient protection against pathogens. However, excessive or 
inappropriate immune responses can result in pathological situations. 
 
1.2. Interleukin-1 and inflammasomes 
1.2.1. Interleukin-1  
IL-1 is a pleiotropic proinflammatory cytokine with many functions and having the potential to 
target a broad range of cell types [7, 33]. Fever, hypotension, tachycardia, vasodilation and 
neutrophilia are consequences of IL-1 signaling, and IL-1 can be produced by keratinocytes, 
monocytes, tissue macrophages, DCs, B lymphocytes, natural killer (NK) cells and other 
epithelial cells [7, 33]. IL-1 signaling is mediated by the common IL-1 receptor type I (IL-1RI) 
in combination with the IL-1R accessory protein (IL-1RAcP) [34]. Upon dimerization of the 
receptor complex, a cytoplasmic Toll/IL-1 receptor (TIR) domain activates intracellular 
signaling pathways including the nuclear factor ĸB (NF-kB), c-Jun N-terminal kinase (JNK), 
and p38 mitogen-activated protein kinase (MAPK) pathways (Figure 2) [35].  
 
 
 
Source: Vincenti et al., 2002 [36] 
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Figure 2. Intracellular IL-1 receptor signal transduction upon binding of IL-1 
By activating the IL-1 receptor complex, IL-1 binding induces recruitment of the myeloid differentiation primary 
response gene 88 (MyD88) to the intracellular portion of the IL-1 receptor, which activates the IL-1 receptor 
kinase (IRAK) cascade. Via tumor necrosis factor-associated factor 6 (TRAF6), the c-Jun N terminus (JNK) and 
p38 mitogen-activated protein (p38 MAPK), NF-κB and AP-1 are translocated to the nucleus [37]. 
 
IL-1/ IL1RI/ IL-1RAcP interaction can be modulated by three distinct mechanisms (Figure 3). 
First, the IL-1 receptor antagonist (IL-1Ra), which competes with IL-1α and IL-1β for IL-1RI 
(without in case of binding inducing the recruitment of IL-1RAcP), can decrease the amount 
of accessible receptors for IL-1α and IL-1β [38]. Second, another IL-1 receptor – the decoy 
receptor IL-1RII – can bind IL-1α and IL-1β, but is not able to dimerize with IL-1RAcP and 
induce the intracellular signaling cascade, and third, shortened soluble forms of IL-1RI (sIL-
1RI) and IL-1RII (sIL-1RII) are able to capture IL-1α, IL-1β and IL-1RAcP in the extracellular 
space. 
 
 
Source: Kopf et al., 2010 [39] 
 
Figure 3. Mechanisms to block IL-1 signaling 
By activating the IL-1 receptor complex, IL-1 binding induces recruitment of MyD88 and activation the IL-1 
receptor kinase (IRAK) cascade. IL-1R antagonist (IL-1Ra) competes with IL-1R signaling by binding with similar 
affinity like IL-1 to IL-1RI without recruitment of IL-1RAcP. The IL-1RII is a decoy receptor, which binds tightly to 
IL-1β, but due to the lack of a cytoplasmic domain does not signal. Proteolytic cleavage of IL-1RI and IL-1RII 
results in soluble forms (sIL-1RI and sIL-1RII, respectively), which negatively regulate IL-1 activity.  
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In order to offer a therapeutic tool for diseases associated with abnormal IL-1 signaling, 
recombinant IL-1Ra (Kineret, Anakinra®) was been developed and is in clinical use to treat 
rheumatoid arthritis [40]. Recently, new inhibitors of IL-1 signaling such as the soluble 
receptor for IL-1 Rilonacept (Arcalyst®) and a monoclonal antibody against IL-1β 
(Canakinumab, Ilaris®) have also been developed. A remarkable drawback of inhibition 
strategies using IL-1Ra however is the high amount of active compound needed to block IL-1 
signaling, despite the fact that IL-1Ra has a similar affinity to IL-1R compared to IL-1α and IL-
1β [41].  
Although the two IL-1 members IL-1α and IL-1β, when actively secreted, have the same 
affinity to IL-1RI, they differ in their binding capacity when they are passively released to the 
extracellular space upon cell lysis. In this state, as immature proforms, proIL-1β cannot bind 
to IL-1RI, whereas proIL-1α is able to, but for complete biological activity, both proIL-1α and 
proIL-1β need to be intracellularly processed and thus activated [42]. NF-ĸB drives the 
mRNA expression of both molecules in response to stimulation, but apart from stimulus-
driven expression, a basal IL-1α mRNA level is constitutively produced [33, 43]. Active 
secretion of both mature cytokines takes place by unconventional protein secretion [27, 44]. 
 
1.2.2. Regulation of IL-1β expression and activation 
Expression, activation and active secretion of the potent proinflammatory cytokine IL-1β are 
strictly regulated. Biologically inactive intracellular proIL-1β can be induced upon stimulation 
[33, 43]. The toll-like receptor (TLR) 4 ligand lipopolysaccharide (LPS) and IL-1 itself activate 
the transcription factor NF-ĸB in macrophages and DCs, which leads to the expression of IL-
1β mRNA [45, 46]. ProIL-1β then requires proteolytic processing by the intracellular protease 
caspase-1 to become biologically active [47]. Although in neutrophil-dependent inflammation, 
the cleavage and activation of proIL-1β in the absence of caspase-1 can be driven by other 
caspases, deficiency of caspase-1 in mice leads to defects in active IL-1β secretion with 
subsequent resistance to septic shock induced by LPS for example [47-51]. 
Since IL-1β lacks a signal peptide at its amino terminus, the mechanism of IL-1β release to 
the extracellular space is not driven by the classical endoplasmic reticulum (ER)/Golgi-
dependent secretion pathway. Rather, secretion of IL-1β has been shown to occur through a 
caspase-1-dependent manner upon activation of the protease in a process termed 
unconventional protein secretion [27, 44].  
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1.2.3. Inflammasomes as mediators of caspase-1 and IL-1β activation 
1.2.3.1. Types and components of inflammasomes  
Except for circulating monocytes, all cell types under homeostatic conditions possess only 
biologically inactive caspase-1 in a proenzyme form, whose activation by homo- or 
heterodimerization or oligomerization is regulated by intracellular innate immune complexes 
termed inflammasomes [47, 52, 53]. 
The nucleotide-binding domain, leucine-rich repeat-containing receptor protein 1 (NLRP1/ 
NALP1) inflammasome was the first inflammasome identified [54]. NLRP1 is the backbone 
protein of this inflammasome, and forms the multiprotein inflammasome complex by binding 
to caspase-5 via the N-terminal caspase recruitment domain (CARD) domain of NLRP1, 
whereas the C-terminal pyrin domain (PYD) of NLRP1 enables binding to the adaptor 
molecule apoptosis-associated speck-like protein (ASC) which contains a PYD and CARD 
domain. The adaptor protein ASC recruits caspase-1 to the complex via its CARD domain, 
thus enabling proteolytic processing and activation of caspase-1 within the NLRP1 
inflammasome complex (Figure 4) [54]. Other inflammasomes like NLRP3 and absent in 
melanoma 2 (AIM2) also use ASC as a critical adaptor protein, however the Nod-like 
receptor family CARD domain-containing protein 4 (NLRC4) can directly interact with 
caspase-1 [55]. Complex oligomerization and cleavage of caspase-1 result in active 
caspase-1, which has the ability to cleave and activate proIL-1β. 
 
1.2.3.2. Activation of the inflammasomes  
The assembly of inflammasomes is induced by proinflammatory stimuli, which are divided 
into PAMPs and DAMPs. Inflammasomes can be activated by a variety of distinct PAMPs 
and DAMPs [55, 56]. 
Activators of the NLRP1 inflammasome include the lethal factor of Bacillus anthracis lethal 
toxin and muramyl dipeptide (MDP), whereas cytosolic flagellin and compounds in the type III 
secretion system of certain gram-negative bacteria such as Salmonella typhimurium, 
Escherichia coli or Shigella flexneri have been shown to be sensed by the NLRC4 
inflammasome [54, 57-59]. 
Double-stranded intracellular viral and bacterial DNA is sensed by the AIM2 inflammasome, 
with subsequent activation of caspase-1 and maturation of proIL-1β and proIL-18 [60-63]. 
Here, caspase-1 is recruited to the nascent inflammasome complex by binding to the CARD 
of ASC which itself is bound to the PYD domain of AIM2 via its own PYD domain [62, 64]. 
The NLRP3 inflammasome is activated by a surprisingly large variety of PAMPs and DAMPs 
(Figure 4). Since the range of activators is so broad and diverse, a direct binding of the 
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activators to the NLRP3 inflammasome appears very unlikely and several mechanisms for 
triggering of NLRP3 inflammasome assembly have been proposed:  
The engulfment by phagocytes of molecules such as monosodium urate (MSU), silica and 
asbestos which are difficult to clear leads to lysosomal damage with release of lysosomal 
proteins including Cathepsin B which can activate the NLRP-3 inflammasome [65-67].  
Additionally, cell damage by inducing the release of adenosine triphosphate (ATP) to the 
extracellular space, where it can bind to its receptor P2X7 on the cell membrane and thereby 
induce cellular efflux of K+ and influx of PAMPs or DAMPs via P2X7 or the P2X7-associated 
pannexin-1 channel [68, 69] has been shown to trigger NLRP3 inflammasome activation. 
A common feature of NLRP3 activators is their ability to induce the generation of reactive 
oxygen species (ROS). Therefore stimulus-driven ROS generation has been proposed as 
trigger for NLRP3 inflammasome activation [70, 71]. ROS can lead to the release of 
thioredoxin from thioredoxin-interacting protein, which subsequently binds NLRP3 and can 
induce inflammasome activation [72]. Danger signals induce ROS generation most probably 
in the mitochondria, and the latter has been shown to play a crucial role in controlling 
inflammasome activation via the release of mitochondrial DNA [73, 74]. Mitochondrial 
involvement in regulating inflammasome activation has also been suggested to involve 
mitochondrial voltage-dependent anion channels (VDAC) and the localization of NLRP-3 and 
ASC at mitochondrial structures upon inflammasome activation [70, 73]. In macrophages, 
scavenging of ROS originating from mitochondria decreases secretion of IL-1β and IL-18, 
whereas induction of ROS production amplifies the secretion of these cytokines [73].  
Furthermore, and beyond the sole activation mechanism for the NLRP3 inflammasome, a 
recent paper provided evidence that spleen tyrosine kinase (Syk) and JNK signaling play a 
role in the activation of inflammasomes that depend on ASC to recruit and activate caspase-
1, thereby the NLRP3 and AIM2 inflammasomes. In this process, kinase activity and 
phosphorylation of ASC lead to the formation of ASC specks, a critical marker of NLRP3 and 
AIM2 inflammasome activation [75]. 
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Source: Contassot et al., 2012 [76] 
 
Figure 4. Models of inflammasome activation 
Current models of inflammasome activation include efflux of K+, release of reactive oxygen species (ROS) and 
mitochondrial DNA (mtDNA) into the cytosol. When encountering PAMPs/DAMPs such as microbes or crystals, 
activation of the NLRP3–inflammasome and resulting IL-1β release trigger localized inflammatory responses. 
 
1.2.3.3. Skin diseases related to inflammasomes and IL-1β 
Keratinocytes constitutively express proIL-1α, proIL-1β, and IL-1Ra [77, 78]. Irradiation with 
UVB light triggers activation and secretion of IL-1β via inflammasome activation, resulting in 
an inflammatory response to ultraviolet (UV) light [77, 79].  
In contact hypersensitivity (CH), an adaptive immune response to haptens that results in T 
cell priming and induction of a local inflammatory response, the earliest or sensitization 
phase has been shown to be dependent on IL-1β and can be blocked with IL-1Ra [6, 78, 80, 
81]. This is indicative of a role of IL-1β and the inflammasomes in the sensing of contact 
sensitizers by the skin. 
An important illustration of the in vivo consequences of dysregulated control of IL-1 and 
inflammasome activation for the skin was recently provided by experiments with mice in 
which the NLRP3 gene mutation causing CAPS (cryopyrin-associated periodic syndromes) 
was knocked in. These mice due to a spontaneously hyperactive inflammasome develop a 
neutrophil-rich skin inflammation with a T helper (Th) 17 dominant immune response [82]. 
Interestingly, a redundant feature of inflammasome activation and IL-1β release in tissues is 
the neutrophilic nature of the inflammatory infiltrates observed at sites of tissue inflammation. 
This feature is also observed in several human autoinflammatory diseases, whereby an 
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autoinflammatory disease is currently defined as a disease in which unprovoked recurrent 
inflammation occurs in the absence of evidence of circulating autoantiobodies or an antigen-
specific T cell response (Figure 5) [83].  
Mutations in NLRP3 resulting in enhanced inflammasome function have been shown to be 
the cause of CAPS including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells 
syndrome and chronic infantile neurological cutaneous and articular syndrome (CINCA). 
Other forms of autoinflammatory diseases including deficiency of interleukin-1 receptor 
antagonist (DIRA), pyogenic arthritis-pyoderma gangrenosum-acne (PAPA) syndrome, 
Schnitzler syndrome, Sweet’s syndrome and Behçet's disease are unrelated to NLRP3 
mutations however [76, 84-87]. 
 
Source: Contassot et al., 2012 [76] 
 
Figure 5. Mechanism of inflammsome-dependent autoinflammatory diseases. 
The NLRP3–inflammasome is constitutively active, which leads to multi-organ involvement and periodic fever in 
patients with the autoinflammatory disorder CAPS. 
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1.2.3.4. IL-1β and cancer 
In cancer, experiments reported in the literature suggest that IL-1β can, depending on the 
model and circumstances have effects on both the tumor and its host. IL-1β has been shown 
to have the ability to trigger anti-tumor immunosurveillance for example by the stimulation of 
γδ T cells IL-17 secretion or by the polarization of CD8+ αβ T cell responses towards 
interferon (IFN)-γ secretion [88-91]. Nevertheless, in most models tumors appear to rather 
benefit from IL-1β activity than the contrary, and this observation is supported by the fact that 
high levels of IL-1β in the tumor microenvironment often correlate with a poor prognosis [92]. 
IL-1β expression can be induced by common oncogenes such as RAS, but also by the 
transcription factor NF-kB which is activated in many malignancies [93]. In multiple myeloma 
release of IL-1β has been shown to activate cells in the tumor microenvironment to produce 
IL-6, and the latter provides a trophic support to cancer cells [94]. Cells derived from acute 
myeoblastic leukemia types have been reported to constitutively produce active IL-1β, which 
can lead to growth and invasiveness [95, 96]. Likewise, cells from acute myeloid leukemia 
(AML) secrete IL-1β, which regulates growth and proliferation, and the latter can be blocked 
with IL-1Ra [96-100]. In gastric cancer, IL-1β is an inhibitor of the secretion of gastric acid 
potentially resulting in gastric atrophy, which is a precursor of gastric cancer. The cancer 
promoting activity was described in genetically modified mice resulting in IL-1β production in 
the stomach and subsequent development of gastric inflammation and cancer [101]. In Lewis 
lung cell carcinoma cells modified so as to produce IL-1β, stronger tumor growth as well as 
increased expression of angiogenic factors was observed in vivo [102]. Growth, invasiveness 
and lung metastasis of murine B16 melanoma cells have been shown to be decreased in 
experimental situations resulting in reduced IL-1 signaling, such as when B16 are injected 
into IL-1β knockout mice or into wild-type (WT) mice treated with recombinant IL-1Ra 
(Kineret) [103, 104]. The involvement of IL-1β in melanoma development is not fully 
understood however as both pro-tumoral [105-108] and anti-tumoral [91, 109] properties of 
this specific cytokine have been described. Clarification of this controversy, which may reflect 
the pleiotropic nature of IL-1β, distinct biological effects at early as compared to late stages 
of cancer development, or functional models that were not able to properly distinguish the 
effects of IL-1β from those of IL-1α, is needed.  
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1.3. Melanoma 
1.3.1. Melanoma development 
Melanoma, a malignant tumor originating from melanocytes, results from mutations in genes 
governing key signaling pathways involved in the control of cell growth (Figure 6). 
Melanocytes produce the pigment melanin, the production of which is increased upon sun 
exposure and absorbs more than 99.9 % of UV light reaching the epidermis. Melanin 
therefore plays a crucial role in protecting the skin from DNA damage caused by UV [110, 
111]. 
 
Source: US national cancer institute (NCI) homepage, 2014 [112] 
 
Figure 6. Location and function of melanocytes within the skin 
The basal cell layer contains cells called melanocytes. Melanocytes are the source of the pigment melanin, which 
provides skin its tan or brown color and protects the deeper skin layers from the harmful effects of UV. 
 
The most important risk factor considered to contribute to the development of etiology of 
melanoma is UV light exposure [113]. It is very likely however that a combination of factors, 
including environmental and genetic factors, is involved in melanoma genesis [113-116]. 
Indeed, UV light does not cause all melanomas, especially those occurring in places on the 
body that are not exposed to sunlight. It is considered that cumulative genetic alterations 
affecting apoptotic pathways (programmed cell death), proliferation and cell cycle control in 
melanocytes can promote a malignant phenotype and initiate melanoma. Important cellular 
events normally involved in regulating cellular and tissue homeostasis have been shown to 
contribute to melanoma development and subsequent metastasis. These include cell growth 
induction including the resistance to growth inhibition signals, resistance to apoptotic cell 
death, unlimited capacity for cell division, stimulation of angiogenesis and acquisition by 
malignant cells of the competence to invade and metastasize [117, 118].   
Unlike many other cancers, the annual incidence of newly detected cases of melanoma is 
increasing [119]. Great efforts aimed at better understanding the pathogenesis of the disease 
have been carried made over the past 2 decades, and these have led to the recent 
development of efficient treatment strategies that have an impact on disease free survival 
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and mortality. These new therapies include small molecule kinase inhibitors, notably B-Raf 
and MEK kinase inhibitors, as well as check-point control inhibitors. The latter enable the 
host anti-tumor immune response to become effective. Despite these improvements, overall 
survival of patients suffering from metastatic melanoma remains low and additional 
therapeutic approaches or combination of existing therapeutic approaches is needed [120-
128]. 
 
1.3.2. Melanoma classification 
Four different main categories of melanoma are classically defined (Figure 7) [129, 130], 
although current classifications are increasingly based on the molecular profile of a 
melanoma than its clinical growth characteristics. Superficial spreading melanoma (SSM) 
represents more than two thirds of melanoma cases and is therefore the most common form 
of cutaneous melanoma in Caucasians. It tends to occur on sun-exposed skin and is 
characterized by a flat growth at the skin surface. SSM can become invasive with melanoma 
cells crossing the basement membrane and entering the dermis. Lentigo maligna melanoma 
(LMM) is similar to SSM, as it initially remains confined to the skin surface. LMM arises 
mostly in elderly patients on sun-exposed, damaged skin on the face, ears, arms and upper 
trunk. Nodular melanoma (NM), which comprises 15-30 % of cases, is the most aggressive 
form of melanoma, presenting as an invasive form of melanoma whose vertical growth is 
more important than its radial growth. Finally, acral lentiginous melanoma (ALM), which 
comprises approximately 2-8 % of melanomas, is the least common melanoma category 
among Caucasians but remains the most common subtype in people with dark skin and 
Asians, mainly occurring on the palms, soles, mucous membranes (mouth, nose and female 
genitals), or underneath the nails. 
 
 
Source: the heterogeneity of melanoma homepage, 2014 [131]  
 
Figure 7. Types of primary melanoma 
Four main subtypes of primary melanoma presentation are shown. From left-to-right: superficial spreading 
melanoma (SSM), nodular melanoma (NM), lentigo maligna melanoma (LM) and acral-lentiginous melanoma 
(ALM). 
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1.3.3. Melanoma stages 
Clinically melanoma can be detected and naturally evolve in different stages of severity, and 
the latter determine to a large extent the clinical prognosis of patients (Figure 4). According 
to the American Joint Committee on Cancer (AJCC) melanoma is classified into different 
stages [132, 133], taking into account tumor thickness (Breslow index [134]), mitoses, 
ulceration, tumor spread to lymph nodes and metastasis.  
At the very onset of melanoma, abnormal melanocytes are confined to the epidermis (stage 
0). Stage I defines melanomas that are either less than 1 mm thick according to the Breslow 
index (if the tumor is ulcerated) or 2 mm thick (if the tumor is not ulcerated). If melanomas 
are thicker than 2 mm or if they have a thickness of more than 1 mm and are ulcerated, they 
are defined as stage II melanomas. In stage III, local draining lymph nodes are involved, and 
stage IV, the melanoma stage with the worst prognosis, is characterized by organ 
involvement with metastases. Depending on the stage of melanoma, the overall patient 
survival varies, and the latter taken together with the molecular characteristics of the tumor 
helps clinicians to guide appropriate therapy (Figure 8). 
 
 
 
Source: the oncology institute of hope and innovation homepage, 2014 [135]  
and the Molecular Melanoma Map Project homepage, 2014 [136] 
 
Figure 8. Melanoma stages 
(a) Stage 0 melanoma.  (c) Stage II melanoma.  (e) Stage IV melanoma (d) Stage III melanoma. 
(b) Stage I melanoma.   (d) Stage III melanoma.  (f) Survival of melanoma patients (c)  
See text for further explanations. 
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1.3.4. Melanoma risk factors 
Although UVB light with an electromagnetic spectrum from 280 – 315 nm is mostly absorbed 
by the ozone layer, exposure of the skin to UV radiation is recognized as the main cause of 
skin cancer [137, 138]. Intermittent exposure to a high dose of sunlight is considered to 
represent a higher risk factor for melanoma development than chronic exposure at lower 
doses [113]. Individuals who have had sunburns are considered to be at higher risk for 
developing melanoma than individuals that have never had sunburns [113, 139]. Not only the 
dose and the exposure time to sunlight, but the constitution of the patient's skin itself affects 
the consequences of sunlight exposure. Indeed, compared to individuals with a skin 
phototype IV (dark skin with brown eyes and dark hair; reaction to sun exposure with tanning 
and very rarely with sunburn), those with a skin phototype I (tendency for freckles, red hair, 
blue or green eyes and high susceptible to sunburn without tendency to tan) are reported to 
have a 2-fold higher risk of developing cutaneous melanoma [140]. People with multiple 
atypical nevi, which are clinically usually larger than normal nevi, have a less distinct border 
and contain elevated zones, have an up to 10-fold higher risk of developing melanoma [116, 
141]. The risk of developing melanoma is also correlated to the number of nevi a patient has 
[116]. Finally and importantly, individuals with a family history of melanoma have a 2-fold 
increased risk of developing melanoma as compared to patients without a positive family 
history [115, 142, 143]. Likewise, individuals who have already experienced melanoma 
themselves have a 15-fold higher risk of developing a second melanoma [144-147]. The 
probability of developing melanoma is also increased in patients who have already been 
diagnosed with other types of cancer including breast cancer [148, 149], leukemia [148], non-
Hodgkin lymphoma [150, 151], thyroid cancer [148] and prostate cancer [148, 152, 153]. 
Reports also suggest that Parkinson's disease may also represent a risk factor [154-156]. 
Immunological defects such as those seen after organ transplantation [157], Crohn’s disease 
[158], severe psoriasis [159] as well as infection with human immunodeficiency virus (HIV) 
[160] have been also been shown to be associated with an increased risk of melanoma 
development.  
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1.3.5. Genetic mutations and main pathways involved in melanoma 
The mutations identified in melanoma mainly influence molecular pathways involved in DNA 
repair, cell cycle progression and apoptosis. These mutations affect RAF, RAS, TP53, 
CDKN2A, MAP2K1, RAC1, PPP6C, STK19, SNX31, ARID2 and TACC1 [161].  
One major signaling pathway affected in melanoma is the MAPK pathway. Members this 
signaling pathway include RAS (rat sarcoma oncogene) encoded by HRAS, NRAS, and 
KRAS; RAF (Rapidly Accelerated Fibrosarcoma) encoded by ARAF, BRAF, and CRAF; ERK 
(Extracellular-signal-Regulated Kinase) encoded by MAPK1 and MAPK3; and MEK 
(MAPK/Extracellular-signal-regulated Kinase kinase) encoded by MAP2K1 and MAP2K2. 
Mutations in these genes that regulate a highly conserved signaling pathway necessary for 
normal cell function result in aberrant cell proliferation and impaired regulation of apoptotic 
cell death [162, 163]. The first member of the MAPK pathway identified to have mutations in 
melanoma rendering it oncogenic was NRAS [164]. More recently, mutations in the gene of 
the serine/threonine kinase BRAF were found in around half of all melanoma cases [165]. 
The most frequent mutation (>90%) within BRAF is a point mutation in the nucleotide at 
position 1799 resulting in an amino acid change from valine to glutamic acid at amino acid 
600 (V600E) [166]. In addition to its capability to transform cells via the MAPK pathway, 
mutated BRAF also influences tumor progression by modifying the expression of hypoxia-
inducible factor 1α (Hif-1α), the extracellular matrix protein matrix metalloproteinase-1 (MMP-
1) and the pro-apoptotic molecule BIM (B-cell lymphoma 2 Interacting Mediator of cell death) 
[167, 168]. At later stages of tumor development, oncogenic BRAF affects the tumor 
microenvironment by stimulating tumor cells to either produce factors that suppress anti-
tumor immune responses or angiogenesis via VEGF (Vascular Endothelial Growth Factor) 
[169, 170].  
Another pathway that is frequently altered in melanoma is the p16INK4A/ cyclin D/ cyclin-
dependent kinase (CDK) 4/6/ Retinoblastoma protein (Rb) pathway that regulates cell cycle 
arrest at the G1/S checkpoint. In melanoma, genomic alterations activating this pathway can 
be detected in 90 % of cases [166, 171]. P16INK4A, which is encoded by CDKN2A, is a 
negative regulator of the serine/threonine kinases CDK4 and CDK6 by preventing the 
formation and activation of cyclin D/ CDK4/6 complexes. A cooperative connection of the 
p16INK4A/ cyclin D/ CDK 4/6/ Rb pathway with the MAPK pathway is established by MAPK 
pathway-dependent increased expression of cyclin D1 [172, 173]. In case of p16INK4A 
dysfunction, the cyclin D/ CDK4/6 complexes together with cyclin E/ CDK2 complexes 
phosphorylate Rb, which in the phosphorylated form no longer suppresses the activities of 
RNA polymerases I and III, the E2F family of transcription factors and the recruitment of 
histone deacetylases [174-176]. This leads to cell-cycle progression, nucleotide biosynthesis 
and DNA replication [177]. A second product of CDKN2A, which is generated by transcription 
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of an alternate reading frame (ARF), is p14ARF. P14ARF regulates cell cycle at G1 and G2/M 
checkpoints by sequestering MDM2 (Mouse Double Minute 2 homolog), therefore preventing 
the degradation of the tumor suppressor p53 [178, 179].  
Mutations in the PTEN gene coding for Phosphatase and Ten sin homolog (PTEN) are also 
common in many cancer types including melanoma [180-185]. PTEN exerts its biological 
activity as a protein and lipid phosphatase [186, 187], with a suggested role for PTEN protein 
phosphatase activity in the regulation of the cell-cycle and in inhibiting cell invasion [188-
192]. Nevertheless, the main tumor suppressor functions are considered to be due to the 
lipid phosphatase activity. It dephosphorylates Phosphatidylinositol (3,4,5)-tris-phosphate 
(PtdIns(3,4,5)P3) [193], which is the product of phosphatidylinositol-3 kinase (PI3K) and 
subsequently induces inactivation of phosphoinositide-dependent kinase 1 (PDK1) and 
downstream of it Akt with functions in apoptosis and cell cycle: blocking of Akt signaling 
affects the action of mammalian target of rapamycin (mTOR), p21, p27, BCL-2-associated 
agonist of cell death (BAD) and members of the forkhead transcription factor family (for 
example, FOXO1, FOXO3, and FOXO4) [194]. This has consequences on cell cycle 
progression, metabolism, migration, apoptosis, transcription and translation (Figure 9). 
 
 
 
 
 
Source: Thompson et al., 2005 [195] 
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Figure 9. Major molecular pathways involved in the genesis and regulation of melanoma 
SCF = stem cell factor. FGF = fibroblast growth factor. Ras = Rat sarcoma oncogene. BRAF = v-raf murine 
sarcoma viral oncogene homologue B1. MEK = MAPK/Extracellular-signal-regulated Kinase kinase. ERK = 
extracellular signal-regulated kinase. MAPK = mitogen-activated protein kinase. Mitf = microphthalmia 
transcription factor. PI3K = phosphatidylinositol-3 kinase. Akt = murine v-akt oncogene homologue. mTOR = 
mammalian target of rapamycin. CDKN2A = cyclin dependent kinase inhibitor-2A. CDK = cyclin dependent 
kinase. Rb = retinoblastoma protein. p16 = 16 000 MW protein. ARF (p14ARF) = 14 000 MW alternate reading 
frame protein. cAMP = cyclic AMP. Bcl = B-cell lymphoma derived protein. Hdm = human double minute 
chromosome-associated protein. E2F: E2F cell cycle regulated transcription factor. MSH = melanocyte stimulating 
hormone (melanocortin). MC1R = melanocortin-1 receptor. 
 
In addition to classical therapies including surgery, chemotherapy and radiotherapy, small 
molecule therapies targeting the above described dysfunctional signaling pathways is 
proving to be an effective way of treating melanoma. The MAPK signaling pathway has 
become a major target of interest for targeted therapies and, in order to revoke its activation, 
BRAF inhibitors such as Dabrafenib, LGX 818 and Vemurafenib as well as MEK inhibitors 
like Mek163, Cobimetinib, Trametinib and Selumetinib have been developed. Targeting 
MAPK pathways has shown positive effects on parameters of disease activity in patients 
suffering from metastatic melanoma [124,126,196-198]. However, acquired resistance to 
such treatments  represent a current limiting factor for their sustained efficacy [199]. 
Encouragingly however, very recent studies combining BRAF and MEK inhibition have 
reported improved progression-free survival of BRAF V600 mutated patients with metastatic 
melanoma [200, 201]. 
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1.4. The role of innate and adaptive immune reactions in cancer 
Population-based studies have revealed an increased risk for the development of cancer in 
individuals with chronic inflammatory diseases (Figure 10) [202, 203].  
Several potentially tumorigenic pathogens including hepatitis B (HBV) or C (HCV) viruses 
involved in hepatocellular carcinoma (HCC), and Schistosoma or Bacteroides involved in 
bladder and colon cancer initiation induce a weak, but chronic inflammation in the host [204, 
205]. Chronic inflammation can also be initiated by dysfunctional immune responses as 
observed in autoimmune diseases such as inflammatory bowel disease, which is associated 
with a higher risk of developing colorectal cancer [206]. The risk of lung cancer is significantly 
increased by the exposure to environmental factors such as tobacco and asbestos, the latter 
being a DAMP and known to be a potent inducer of inflammasome-dependent IL-1β-
mediated inflammation [67, 207]. An inadequate diet and associated obesity is another factor 
shown to promote chronic inflammation, and subsequently increase the risk for 
hepatocellular carcinoma [208-210]. In the skin, acute UV exposure is known to trigger 
inflammation and DNA damage, two factors that independently have been shown to 
contribute to skin cancer development [211, 212]. 
 
 
Source: Grivennikov et al., 2010 [213] 
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Figure 10. Types of inflammation in tumorigenesis and cancer 
Chronic inflammation related to infections or autoimmune disease precedes tumor development and can be 
involved in it by inducing oncogenic mutations, instability of the genome, early tumor promotion, and enhanced 
angiogenesis. Prolonged exposure to environmental irritants or obesity can also be a cause of low-grade chronic 
inflammation preceding tumor development and can be involved in it through the mechanisms described above. 
Tumor-associated inflammation goes hand in hand with tumor development and the inflammatory response can 
amplify neo-angiogenesis, promote progression and metastasis of tumors, induce local immunosuppression, and 
further enhance instability of the genome. Also cancer therapy can induce an inflammatory response by causing 
trauma, necrosis, and tissue injury that stimulate tumor re-emergence as well as therapy resistance to. In some 
cases, inflammation induced by therapy can enhance presentation of antigens, which leads to immune-mediated 
tumor eradication. Tumor promoting mechanisms are displayed in red, whereas anti-tumorigenic mechanisms are 
shown in green. 
 
Once established, increasing evidence suggest that tumors can also themselves trigger 
inflammation, and the latter may result in a pro-tumorigenic microenvironment [214]. 
Oncogenes such as the RAS and MYC family members regulate the transcription of genes 
that encode for tumor-promoting chemokines and cytokines, induce angiogenesis and 
promote the attraction of immune cells to the tumor site [215, 216]. In advanced stage 
tumors, the high energy consumption (“Warburg effect”) and inefficient blood supply within 
tumors results in a certain level of nutrient and oxygen deprivation, which can cause necrotic 
cell death, the release of proinflammatory mediators such as IL-1β and HMGB1, and 
subsequent neo-angiogenesis and immune cell recruitment [204, 217]. In consequence of 
the above, tumor stroma has been shown to contain inflammatory cells including 
macrophages, myeloid derived suppressor cells (MDSCs), DCs, neutrophils, eosinophils, 
MCs, and T cells (Figure 11). 
 
1.4.1. Macrophages 
Several tumor types have been reported to be infiltrated by inflammatory myeloid cells, 
including macrophages [213, 214, 218, 219]. To date, two types of macrophages have been 
defined based on the polarization of their cytokine secretion profile, and classified by analogy 
with Th cell subsets into M1 and M2 macrophages [220-224]. Activation of proinflammatory 
M1 macrophages is reported to be driven by pathogen-derived factors such as LPS or host-
derived factors such as IFN-γ. M1 macrophages are considered to be involved in anti-tumor 
immune responses by releasing TNF-α, IL-12 and reactive nitrogen and oxygen 
intermediates (RNI/ ROI) including nitric oxide and superoxide [203, 225, 226]. Furthermore, 
M1 macrophages have been shown to be able to promote adaptive immunity by inducing 
Th1 responses [227, 228]. At early stages of tumorigenesis, M1 macrophages are reported 
to be the predominant type of tumor-associated macrophages (TAMs) found in the tumor 
infiltrate [229, 230], whereas more advanced stages of tumor development are associated 
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with infiltrates containing a majority of M2-like macrophages [231-233]. M2 macrophages are 
considered to be immunosuppressive and have been shown to release IL-10 and Arginase-1 
[234, 235]. M2 macrophage polarization can be driven by IL-4, IL-13, IL-10 and 
glucocorticoid hormones and these macrophages are able to induce Th2 responses [223, 
236, 237]. 
 
1.4.2. Myeloid derived suppressor cells 
Another important cell type reported to infiltrate tumors and promote their progression, are 
immunosuppressive myeloid derived suppressor cells (MDSCs) [238]. The family of MDSCs 
is very heterogeneous. However, MDSCs in melanoma patients are usually characterized as 
CD11b+, CD14+ and HLA-DR- cells [239]. MDSCs present in tumors favor immune escape by 
inhibiting both innate and adaptive immunity [240-244]. MDSCs can secrete IL-10 and 
VEGF-α, which inhibit the maturation of DCs [245]. Furthermore, MDSC-derived transforming 
growth factor (TGF)-β upon IL-13 stimulation has been shown to decrease tumor 
immunosurveillance by cytotoxic T cells [246, 247]. MDSCs express high levels of inducible 
NO synthase (iNOS or NOS2) and arginase1 [248], and therefore control the availability of 
the amino acid L-arginine in the tumor microenvironment. In absence of L-arginine, T cell 
function is affected [249, 250]. Arginase 1, iNOS and prostaglandin E2 (PGE2) are regulated 
by cyclooxygenase-2 (COX2) which is produced by many tumors [251]. Finally, MDSCs 
produce ROS that inhibits the functions of cluster of differentiation (CD) 8+ T cells by 
preventing peptide-major histocompatibility complex (MHC) interactions [252]. The ROS 
production of MDSCs can be initiated by tumor-derived factors such as TGF-β, IL-3, IL-6,   
IL-10 and platelet-derived growth factor (PDGF) [248, 253].  
One of the major functions of M2 macrophages and MDSCs consists in vascular remodeling. 
Both cell types produce pro-angiogenic factors including VEGF-A, VEGF-C, IL-1β, TNF-α 
and the chemokines CXCL8 and CXCL12 [254, 255]. TAMs additionally produce urokinase-
type plasminogen activator (uPA), elastase and the matrix metalloproteinases MMP-2, MMP-
7, MMP-9 and MMP-12 [256, 257]. MMPs participate to the disruption of the extracellular 
matrix (ECM), which favors the migration of tumor cells [258, 259]. Additionally, both cell 
types share immunosuppressive properties as described above [236, 245-247, 260]. 
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1.4.3. Neutrophils 
Infiltration of neutrophils has been observed in several cancers [261, 262]. Tumor-associated 
neutrophils (TANs) produce MMP9 and promote angiogenesis by the release of angiogenic 
factors such as VEGF [263, 264]. Similarly to macrophages, two distinct subpopulations (N1 
and N2) have been defined with the TGF-β-induced tumor-promoting N2 neutrophils being 
more prevalent in tumors than anti-tumoral N1 neutrophils [265, 266]. 
 
1.4.4. Eosinophils 
Eosinophilic infiltration has been also reported in several tumors [267-270] and is considered 
to be mediated by the CCL11/CCR3 axis [271]. Eosinophils are predominantly found in 
necrotic tumor areas and are therefore believed to have an anti-tumor activity in this setting 
[272]. Eosinophils like neutrophils possess VEGF-α in their granules, which can be released 
upon IL-15 stimulation [273]. Together with IL-6, IL-8, PDGF, and MMP9, molecules that can 
also be released by eosinophils, VEGF-α can drive angiogenesis in cancer [274]. 
 
1.4.5. Mast cells 
Bone-marrow-derived MCs are early infiltrating immune cells in cancer. They can often be 
found in proximity of blood vessels within the tumor microenvironment and express pro-
angiogenic factors such as VEGF, MMP9 and IL-8. In line with this property, MC density in 
several tumors is correlated with the density of microvessels [275]. 
 
1.4.6. Dendritic cells 
Due to their ability to trigger T cell responses, DCs have an important function in cancer 
immunosurveillance. Several factors released by tumors cause defects in myeloid DCs 
(mDCs) resulting in a loss of their immunostimulatory potential [276]. Also, immature DCs 
(iDCs) provide help to the tumor by inducing an endothelial-like phenotype of precursor DCs 
in a VEGF-A-dependent manner. These vascular leukocytes (VLCs) can build up blood 
vessels or act as antigen-presenting cells (APCs) [277, 278]. In addition to VEGF-a, IL-8 is 
up-regulated in iDCs under hypoxic conditions in vitro and may potentially participate in 
tumor angiogenesis [279]. 
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1.4.7. T cells 
The establishment of an effective adaptive immune response is complicated by defects in 
antigen-presentation and co-stimulation as well as by an immunosuppressive tumor 
microenvironment and the presence of regulatory T cells (Tregs). The latter which express 
CD25 (IL-2 receptor α chain), inhibit cytotoxic T cell responses via the release of 
immunosuppressive molecules, consumption of IL-2 and direct cell-to-cell contact [280].  
CD4+ CD25+ FoxP3+ Tregs present in advanced melanoma have been shown to block anti-
tumor activity via direct contact inhibition and IL-10 release [281]. High Treg levels in patient 
serum seem to be associated with poor prognosis, poor treatment responses and the risk of 
relapse in melanoma [282]. T cell-mediated anti-tumor activity can additionally be impaired 
by defects in their interaction with APCs. Differentiation and expansion of T cells needs 
antigen presentation of tumor-associated antigens (TAAs) on MHC by APC to the T cell 
receptor (TCR). Unfortunately, in melanoma MHC class I expression is often down-regulated 
[283]. In metastatic melanoma, although melanoma-specific CD8+ T cells can be found in 
patients, tumor progression is not affected significantly [284]. MHC class II molecules have 
also been reported to be down-regulated in melanoma [285]. Another defect in antigen 
presentation results from the changed expression of acidic cathepsins in melanoma, which 
leads to decreased antigen processing in endolysosomal compartments and production of 
antigens needed for T cell activation [285].  
In addition to antigen-MHC-TCR interactions, co-stimulation is crucial for efficient T cell 
activation [286]. In melanoma the immune checkpoint molecule cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) is highly expressed. CTLA-4 interacts with binding partners of 
CD28 (CD80/B7-1 and CD86/B7-2) and thus consumes one interaction partner in the T cell 
co-stimulatory CD28-CD80/CD86 pathway [287-290]. Another co-inhibitory pathway involves 
programmed death 1 protein (PD-1) present on activated melanoma-infiltrating T cells [291]. 
The binding of the ligands PD1-L1 (B7-H1) and PD-L2 (B7-DC), which can be highly 
expressed in melanoma [292], induces impaired T cell effector function and apoptosis [291, 
293]. Interestingly, PD-L1 expression in cells of the melanoma microenvironment may not 
only be a cause of defective T cell activation, but also the consequence of an initial proper T 
cell function [294]. Since CTLA-4 and PD-1 co-inhibitory pathways play an important role in 
mediating functional anti-tumor T cell defects, both present as promising targets for 
melanoma therapy. The anti–CTLA-4 monoclonal antibody ipilimumab or antibodies directed 
against PD-1 and its ligand such as pembrolizumab, which target immune checkpoint 
inhibition, are currently showing very encouraging therapeutic effects in patients with 
metastatic melanoma [122, 295-297]. 
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Source: Grivennikov et al., 2010 [213] 
 
Figure 11. Inflammation during tumor initiation and promotion 
(a) Tumor initiation. Reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI), which are 
produced by inflammatory cells can induce mutations in neighboring epithelial cells. Intracellular ROS and RNI in 
pre-malignant cells can be enhanced by cytokines derived from inflammatory cells. Inflammation can also lead to 
epigenetic changes that favor tumor initiation. Tumor-associated inflammation contributes to further ROS, RNI 
and cytokine production. 
(b) Tumor promotion. Tumor infiltrating immune cells produce cytokines that activate transcription factors in pre-
malignant cells, such as NF-κB or STAT3, to control numerous pro-tumorigenic processes, including survival, 
proliferation, growth, angiogenesis, invasion and metastasis.  
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1.5. Hypoxia and cell death 
1.5.1. Hypoxia in melanoma 
Many cancers are characterized by high proliferation rates and energy consumption. In 
melanoma, the imbalance between oxygen supply and the actual use of oxygen creates 
hypoxic or even anoxic regions within the tumor [298, 299], affecting the course of disease 
negatively [300]. O2 levels of less than 0.5 % are toxic for both normal and tumor cells, but 
tumor cells carrying mutations providing them a selection advantage have been shown to be 
able to survive in such an environment [301, 302]. Still, hypoxia results in tumor cell necrosis 
associated with the release of cellular components into the extracellular space [303-305]. In 
contrast to apoptosis, during necrosis cytosolic elements are not packed into apoptotic 
bodies and are therefore immunogenic [306, 307]. 
 
1.5.1.1. Hypoxia as an inducer of angiogenesis and metastasis 
Hypoxia is known to promote angiogenesis via VEGF, IL-8 and angiopoietin-2 [308-310]. 
Hypoxia can promote an epithelial-mesenchymal transition (EMT)-like process with the 
involvement of E-cadherin, which enables melanoma cells to migrate to distant tissues. 
Under hypoxic conditions, Hif-1α is stabilized and negatively influences E-cadherin via snail, 
SIP1 (E-cadherin repressors) and twist (E-cadherin activator) [311]. Other targets of hypoxia 
are urokinase receptor (uPAR) and MMP2 being drivers in the degradation and remodeling 
of the ECM [312].  Metastasis is further favored by Hif-1α-driven expression of lysyl oxidase, 
which is involved in attracting bone marrow-derived cells to the location of the secondary 
tumors [313]. Reduced activity of microphthalmia transcription factor (MITF), a factor 
regulating melanocyte differentiation, which is driven via Hif-1α and class E basic helix-loop-
helix protein 40 (BHLHB2, DEC1) also increases the probability of metastasis [314, 315].  
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1.5.1.2. Hypoxia and anti-tumor therapy 
Hypoxia also has an impact on the efficacy of cancer treatment. Indeed, resistance genes 
have been shown to be up-regulated under hypoxic conditions [316, 317] and tumors 
respond less to radiotherapy [318, 319]. Heterogeneity of the tumors is another obstacle for 
melanoma treatment [320]. Gene expression profiling of isolated melanoma cells has 
provided evidence that there are two distinct melanoma cell phenotypes within tumors, 
namely the proliferative and invasive phenotypes, which can be distinguished by their 
morphology, proliferation rate, invasion and in vivo tumor growth kinetics [321-323]. Both 
phenotypes have been demonstrated to be present in primary melanomas as well as in 
metastases [324, 325]. Recently, it has been shown that hypoxia is also involved in the 
above phenotype determination by regulating the switch between proliferative and invasive 
phenotype via Hif-1α activity [326]. 
 
1.5.2. Cell death 
Research on cell death was initiated by Lockshin and Williams describing a regulated form of 
cell death termed apoptosis, which is characterised by zeiosis, cell shrinkage, condensation 
of chromatin, arrangement of the cell contents in apoptotic bodies and clearance by 
phagocytes [327-331]. Beside apoptosis, there are two other main forms of cell death, 
namely necrosis and autophagy-related cell death [332]. Additional death mechanisms like 
pyroptosis or necroptosis have been described more recently and are currently under 
investigation. 
 
1.5.2.1. Apoptosis 
Apoptosis takes place already during development [333]. In adults, apoptosis is a way to 
eliminate cells without inducing immune responses [334, 335]. Major players in apoptosis are 
effector caspases [336], which can be divided into initiator and executioner caspases [53].  
Crucial for the activation of apoptotic caspases in the extrinsic  pathway is activation of death 
receptors such as Fas (CD95), TRAIL or TNF-receptor leading to the formation of the 
membrane bound death-inducing signaling complex (DISC) [337]. The initiator caspases 
(caspase-8 and -10) also recruited to the DISC then activate the executioner caspases 
(caspase-3, -6 and -7) [338, 339].  
In the intrinsic pathway, members of the B-cell lymphoma 2 (Bcl-2) family, upon sensing of 
cellular stress such as deprivation of growth factors and DNA damage promote mitochondrial 
outer membrane permeabilization (MOMP) by the formation of pores [340, 341]. Through the 
defective outer mitochondrial membrane, apoptosis-promoting factors leak into the 
Introduction 29 
  
cytoplasm. Cytochrome C for example binds to apoptotic protease-activating factor-1 (Apaf-
1) [342, 343], thereby promoting the assembly of the heptameric apoptosome including 
procaspase-9 [342, 343]. Active caspase-9 then cleaves and activates the executioner 
caspases-3, -6 and -7, which translocate to the nucleus and promote inhibition of DNA repair, 
DNA fragmentation and chromatin condensation [344-347]. 
 
1.5.2.2. Autophagy 
The most studied form of autophagy is macroautophagy, which stressed cells use to dispose 
suspicious organelles and protein aggregates [348]. Triggered by starvation, inhibition of the 
protein kinase mTOR induces autophagosomal formation by translocation of the mTOR 
substrate complex to the membrane of the ER [349]. The main function of autophagy is the 
promotion of cell survival, but autophagy-associated cell death as backup mechanisms of 
apoptosis has been demonstrated [350]. 
 
1.5.2.3. Necrosis and Necroptosis 
One dogma in the field of cell death for a long time was that if a type of cell death is 
regulated, then it is apoptosis, whereas other forms of cell death were considered to be 
uncontrolled. The establishment of knockout mice for apoptosis relevant factors such as 
apoptotic caspases, Apaf-1 and Bcl-2 family members showed that apoptosis-dependent 
developmental steps can still be fulfilled and mice develop to the adult stage [351-356], 
indicating the existence of a regulated cell death mechanism compensating apoptosis. Digit 
separation by elimination of interjacent skin is still carried out in Apaf-1 knockout mice, and a 
closer look at morphological parameters identified necrotic rather than apoptotic cell death in 
these mice [354, 356]. In an in vitro setting, caspase-deficient cells stimulated with apoptosis 
inducers undergo necrosis [357, 358]. During necrosis, swelling of the cell, loss of membrane 
stability and cell lysis can be observed. Triggers of necrosis are severe forms of cellular 
stress such as hypoxic or ischemic damage. Though being considered to be an unregulated 
process, a controlled version of necrotic cell death with certain resemblance to necrosis 
named necroptosis has been defined [359-362].  
TLR3 and 4 are also activators of necrotic cell death. TLR4 ligation provokes caspase-8 
activity with induction of the extrinsic apoptotic pathway, but by blocking caspase-8, necrotic 
cell death is induced [363]. Additional triggers of necrosis are elevated Ca2+ or ROS levels, 
that can induce generation of hydroperoxides or the activation of proteases like calpain or 
cathepsin B [364]. 
One major difference between apoptosis and necrosis is that necrosis causes a local 
inflammatory response. While in apoptosis the cell contents are packed into apoptotic 
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bodies, necrotic cells release their cytoplasmic contents to the extracellular space, where 
they function as danger signals and activate innate immune system components such as the 
NLRP3 inflammasome [365]. In turn TLR signaling or the NLRP3 inflammasome can also 
contribute to cell death [366, 367]. Although necrotic cell death is linked to severe stress, it 
can partially escort or replace apoptosis, for example in the above-mentioned development 
of fingers but also in cellular turnover of the intestine and other conditions [364]. 
In the setting of cancer, necrotic cell death mostly takes place under hypoxic conditions and 
is thought to contribute to attracting inflammatory cells to the tumor [213, 304, 305, 307].  
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1.6. HMGB1 
1.6.1. HMGB1 structure and domains 
HMGB1 protein is a highly conserved DNA-binding protein with 98.5 % sequence homology 
across mammals. It is involved in gene expression and chromatin remodeling [368, 369]. 
HMG proteins were initially described by Godwin et al. and named according to their mobility 
in polyacrylamide gel electrophoresis systems [370]. The 215 amino acid protein HMGB1 
contains two DNA binding domains, HMG A box at position 9-79 and HMG B box at position 
185-215, and an acidic tail at the C-terminus (Figure 12) [371]. The DNA binding domains 
unspecifically bind DNA, a process that is ensured by two nuclear-localization signals (NLS) 
at positions 28-44 and 179-185, keeping HMGB1 in the nucleus in the steady state [372]. 
The B box of HMGB1 has proinflammatory properties, whereas the A box is an HMGB1 
antagonist [373]. Residues at position 150-183 interact with RAGE, residues at position 89-
108 are responsible for the binding of HMGB1 to TLR4 and residues at position 7-74 are 
transactivating domains of p53 [374-376]. The acidic C-terminal tail of HMGB1 mediates the 
antibacterial properties of HMGB1 as well as the DNA binding [377-379]. 
 
 
 
  
 
Source: Kang et al., 2013 [380] 
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Figure 12. HMGB1 structure and functions 
(a) HMGB1 is structurally composed of three different major domains: two homologous DNA-binding domains 
termed box A and box B, and a negatively charged C-terminal domain. Residues at positions 150 – 183 drive 
binding to RAGE, whereas residues at positions 7-74 and 89-108 are responsible for binding to p53 
transactivation domain and Toll-like receptor 4 (TLR4). Two nuclear localization signals (NLS1 and NLS2) control 
transport of HMGB1 to the nucleus. HMGB1 contains three cysteine residues at positions 23, 45 and 106, which 
are redox-sensitive and are important for HMGB1 activity. 
(b) Depending on its localization, HMGB1 has multiple roles. 
 
1.6.2. Nuclear functions of HMGB1 
Nuclear HMGB1 acts as an architectural transcription factor regulating gene transcription and 
genomic stability by interaction with nucleotides, histones, transcription factors and other 
proteins (Figure 12) [381-383].  
HMGB1 participates in the assembly of nucleosomes and chromatin replication, relaxes 
nucleosomes and makes chromatin more accessible [384-387]. This interaction of HMGB1 
with nucleosomes is short-lived and reversible during chromatin remodeling [388]. HMGB1 
also exerts chaperone activity and accelerates nucleosome assembly to naked DNA [389]. 
Another HMGB1 interaction partner besides nucleosomes is DNA. HMGB1 acting as a DNA 
chaperone binds DNA in a sequence-unspecific manner [390], a process that is regulated by 
the areas close to the HMGB1 DNA binding boxes, the acidic C-terminal tail and post-
translational modifications [378, 391-396]. DNA-bound HMGB1 can bend the latter and 
induce DNA conformation changes [397-401].  
HMGB1 influences gene transcription via HMGB1-TATA binding protein (TBP)/TATA-box 
complex interactions [402, 403], or by acting as an activator, enhancer, repressor or silencer 
of steroid nuclear receptors, p53, retinoblastoma (Rb) protein and estrogen receptor [375, 
404-410]. 
Additionally, HMGB1 plays an essential role in V(D)J recombination by formation of 
recombination-activating genes (RAG)/ recombination signal sequence (RSS)/ HMGB1 
complexes that enhance RAG1/RAG2 activity [411-413]. 
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1.6.3. Extracellular functions of HMGB1 
Under homeostatic conditions, HMGB1 is kept inside the cells with a preferential nuclear 
localization, but it can be actively secreted or passively released upon cell damage [414]. 
When released into the extracellular space HMGB1 can stimulate immune responses either 
alone or in conjunction with other molecules. Translocation of HMGB1 from the nucleus to 
the cytoplasm and its subsequent secretion can occur in various situations such as during 
activation of immune cells, including for example macrophages upon LPS stimulation or 
monocytes upon Lysophosphatidylcholines (LPC) exposure, and during cell death (necrosis 
and apoptosis) and ischemia/reperfusion injury [415-417]. 
Three critical cysteine residues at positions 23, 45 and 106 regulate HMGB1 translocation to 
the cytoplasm (Cys 106) and its effector function in the extracellular space [374, 418, 419]. 
Depending on HMGB1 redox state at these three residues, HMGB1 can be inactive or exert 
chemo-attractant or cytokine-inducing activities (Figure 13). 
 
 
 
Source: Tang et al., 2012 [420] 
 
Figure 13. HMGB1 activity is dependent on its redox state 
To act in the extracellular space as a DAMP/danger signal and inflammatory mediator, HMGB1 is released from 
cells by two main mechanisms: living inflammatory cells such as macrophages actively secrete it, whereas 
necrotic cells release HMGB1 passively. The redox state of HMGB1 determines its action in the extracellular 
space: all-thiol-HMGB1 induces chemokine production and leukocyte recruitment, whereas disulfide-HMGB1 
promotes release of proinflammatory cytokines and thus participates to the inflammatory response. ROS from 
leukocytes induces terminal oxidation of HMGB1, which is inactivated during resolution of inflammation. 
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HMGB1 has been reported to act as a DAMP or an alarmin [421], linking tissue damage and 
stress to activation of innate immune responses. Notably, HMGB1 has been shown to be 
involved in diseases in which chronic inflammation plays a role, such as arthritis and cancer 
[414, 421-423]. 
HMGB1 induces signaling through the binding to RAGE and certain TLRs [421, 423-432]. 
HMGB1 might be involved in regulating TLR9 signaling, as indicated by the fact that 
activation of TLR9 is substantially decreased in macrophages and DCs deficient for HMGB1 
[433]. It has been suggested that the binding of immunogenic nucleic acids to HMGB1 is 
required for subsequent recognition by specific PRRs such as TLR3, TLR7 and TLR9, and 
subsequent activation of innate immune responses [434]. Indeed, in the absence of cytosolic 
HMGB proteins, the secretion of cytokines including type-I interferons, TNF-α, IL-6 and IL-1β 
is dramatically impaired upon exposure to immunogenic nucleic acids [433-435]. In addition 
to this cytokine activity, HMGB1 can also participate in the transactivation of the IL-1β gene 
promoter [436].  
The majority of immune cells can respond to extracellular HMGB1. HMGB1 can act as a 
powerful DAMP/alarmin that can induce a broad range of proinflammatory effector pathways. 
Target cells interacting with HMGB1 via RAGE and TLRs include macrophages, monocytes, 
neutrophils, fibroblasts, keratinocytes, DCs and T cells [437-444]. Induction of signaling in 
these cells by HMGB1 results in production of a variety of cytokines including TNF-α, IL-1α, 
IL-1β, IL-6, IL-8, IL-10, macrophage inflammatory protein (MIP)-1α and MIP-1β as well as 
chemokines such as CCL5, CXCL1, CXCL2, CCL2, CCL20 and CCL3 [437-439, 441, 443, 
445-449]. Interestingly, while HMGB1 alone has a low proinflammatory potential, its 
association to other DAMPs or PAMPs like LPS, CpG-ODN, Pam3CSK4 or lipids, results in 
very potent proinflammatory stimuli [450-452]. 
 
1.6.4. HMGB1 and cancer 
A pivotal role for HMGB1 has been shown in several cancer types including colon, breast, 
lung, prostate, cervical, skin, kidney, stomach, pancreatic, liver, bone, and blood cancer [422, 
423, 453, 454]. HMGB1 has been shown to exert anti- or pro-tumor effects depending on the 
cancer type, its location and redox status state [380].  
A suppressive role for HMGB1 in tumorigenesis is supported by the fact, that nuclear 
HMGB1 binds to the transcription factor Rb, which acts as a tumor suppressor by inducing 
cell cycle arrest in the G1 phase and apoptosis of breast cancer cells [455]. As a DNA 
chaperone, HMGB1 prevents cells from genome instability and telomere shortening, which 
also supports an anti-tumor effect of nuclear HMGB1 [389, 456, 457]. Defects in autophagy 
result in genomic instability, inflammation and damaged organelles, three abnormalities that 
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can result in tumorigenesis [459-462]. By acting as a positive regulator of autophagy, 
HMGB1 has been suggested to prevent tumor development. [458],  
On the contrary, a substantial number of reports have shown that HMGB1 can facilitate 
tumor growth and cancer progression. In tumors, the cellular sources of HMGB1 are multiple 
and variable from tumor to tumor. During malignant mesothelioma development, HMGB1 has 
been shown to be released by mesothelial cells exposed to asbestos and erionite with 
implications for HMGB1 in malignant mesothelioma development in an autocrine manner, i.e. 
by directly stimulating tumor cell growth [459-461]. Also, activated macrophages, monocytes 
and T cells can secrete HMGB1 under conditions of hypoxia, injury or inflammatory stimuli 
[462-464]. In addition, it has been recently reported that MDSCs present in tumors secrete 
HMGB1 [465].  
Via RAGE and TLR signaling pathways, extracellular HMGB1 can activate cytokine release. 
In a DMBA/TPA-induced skin carcinogenesis model, mice deficient for RAGE, a known 
receptor of HMGB1, were shown to be more resistant to inflammation and tumor formation 
[466]. In melanoma and colon cancer the recruitment of inflammatory cells contributing to 
tumor development is impaired upon blockade of TLR4/ HMGB1 interaction [467].  
Recently, HMGB1 has been shown to be released from keratinocytes after UVB irradiation 
and to promote the attraction of neutrophils to the microenvironment of melanoma in a TLR4-
dependent manner with subsequent promotion of metastasis [468]. Also relevant to 
metastasis is the expression of matrix metalloproteinases like MMP2 and MMP9, which has 
been shown to be decreased when HMGB1 signaling through RAGE is blocked [469]. 
Coherent observations were made in gastric cancer and colorectal adenomas, where RAGE 
expression was closely associated with metastasis [470, 471].  
In certain settings, anti-tumor immune surveillance is impaired by HMGB1. In colon cancer, 
HMGB1 has been reported to trigger apoptosis of DCs and to limit antigen presentation and 
adaptive immune responses [472]. Cytotoxic CD8+ T cell function is indirectly inhibited by 
HMGB1 since IL-10-mediated T cell suppression can be prevented by blockade of tumor-
derived HMGB1 [473]. A direct influence of HMGB1 on T cells is supported by the elevated 
expression of Lymphotoxin α1β2 on tumor-infiltrating T cells in the presence of HMGB1 in 
prostate cancer with subsequent recruitment of macrophages providing growth factors and 
initiating angiogenesis [474]. Angiogenesis has been shown to be promoted by stimulation of 
the HMGB1 receptor RAGE [471].  
Finally, HMGB1 has been shown to assist tumors in accelerating their metabolism to ensure 
their increased energy needs. During pancreatic tumor growth, HMGB1 contributes to the 
regulation of mitochondrial bioenergetics via RAGE, a process which might be driven by heat 
shock protein (HSP) 27 leading to less ATP production [475-477]. 
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1.7. Aim of this PhD thesis 
In this thesis I report my contribution to the investigation of two processes that are relevant to 
tumor-stroma interactions. In a first project I have analyzed the ability of melanoma cell lines 
to process and secrete the proinflammatory cytokine IL-1β as well as the ability of necrotic 
tumor cells (melanoma) to induce inflammasome activation and IL-1β secretion in 
macrophages. I have also analyzed the pattern of expression of IL-1β protein in benign and 
malignant human melanocytic lesions in order to gain insight of the site of production of IL-1β 
in human melanomas in vivo. In the second project, and intrigued by a finding in the first 
project showing that macrophages in the melanoma tumor microenvironment secrete high 
amounts of IL-1β, observed in vitro upon exposure to necrotic cell debris and the supernatant 
thereof, we were interested to investigate the role of the DAMP/alarmin HMGB1 that is 
known to be released upon cell necrosis, in melanoma development. The results of these two 
projects relevant to tumor stroma interactions are presented here in the form of two 
manuscripts and then discussed in detail in the discussion section.  
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General Remarks  
The materials and methods part is adapted from the dissertation of Dr. Gabriel Sollberger 
(ETH-Diss.-No 19973). Standard methods are only briefly described, but if protocols were 
modified, it is mentioned. Detailed specifications of single experiments can be found in the 
appropriate figure legends. 
 
2.1. Materials 
2.1.1. Chemicals, consumables and equipment 
Chemicals and consumables 
3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT)  SIGMA, Munich, Germany 
β-Mercaptoethanol  SIGMA, Munich, Germany 
Acetic acid FLUKA CHEMIE, Buchs, Switzerland 
Acrylamide/ bisacrylamide (30:0.8) ROT, Karlsruhe, Germany 
Agar DIFCO, Detroit, US-MI 
Agarose  SIGMA, Munich, Germany 
Ammonium persulfate (APS) SIGMA, Munich, Germany 
Ampicillin SIGMA, Munich, Germany 
Annexin V  BECTON-DICKINSON,                   
Franklin Lakes, US-NJ) 
Antibody Diluent  DAKO, Glostrup, Denmark  
Aza-2′-deoxycytidine (AZA)  SIGMA Munich, Germany 
Bovine serum albumin (BSA) SIGMA, Munich, Germany 
BoxA from HMGB1 HMGBIOTECH, Milano, Italy  
Bromophenol blue SIGMA, Munich, Germany 
BSA Fraction V PAA, Pasching, Austria 
Calcium chloride (CaCl2) FLUKA CHEMIE, Buchs, Switzerland 
Caliper  MITUTOYO, Kawasaki, Japan 
Carboxyfluorescein succinimidyl ester (CFSE) THERMO FISHER SCIENTIFIC, 
Waltham, US-MA 
CD14 magnetic beads MILTENYI,                     
Bergisch Gladbach, Germany 
DAKO Delimiting pen DAKO, Glostrup, Denmark  
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Dimethylsulfoxide (DMSO) MERCK, Darmstadt, Germany 
DL-Dithiothreitol (DDT)   SIGMA, Munich, Germany 
DNA-restriction enzyme buffers NEB, Ipswich, US-MA 
Ethanol 70 % V/V Kantonsapotheke Zurich, Zurich, 
Switzerland 
Ethanol 80 % V/V KA PhEur Kantonsapotheke Zurich, Zurich, 
Switzerland  
Ethanol 96 % V/V KA PhEur Kantonsapotheke Zurich, Zurich, 
Switzerland  
Ethanol absolut KA PhEur Kantonsapotheke Zurich, Zurich, 
Switzerland 
Ethidium Bromide SIGMA, Munich, Germany 
Ethylenediaminetetraacetic acid (EDTA) FLUKA CHEMIE, Buchs, Switzerland 
Faramount Mounting Medium DAKO, Glostrup, Denmark 
FastStart Universal SYBR Green Master  ROCHE, Rotkreuz, Switzerland 
Ficoll-Paque PLUS  GE HEALTHCARE,   
 Little Chalfont, UK 
Flasks and (multiwell)-dishes for cell culture NUNC, Roskilde, Denmark 
Fluorescence Mounting Medium  DAKO, Glostrup, Denmark 
Glycerol MERCK, Darmstadt, Germany 
Glycine ROT, Karlsruhe, Germany 
Goat serum SIGMA, Munich, Germany 
Hematoxylin Solution  SIGMA, Munich, Germany 
HEPES SIGMA, Munich, Germany 
Hydrogen chloride (HCl) FLUKA CHEMIE, Buchs, Switzerland  
Insulin Syringes (30G x 8mm) BECTON-DICKINSON,                           
Franklin Lakes, US-NJ 
Ionomycin  SIGMA, Munich, Germany 
LS columns   MILTENYI,                                         
Bergisch Gladbach, Germany 
Magnesium chloride (MgCl2) FLUKA CHEMIE, Buchs, Switzerland 
Methanol FLUKA CHEMIE, Buchs, Switzerland 
MicroAmp® Fast Optical 96-Well Reaction Plates  LIFE TECHNOLOGIES,  
 Carlsbad, US-CA 
Microscope Cover Slips, 24 x 36 mm  THERMO FISHER SCIENTIFIC, 
Waltham, US-MA 
Milk powder (low fat) MIGROS, Zürich, Switzerland 
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Monosodium urate crystals (MSU) provided by L. French,  
 University Hospital Zürich 
Triton-X100 SIGMA, Munich, Germany 
Microfilter units 0.45 µm MILLIPORE, Billerica, US-MA 
Nigericin  ENZO LIFE SCIENCES, New York, 
US-NY 
Nitrocellulose membrane (Protran) SCHLEICHER & SCHUELL, 
 Dassel, Germany 
NP40 lysis buffer LIFE TECHNOLOGIES, Carlsbad, 
US-CA 
Nylon cell strainer 40 μm CORNING INC., New York, US-NY 
Nylon cell strainer 70 μm CORNING INC., New York, US-NY 
Orange G SIGMA, Munich, Germany 
PBS  GIBCO, Lausanne, Switzerland 
PBS (10x powder) APPLICHEM, Darmstadt, Germany 
Phorbol-12-myristate-13-acetate (PMA) SIGMA, Munich, Germany  
Polybrene SIGMA, Munich, Germany 
Polystyrene Round-Bottom Tubes 5 ml BECTON-DICKINSON,                       
Franklin Lakes, US-NJ  
Pre-mixed gas composed with 1 % O2    CARBAGAS, Guemlingen,  
 Switzerland 
Propidium iodide  ROCHE, Rotkreuz, Switzerland 
Puromycin SIGMA, Munich, Germany 
Rec. M-CSF  PEPROTECH, Rocky Hill, US- NJ 
Rec. HMGB1  HMGBIOTECH, Milano, Italy 
Rec. IFN-γ  PEPROTECH, Rocky Hill, US- NJ 
Rec. IL-4  PEPROTECH, Rocky Hill, US- NJ 
Sodium chloride (NaCl) FLUKA CHEMIE, Buchs, Switzerland 
Sodium dodecyl sulfate (SDS) SIGMA, Munich, Germany 
Sodium hydroxide (NaOH) FLUKA CHEMIE, Buchs, Switzerland 
Target Retrieval Solution   DAKO, Glostrup, Denmark  
Tetramethylethylenediamine (TEMED) SIGMA, Munich, Germany 
Triton-X100 SIGMA, Munich, Germany 
TRIZMA Base (TRIS) SIGMA, Munich, Germany 
Tryptone DIFCO, Detroit, US-MI 
Tween 20 ROT, Karlsruhe, Germany 
Ultra-pure LPS (Lipopolysaccharide) INVIVOGEN, Toulouse, France  
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Whatman 3MM paper WHATMAN, Maidstone, England 
Xylene   THOMMEN FURLER AG, Rüti bei 
Büren, Switzerland 
Yeast extract DIFCO, Detroit, US-MI 
Z-VAD-fmk (Z-VAD)   ENZO LIFE SCIENCES, New York, 
US-NY 
 
Equipment 
Agarose gel electrophoresis system  BIORAD, Cressier, Switzerland  
CanonScan 9950F device  CANON, Tokio, Japan 
Digital slide scanner NanoZoomer-XR C12000 HAMAMATSU Photonics, 
Hamamatsu, Japan  
Electric animal shaver Favorita II AESCULAP, Suhl, Germany 
Eppendorf Thermomixer Compact EPPENDORF, Hamburg, Germany 
FACS Canto II   BECTON-DICKINSON,                              
Franklin  Lakes, US-NJ 
Flowmeter RMA-23-SSV  DWYER, Michigan City, US-IN 
GeneFlash SYNGENE, Cambridge, UK 
Hyrax M25 microtome  CARL ZEISS, Oberkochen, Germany 
Lab Therm shaker  KUHNER AG, Birsfelden, Switzerland 
Long-Term Storage Cryogenic Tubes   THERMO FISHER SCIENTIFIC, 
Waltham, US-MA 
MIC-101 Modular Incubator Chamber   BILLUPS-ROTHENBERG,  
 Del Mar, US-CA 
Oxygen cell oxygen sensor VTI-122  VASCULAR TECHNOLOGY, 
Nashua, US-NH 
TProfessional Thermocycler  BIOMETRA, Göttingen, Germany 
SE 250 mini gel system  AMERSHAM, Uppsala, Sweden 
Semi-dry blotter Z340502  SIGMA, Munich, Germany 
Spectra Max190 plate reader   MOLECULAR DEVICES, Sunnyvale, 
US-CA 
Speed Vac apparatus EPPENDORF, Hamburg, Germany 
Steamer MultiGourmet Typ 3216   BRAUN, Kronberg, Germany  
UVS-99 Micro-Volume Spectrophotometer  ACTGene, Piscataway, US-NJ 
ViiA™ 7 Real-Time PCR System  LIFE TECHNOLOGIES,  
 Carlsbad, US-CA 
Widefield BX61 multicolor fluorescence microscope  OLYMPUS, Tokyo, Japan 
Materials and Methods 77 
  
Software 
Analysis Pro software  SOFT IMAGING SYSTEMS, 
Münster, Germany 
FACS DIVA software  BECTON-DICKINSON,                          
Franklin Lakes, US-NJ 
ImageJ 1.47 National Health Institutes, USA 
Nimblescan 2.5  ROCHE NIMBLEGEN INC, 
 Madison, US-WI 
Photoshop software  ADOBE SYSTEMS SOFTWARE, 
San Jose, US-CA 
Prism Software   GRAPHPAD SOFTWARE,  
  San Diego, US-CA 
R package DMR  ROCHE NIMBLEGEN INC, Madison, 
US-WI 
Spectra Max190 plate reader Softmax software 4.3.1 MOLECULAR DEVICES, Sunnyvale, 
US-CA 
ViiA™ 7 Real-Time PCR System software  LIFE TECHNOLOGIES,  
 Carlsbad, US-CA 
 
2.1.2. Protein size standards 
Prestained Protein Molecular Weight Marker MBI FERMENTAS (MBI),  
 Nunningen, Switzerland 
 
2.1.3. DNA size standards 
1 kb DNA ladder NEW ENGLAND BIOLABS (NEB) 
 Beverly, US-MA 
pUC mix DNA marker MBI FERMENTAS (MBI), 
 Nunningen, Switzerland 
 
2.1.4. Cell culture media and additives 
DMEM  SIGMA, Munich, Germany 
Fetal calf serum (FCS) BIOCONCEPT, Allschwil, Switzerland 
GlutaMAX GIBCO BRL, Paisley, Scotland 
OptiMEM  GIBCO BRL, Paisley, Scotland 
Penicillin/ Streptomycin (P/S) SIGMA, Munich, Switzerland 
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Puromycin SIGMA, Munich, Germany 
RPMI 1640  GIBCO BRL, Paisley, Scotland 
Sodium Pyruvate 100 mM GIBCO BRL, Paisley, Scotland 
 
2.1.5. Transfection reagents 
Lipofectamine 2000 INVITROGEN, Basel, Switzerland 
 
2.1.6. Kits 
BCA protein assay PIERCE, Rockford, US-IL 
CytoTox 96 LDH assay kit PROMEGA, Madison, US-WC 
DAKO real detection system DAKO, Glostrup, Denmark 
ELISA kit for human IL-1β R&D SYSTEMS, Minneapolis,      
US-MN 
ELISA kit for human and murine HMGB1  IBL INTERNATIONAL, Hamburg, 
Germany 
Gel Extraction Kit  QIAGEN, Düsseldorf, Germany 
NBT/ BCIP substrate kit  PROMEGA, Madison, US-WC 
PCR Purification kit QIAGEN, Düsseldorf, Germany 
Plasmid Midi/ Maxi Kit 0 QIAGEN, Düsseldorf, Germany 
RevertAid First Strand cDNA Synthesis Kit  THERMO FISHER SCIENTIFIC, 
 RevertAid Reverse Transcriptase (200 U/µL)  Waltham, US-MA 
 RiboLock RNase Inhibitor (40 U/µL)  
RNeasy Mini kit  QIAGEN, Düsseldorf, Germany 
 
2.1.7. Enzymes 
Accutase PAA, Pasching, Austria 
Trypsin GIBCO BRL, Paisley, Scotland 
Collagenase D  ROCHE DIAGNOSTICS, Rotkreuz, 
Switzerland 
DNA-restriction enzymes NEB, Ipswich, US-MA 
 SalI (20.000 U/ ml) 
 BamHI (20.000 U/ ml) 
 HindI (20.000 U/ ml) 
 BglII (20.000 U/ ml) 
T4 DNA ligase ROCHE, Rotkreuz, Switzerland 
  
Materials and Methods 79 
  
2.1.8. Primary antibodies 
α-human ASC (rabbit, polyclonal, AL117)  ENZO LIFE SCIENCES, New York, 
US-NY 
α-human β-Actin (mouse, monoclonal, A5441) SIGMA, Munich, Germany 
α-human CD163 (mouse, monoclonal, NCL-L-CD163) LEICA BIOSYSTEMS, Wetzlar, 
Germany 
α-human IL-10 (rabbit, polyclonal, ab34843) ABCAM, Cambridge, UK 
α-mouse 7/4  ABCAM, Cambridge, UK 
(FITC-conjugated, rat monoclonal, ab53453)  
α-mouse β-Actin (rabbit, polyclonal, #4970S) CELL SIGNALING TECHNOLOGY,
 Danvers, US-MA 
α-mouse CD11b  BIOLEGEND, San Diego, US-CA 
(PE-conjugated, rat, monoclonal, 101207)   
α-mouse CD45  BECTON-DICKINSON, Franklin 
(APC-conjugated, rat, monoclonal, 559864) Lakes, US-NJ 
α-mouse Hif-1α (mouse, monoclonal, ab16066) ABCAM, Cambridge, UK 
α-mouse and human HMGB1  ABCAM, Cambridge, UK 
(rabbit, polyclonal, ab65003)   
α-mouse IL-10 (rat, monoclonal, 504902) BIOLEGEND, San Diego, US-CA 
 
2.1.9. Secondary antibodies 
Alexa Fluor® 546 α-rabbit IgG (A-11035) LIFE TECHNOLOGIES, Carlsbad, 
US-CA 
DyeLight® 650 α-mouse IgG (ab96882) ABCAM, Cambridge, UK 
α-mouse IgG (biotinylated, ab64255) ABCAM, Cambridge, UK 
α-mouse IgG (AP-conjugated, S372B) PROMEGA, Madison, US-WC 
α-rabbit IgG (AP-conjugated, S373B) PROMEGA, Madison, US-WC 
 
2.1.10. Staining reagents 
7-AAD   Becton-Dickinson, Franklin Lakes,  
  US-NJ  
Annexin V  Becton-Dickinson, Franklin Lakes,  
  US-NJ  
Propidium iodide ROCHE, Rotkreuz, Switzerland 
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2.1.11. shRNAs 
shRNAs were bought from SIGMA (Munich, Germany). 
 
2.1.12. Primers 
for human NLRP1: forward  5′-GACCTGGCCTCTGTGCTTAG-3′,                               
reverse   5′-AGTCCCCAAAGGCTTCGTAT-3’,  
for human NLRP3: forward  5′-TGCCTTTGACGAGCACATAG-3′,                               
reverse   5′-GCAGCAAACTGGAAAGGAAG-3’,  
for human ASC:  forward  5´-GCCGAGGAGCTCAAGAAGTT-3´,                                   
reverse   5´-CAGGCTGGTGTGAAACTGAA-3´, 
for human Casp.-1: forward  5′-GAAGGCATTTGTGGGAAGAA-3′,                               
reverse  5′-CATCTGGCTGCTCAAATGAA-3’,  
for human IL-1β: forward  5′-AGCTGATGGCCCTAAACAGA-3′,                               
reverse  5′-TCTTTCAACACGCAGGACAG-3’,  
for human IL-18:  forward  5´-CCAAGGAAATCGGCCTCTAT-3´,                                   
reverse  5´-CCCCCAATTCATCCTCTTTT-3´. 
for human GAPDH:  forward  5´-AAGGTGAAGGTCGGAGTCAACG-3´,                                   
reverse  5´-CAGGGATGATGTTCTGGAGAGC-3´. 
for human RPL27:  forward  5′-ATCGCCAAGAGATCAAAGATAA-3′,  
reverse   5′-TCTGAAGACATCCTTATTGACG-3’,  
for human VEGF-α:  forward   5′-TACCTCCACCATGCCAAGTG-3′,  
reverse  5′-GATGATTCTGCCCTCCTCCTT-3’, 
for mouse CD80:  forward 5´-TCAGTTGATGCAGGATACACCA-3´, 
reverse  5´-AAAGACGAATCAGCAGCACAA-3´, 
for mouse CXCR4: forward 5′-GACTGGCATAGTCGGCAATG-3′,                                                                  
   reverse  5′-AGAAGGGGAGTGTGATGACAAA-3′, 
for mouse Fizz1: forward 5′-CCAATCCAGCTAACTATCCCTCC-3′,                                                                             
reverse  5′-ACCCAGTAGCAGTCATCCCA-3’ 
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for mouse HMGB1: forward 5′-GGCGAGCATCCTGGCTTATC-3′,                                                           
reverse  5′-GGCTGCTTGTCATCTGCTG-3’,  
for mouse IL-1β:  forward 5´-ATCTTTTGGGGTCCGTCAACT-3´,                                                         
   reverse  5´-GACAGCACACATTTGCAGCTC-3´, 
for mouse IL-6:  forward 5´-TAGTCCTTCCTACCCCAATTTCC-3´,                                    
   reverse  5´-TTGGTCCTTAGCCACTCCTTC-3´, 
for mouse IL-10: forward 5′-GCTCTTACTGACTGGCATGAG-3′,                                                        
   reverse  5′-CGCAGCTCTAGGAGCATGTG-3’,  
for mouse RPL27: forward 5′-AAAGCCGTCATCGTGAAGAAC-3′,                     
   reverse  5′-GCTGTCACTTTCCGGGGATAG-3’,  
for mouse TNF-α: forward 5′-CCCTCACACTCAGATCATCTTCT-3′,                                                                  
   reverse  5′-GCTACGACGTGGGCTACAG-3’. 
for mouse Ym1: forward 5′-AGAAGGGAGTTTCAAACCTGGT-3′,                                                                                                   
reverse  5′-GTCTTGCTCATGTGTGTAAGTGA-3’. 
 
2.1.13. Plasmids 
psPAX2 provided by J. Tschopp,  
 Biochemistry Institute Lausanne 
pMD2-VSVG provided by J. Tschopp,  
 Biochemistry Institute Lausanne  
pSP-93 OLIGOENGINE, Seatlle, US-WA 
pSUPER.basic vector OLIGOENGINE, Seatlle, US-WA 
 
2.1.14. Bacterial strains 
E.coli BL21 AMERSHAM, Uppsala, Sweden 
E.coli XL1-Blue MRF STRATAGENE, La Jolla, US-CA 
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2.1.15. Eukaryotic cell lines 
B16-F10 provided by L. French,  
 University Hospital Zürich 
THP-1 ATCC, Manassas, US-VA 
HEK293T ATCC, Manassas, US-VA  
Human metastatic melanoma cell lines provided by R. Dummer,  
 University Hospital Zürich 
 
2.1.16. Standard buffers and solutions 
AP buffer 
NaCl      100 mM 
MgCl2      5 mM 
TRIS/ HCl (pH 9.5)    100 mM 
 
FACS buffer 
PBS       
FCS      2 %(v/v) 
 
MACS buffer 
PBS      100 mM 
BSA      0.5 % (w/v) 
EDTA      2 mM 
 
PBS 
NaCl      140 mM 
KCl      30 mM 
Na2PO4     6.5 mM 
KH2PO4     1.5 mM 
Adjusted to pH 7.4 
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PBST 
PBS 
Tween 20     0.1 %(v/v) 
 
TAE  
TRIS/ HCl     40 mM 
Acetic acid     40 mM 
EDTA      1 mM 
pH 8.0 
 
TBST 
NaCl      150 mM 
Tween 20     0.05 % (v/v) 
TRIS/ HCl (pH 8.0)     10 mM 
 
2.1.17. Biological samples from melanoma patients and healthy donors 
Serum and tumor biopsies were collected from patients with primary melanoma, metastatic 
melanoma (stage 4) and patients seen in our Department for sentinel lymph node biopsy. 
Serum was obtained from healthy blood donors and healthy skin was obtained from plastic 
surgery. All human biological samples were collected with informed written consent upon 
approval of Local Ethical Committees and were conducted according to the Declaration of 
Helsinki Principals. 
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2.2. Methods 
2.2.1. Cell biological methods 
2.2.1.1. Cultivation and storage of eukaryotic cells 
Cells were grown in petri dishes or flasks as adherence or suspension cultures. They were 
incubated in a CO2 incubator (37 °C, 95 % relative humidity, 5 % CO2), cultivated in growth 
medium and propagated as specified in the following table: 
 
Cell type Growth  medium Propagation Passages 
 Basal medium Supplements   
HEK293T RPMI 1640 
10 % FCS, P/S (100 
U/ ml), Sodium 
Pyruvate (1 mM), 
GlutaMAX (1:100) 
Splitting 1/ 10 – 1/ 25 when 
confluency was reached 
~P10 – 
P35 
THP-1 
macrophages 
RPMI 1640 
10 % FCS, P/S (100 
U/ ml) 
Splitting 1/ 10 – 1/ 25 at a density 
of about 106 cells/ ml with a 
medium change every third day 
~P10 – 
P35 
Murine 
primary 
macrophages 
RPMI 1640 
10 % FCS, P/S (100 
U/ ml), Sodium 
Pyruvate (1 mM), 
GlutaMAX (1:100) 
No propagation  
Murine B16 
mouse 
melanoma 
DMEM 
10 % FCS, P/S (100 
U/ ml), Sodium 
Pyruvate (1 mM), 
GlutaMAX (1:100) 
Splitting 1/ 5 – 1/ 10 when 
confluency was reached 
~P10 – 
P20 
Human 
metastatic 
melanoma 
RPMI 1640 
10 % FCS, P/S (100 
U/ ml), Sodium 
Pyruvate (1 mM), 
GlutaMAX (1:100) 
Splitting 1/ 5 – 1/ 10 when 
confluency was reached 
~P5   – 
P15 
Human 
monocytes 
DMEM 
10 % FCS, P/S (100 
U/ ml), Sodium 
Pyruvate (1 mM), 
GlutaMAX (1:100) 
No propagation  
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To passage adherent cells, they were washed three times with PBS. To detach from the 
plastic surface, they were incubated 4-5 min with a suitable amount of trypsin (0.05 % [w/v] in 
PBS) at 37 °C in the incubator. The trypsinization was stopped by resuspending the cells in 
fresh medium containing at least 10 % FCS and subsequent seeding. 
For long-term storage, cells were suspended, centrifuged (200x g, 4 min, RT) and 
resuspended in FCS containing 10 % DMSO (MERCK, Darmstadt, Germany). They were 
slowly frozen at ~ 1 °C/ min in Long-Term Storage Cryogenic Tubes (THERMO FISHER 
SCIENTIFIC, Waltham, US-MA) and stored in liquid nitrogen. 
 
2.2.1.2. Establishment of primary eukaryotic cell cultures 
2.2.1.2.1. Primary mouse macrophages 
To generate of M1 and M2 macrophages, bone marrow cells from tibia and fibula of WT 
C57BL/6 mice (HARLAN, Venray, Netherlands) were isolated and 5 × 10
6
 cells/10 cm2 dish 
were cultured at 37 °C in 5 % CO2 in RPMI 1640 medium (supplemented with 10 % FCS,     
1 % GlutaMAX, 1 mM Sodium Pyruvate and 100 U/ ml P/S) with 10 ng/ml rec. M-CSF 
(PEPROTECH, Rocky Hill, US- NJ). Medium was replaced on day 6 and cells were 
harvested on day 8. 
To induce M1 phenotype, cells were stimulated at day 6 for 24 h with 10 ng/ml M-CSF 
(PEPROTECH) and 100 ng/ml IFN-γ (PEPROTECH) and for additional 24 h with 10 ng/ml M-
CSF (PEPROTECH) and 20 ng/ml ultra-pure LPS (INVIVOGEN, Toulouse, France). 
To induce M2 phenotype, cells were stimulated at day 6 for 48 h with 10 ng/ml M-CSF 
(PEPROTECH) and 20 ng/ml IL-4 (PEPROTECH). 
To determine the effect of HMGB1 on M1 and M2 macrophages, culture medium used to 
induce M1 or M2 macrophages was supplemented with 1 µg/ml rec. HMGB1 
(HMGBIOTECH, Milano, Italy).  
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2.2.1.2.2. Human monocytes  
Monocytes from healthy donors were obtained from peripheral blood mononuclear cells 
(PBMC). To isolate PBMC`s, the buffy-coats were mixed with PBS in a ratio of 1:2.5. 35 ml of 
the suspension were slowly applied to 50 ml falcons filled with 15 ml Ficoll (GE 
HEALTHCARE, Little Chalfont, UK) and PBMC were purified by centrifugation (400x g, 20 
min, RT)  using a density gradient. The cells were collected from the inter-phase, washed 
twice with PBS and resuspended in 50 ml cold MACS buffer. After counting, cells were 
pelleted, resuspended in MACS buffer / CD14 magnetic beads (MILTENYI, Bergisch 
Gladbach, Germany) and incubated for 30 min in the dark on ice.  
 
Magnetic beads incubation mix (per 100 x 106 PBMC’s) 
MACS buffer     400 µl 
CD14 magnetic beads   50 µl       
 
After two washing steps in cold MACS buffer, cells were filtered through a 70 µm Nylon cell 
strainer (CORNING INC., New York, US-NY), passed through a LS column (MILTENYI), 
counted and seeded in RPMI 1640 medium (supplemented with 10 % FCS, 1 % GlutaMAX 
and 1 mM Sodium Pyruvate) at required densities for experiments. 
 
2.2.1.3. Stable shRNA transfection of B16-F10 and THP-1 cells 
To generate B16-F10 and THP-1 cells stably transfected with a plasmid encoding shRNA 
sequences for the desired gene, the oligos were cloned into the pSUPER.basic 
(OLIGOENGINE, Seatlle, US-WA) vector that had been linearized with BglII and HindIII, 
followed by sequencing and subcloning of the oligos into the lentiviral pSP-93 
(OLIGOENGINE) vector. Second-generation packaging plasmids pMD2-VSVG and psPAX2 
(kindly provided by Prof. J. Tschopp, Biochemistry Institute, Lausanne, Switzerland) were 
used for lentivirus production and infection. Subsequently, the cells were transfected and 
selected with puromycin. See below for a detailed protocol.  
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2.2.1.3.1. Cloning of shRNA oligos into pSUPER.basic 
pSUPER.basic was linearized with HindIII overnight at 37 °C, following by purification of the 
vector on a 1% agarose gel using the QIAGEN gel extraction kit (QIAGEN, Düsseldorf, 
Germany). Subsequently, the purified vector was digested with BglII overnight at 37 °C and 
purified using the columns of the QIAGEN gel extraction kit. 
 
HindIII digest  
pSUPER.basic    x µl (10 µg) 
5x buffer 2     5 µl 
HindIII (20.000 U/ ml)    5 µl 
ddH2O      add. 50 µl 
 
BglII digest  
HindIII-digested pSUPER.basic  x µl (10 µg) 
5x buffer 3     5 µl 
BglII (20.000 U/ ml)    5 µl 
ddH2O      add. 50 µl 
 
The shRNA oligonucleotide sequences were annealed by mixing 3 µg of the sense and 3 µg 
of the antisense oligo (3 mg/ ml nuclease-free H2O each) with 48 µl annealing buffer (100 
mM NaCl, 50 mM Hepes pH 7.4) and subsequent incubation at 90 °C for 10 min, followed by 
70 °C for 10 min and slow cooling to 10 °C. Annealing efficiency was tested on a 3 % 
agarose gel.  
The annealed oligos were cloned into the linearized pSUPER.basic according to the 
following table for 1h at room temperature. 
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Cloning into pSUPER.basic  
Annealed oligos    4 µl  
T4 DNA ligase buffer    1 µl 
Linearized pSUPER.basic (200-500 mg) x µl 
T4 DNA ligase    1 µl 
 Nuclease-free ddH2O    add. 10 µl 
 
2.2.1.3.2. Subcloning to lentiviral pSP-93 
The lentiviral vector pSP-93 was linearized by digestion with SalI and BamH1 and the shRNA 
oligos as well as the H1 promoter were cut out of pSUPER.basic using the same restriction 
enzymes overnight at 37 °C, followed by purification on a 2% agarose gel using the QIAGEN 
gel extraction kit. The insert was subsequently ligated into pSP-93 using an insert to vector 
molar ratio of 3/1 and using buffer and ligase according to cloning into pSUPER.basic. 
 
SalI/ BamHI digest  
10 µg pSP-93     x µl  
5x buffer 3     5 µl 
100x BSA     5 µl 
SalI (20.000 U/ ml)    2.5 µl 
BamHI (20.000 U/ ml)   2.5 µl 
ddH2O      add. 50 µl 
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2.2.1.3.3. Lentivirus production and transfection 
Lentivirus was produced by transfection of HEK293T cells with a mix of the pSP-93 vector 
encoding for the desired shRNA oligo and the two packaging vectors psPAX2 and pMD2-
VSVG. 5x106 cells were plated in 10-cm dishes in RPMI 1640 medium (supplemented with 
2 % FCS, 1 % GlutaMAX and 1 mM Sodium Pyruvate) and transfected the day after seeding.  
For transfection, the medium was changed to 15 ml OptiMEM (GIBCO BRL, Paisley, 
Scotland). Plasmids were mixed in a ratio of 1:3:4 to a total of 24 µg (3 µg psPAX2, 9 µg 
pMD2-VSVG, 12 µg pSP-93) in 1.5 ml OptiMEM (GIBCO BRL) and combined with 1.5 ml 
OptiMEM (GIBCO BRL) containing 60 µl Lipofectamine 2000 (INVITROGEN). 
After 20 min incubation at room temperature, the transfection mix was added onto the 
HEK293T cells and the medium was changed to 5-10 ml RPMI 1640 medium (supplemented 
with 2 % FCS, 1 % GlutaMAX and 1 mM Sodium Pyruvate) 16-24 h after transfection, 
depending on the concentration of virus intended to produce.  
36 h later, the conditioned medium containing the lentivirus was harvested, centrifuged at 
200x g for 4 min at room temperature, filtrated using 0.45 µm Microfilter units (MILLIPORE, 
Billerica, US-MA), mixed with 8.4 µg/ml Polybrene (SIGMA, Munich, Germany), aliquoted 
and stored at -80 °C.  
For transduction, 1x106 THP-1 or B16-F10 cells were seeded in a well of a 6-well plate and 
transduced with 1 ml of conditioned virus-containing medium. 24h after transfection the 
medium was changed and puromycin of an optimized concentration (5 µg/ ml) was used to 
select transduced cells. 
 
2.2.1.3.4. Control of knock-down efficiency and stability  
To determine the knock-down efficiency of B16-F10 mouse melanoma cell line stably 
expressing shRNA to HMGB1, shHMGB1-B16 as well as shLamin-B16 were cultured at 
37 °C in 5 % CO2 in DMEM medium (supplemented with 10 % FCS, 1 % GlutaMAX, 1 mM 
Sodium Pyruvate and 100 U/ml  P/S). 1 × 105 cells/well of a 6-well plate were seeded, 
cultured for one week and lysed with NP40 lysis buffer (LIFE TECHNOLOGIES).The 
procedure was repeated 3 times to observe the HMGB1 protein level after 0, 7, 14, 21 and 
28 days. Protein concentration of the cell lysates was determined by the BCA protein assay 
and proteins levels were analyzed with western blot.  
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2.2.1.4. Differentiation and priming of human monocytes and THP-1 macrophages 
For necrosis experiments THP1 macrophages were differentiated for 3h with 500nM phorbol-
12-myristate-13-acetate (PMA) (SIGMA), washed and plated one day before stimulation. 
Human monocytes and THP1 macrophages were primed overnight with 100 ng/ ml ultra-pure 
LPS. 
 
2.2.1.5. Induction of necrosis 
Necrosis was induced in A2058 and A375 with repeated heat/ thaw cycles. Counted cells 
were dry-pelleted and treated with 3 cycles of freezing in liquid nitrogen and heating in water 
bath at 37°C. The necrotic cell contents were resuspended and centrifuged (200x g, 10 min, 
RT) to separate soluble and debris fraction. The supernatant after the centrifugation step was 
considered to be the soluble fraction, whereas the pellet represented the debris fraction. The 
pellet was resuspended in the same volume of the supernatant and both debris and soluble 
fraction where diluted several times before addition to target cells.  
 
2.2.1.6. Stimulation of human monocytes and THP-1 macrophages 
After overnight priming with ultra-pure LPS the medium of human monocytes and THP1 
macrophages was replaced and cells were incubated with soluble and debris fractions of 
necrotic cells or stimulated with 1.5 mM ionomycin (SIGMA), 150 µg/ ml monosodium urate 
crystals (MSU) (provided by L. French, University Hospital Zürich) or 20 µM Nigericin (ENZO 
LIFE SCIENCES, New York, US-NY) for indicated time. 
The soluble and the debris fractions of necrotic A2058 and A375 were diluted to have the 50-
, 25-, 12.5-, 6.25- and 3.12-fold amount of necrotic cells added to the target cells. 
Chemical inhibition was performed with addition of 5 µM Z-VAD-fmk (Z-VAD) (ENZO LIFE 
SCIENCES) 30 min before cell stimulation. 
All experiments for western blotting analysis were performed in serum-free OptiMEM medium 
GIBCO BRL). 
To de-methylate methylated genes, A375 melanoma cells were incubated with 2.5 µM 5-Aza-
2′-deoxycytidine (AZA) (SIGMA) for 24 h. 
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2.2.1.7. In vitro cell proliferation and apoptosis 
To compare in vitro proliferation of B16-F10 mouse melanoma cell line stably expressing 
shRNA to HMGB1 or Lamin, cells were cultured at 37 °C in 5 % CO2 in DMEM medium 
(supplemented with 10 % FCS, 1 % GlutaMAX, 1 mM Sodium Pyruvate and 100 U/ml  P/S) 
and samples were analyzed at different timepoints. 
Appropriate cell numbers to have 1.5 × 10
5
 cells at the timepoint of sample collection were 
seeded in 12-well plates.  At days 0, 1, 2 and 3, mitochondrial dehydrogenase activity of 
living cells was measured by addition of 10 % MTT (SIGMA) for 4 h at 37 °C. Optical 
densities were measured by the SpectraMax190 plate reader (MOLECULAR DEVICES, 
Sunnyvale, US-CA). 
Cells were incubated with PBS + 1µM CFSE (THERMO FISHER SCIENTIFIC) for 10 min at 
37°C and appropriate cell numbers to have 6 × 10
5
 cells at the timepoint of sample collection 
were seeded in 6-well plates. At days 0, 3, 6 and 8, cells were detached and CFSE-derived 
fluorescence intensity in cells was determined on a single-cell level using flow-cytometry. 
Acquisition was performed with a FACS Canto II (BECTON-DICKINSON, Franklin Lakes, 
US-NJ) and sample analysis was done using FACS DIVA software (BECTON-DICKINSON). 
Appropriate cell numbers to have 1.5 × 10
5
 cells at the timepoint of sample collection were 
seeded in 12-well plates.  At days 0, 3, 6 and 9, cells were detached and stained with 1.0 
µg/ml Propidium iodide (ROCHE, Rotkreuz, Switzerland) and 5 % Annexin V (BECTON-
DICKINSON) for 15 min on ice. Acquisition was performed with a FACS Canto II and sample 
analysis was done using FACS DIVA software. 
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2.2.1.8. Hypoxia culture condition 
To determine the release of HMGB1 under hypoxic conditions in vitro, primary cell cultures 
from 7 metastatic melanoma patients were cultured under hypoxic conditions and compared 
to cells cultured under normoxic conditions.  
One million cells were cultured in 2.5 ml RPMI 1640 medium (supplemented with 10 % FCS, 
1 % GlutaMAX, 1 mM Sodium Pyruvate and 100 U/ml  P/S)  in a MIC-101 Modular Incubator 
Chamber (BILLUPS-ROTHENBERG, Del Mar, US-CA) for 72 h.  
At day 0, the chamber was flushed with 20 l/min (flowmeter: RMA-23-SSV. DWYER, 
Michigan City, US-IN) of certified pre-mixed gas composed of 1 % O2, 5 % CO2, and 94 % N2 
(CARBAGAS, Guemlingen, Switzerland).  
The O2 concentration inside the chamber was measured with a disposable VTI-122 Polaro- 
graphic oxygen cell oxygen sensor (VASCULAR TECHNOLOGY, Nashua, US-NH). The 
hypoxia chamber as well as the control samples cultured under normoxic conditions were 
placed in an incubator at 37 °C for 72 h. 
 
2.2.1.9. Viability measurement  
For lysis analysis, LDH activity was measured in cell culture supernatants without cells 
(centrifuged at 1’500 g for 5 min at 4 °C) as well as cell lysates produced by incubation for 10 
min with 2.5 ml culture medium containing 10 % Triton-X100 (SIGMA) with the CytoTox 96 
assay (PROMEGA, Madison, US-WC). The samples were diluted as desired and analyzed in 
triplicates in 96-well plates according to the manufacturer’s instructions. Optical densities 
after stop of the chromogenic reactions were measured by the Spectra Max190 plate reader 
(MOLECULAR DEVICES) at a wavelength of 490 nm using the Softmax software. 
The percent of release was individually calculated for each well according to the formula % 𝑙𝑦𝑠𝑖𝑠 =  𝑆𝑁
𝑆𝑁 + 𝐿𝑦𝑠 
where SN is supernatant and Lys is lysate. 
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2.2.2. Animal experiments 
2.2.2.1. Mice 
Six to 8-week-old female C57BL/6 mice (HARLAN) were used in this study. TLR2-/- C57BL/6 
mice were kindly provided by Prof. Marc Donath (Department of Biomedicine, University 
Hospital Basel, Switzerland), TLR4-/- C57BL/6 mice were kindly provided by Prof. Markus 
G. Manz (Division of Hematology, University Hospital Zurich, Switzerland) and RAGE-/- 
C57BL/6 mice were kindly provided by Prof. Peter P. Nawroth (Department of Internal 
Medicine I and Clinical Chemistry, University of Heidelberg, Germany). All experimental 
procedures were approved by the Veterinary Office of Zurich and the institutional animal 
care. 
 
2.2.2.2. Tumor growth and metastasis experiments 
Before subcutaneous injection of tumor cells into mice, the back skin was shaved with the 
electric animal shaver Favorita II (AESCULAP, Suhl, Germany). 
1 x 105 Lamin-shRNA-transduced B16 or 1 x 105 HMGB1-shRNA-transduced B16 cells were 
injected subcutaneously in a volume of 100 µl PBS into the flank of WT C57BL/6 mice 
(HARLAN). Mice were monitored every other day and tumor size was measured using a 
caliper (MITUTOYO, Kawasaki, Japan). Tumor volume was expressed as the square of the 
smallest diameter multiplied by the largest diameter.  
1 x 105 B16-F10 cells were injected subcutaneously in a volume of 100 µl PBS into the flank 
of WT C57BL/6 mice (HARLAN). Additionally, mice were injected intraperitoneally with 100 µl 
500 µg/ml BoxA (HMGBIOTECH), an antagonist for HMGB1 receptor binding, or PBS at the 
day of injection. Mice were monitored at least every third day and tumor size was measured 
using a caliper. Tumor volume was expressed as the square of the smallest diameter 
multiplied by the largest diameter 
1 x 105 Lamin-shRNA-transduced B16 or 1 x 105 HMGB1-shRNA-transduced B16 cells were 
injected subcutaneously in a volume of 100 µl PBS into the flank of WT C57BL/6 mice 
(HARLAN). Additionally, mice were injected intraperitoneally with 100 µl 0.5 mg/ml anti-
mouse IL-10 antibody (BIOLEGEND, San Diego, US-CA) or PBS every other day. Mice were 
monitored at least every second day and tumor size was measured using a caliper. Tumor 
volume was expressed as the square of the smallest diameter multiplied by the largest 
diameter. 
To generate lung metastasis, 1 x 105 Lamin-shRNA-transduced B16 or 1 x 105 HMGB1-
shRNA-transduced B16 cells were injected intravenously in a volume of 100 µl PBS into the 
tail vein of WT C57BL/6 mice (HARLAN). Mice were sacrificed by CO2 inhalation 13 days 
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after tumor cell inoculation, and the number of macroscopically visible melanoma metastases 
on the surface of the lungs was counted in a masked manner by two different experimenters. 
 
2.2.2.3. Flow cytometry analysis of tumor-infiltrating cells 
For the preparation of tumor infiltrating cell suspensions, minced tumors were placed in 
Eppendorf tubes filled with 1 ml RPMI 1640 medium (supplemented with 2 % FCS, 1 % 
GlutaMAX, 1 mM Sodium Pyruvate and 100 U/ml P/S) and 1.5 mg/ml Collagenase D 
(ROCHE DIAGNOSTICS, Rotkreuz, Switzerland) and incubated for 60 min at 300 rpm and 
37 °C in an Eppendorf Thermomixer Compact (EPPENDORF, Hamburg, Germany). The cell 
suspensions were filtered through a 40 μm Nylon cell strainer (CORNING INC.), washed 
twice with cold PBS, transferred to a 96-Well Round Bottom Plate and stained for 30 min on 
ice with anti-mouse 7/4 antibody (ABCAM, Cambridge, UK), anti-mouse CD11b 
(BIOLEGEND) and anti-mouse CD45 (BECTON-DICKINSON) antibodies. 
Stained samples were washed twice with cold FACS buffer (2% FCS in PBS) and transferred 
to 5 ml Polystyrene Round-Bottom Tubes (BECTON-DICKINSON). The absolute numbers of 
each cell subset were calculated by flow cytometry and presented are the numbers per mm3 
of tumor. Flow-cytometric analysis was performed with a FACS Canto II. Sample analysis 
was done using FACS DIVA software. 
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2.2.3. Histology and Immunohistochemistry  
For histological examination, tissues embedded in paraffin were cut in sections of 2 µm 
thickness with a Hyrax M25 microtome (CARL ZEISS, Oberkochen, Germany). After heating 
the slides for 30 min at 70 °C, they were incubated for 10 min in Xylene (THOMMEN 
FURLER AG, Rüti bei Büren, Switzerland) and for 5 min in each concentration of a 
descending alcohol series (Ethanol absolut, 96 %, 80 % and 70 %) followed by incubation in 
PBS for 5 min. The slides were plunged into Target Retrieval Solution (DAKO, Glostrup, 
Denmark) and vaporized for 25 min in a Steamer MultiGourmet Typ 3216 (BRAUN, 
Kronberg, Germany). When cooled down to room temperature, the samples were washed 
once in PBS and placed into a chamber covered with aluminium foil. To economize the need 
of liquid materials in the following steps, the borders of the sections were surrounded with a 
delimiting pen (DAKO). Antibody penetration was improved by incubation of the slides for 10 
min with 0.03 % Triton-X100 in PBS. After three washing steps in PBS, the slides were 
incubated with blocking solution consisting of 5 % BSA (PAA, Pasching, Austria) and 5 % 
Goat serum (SIGMA) in PBS and then directly without further washing in PBS stained with 
appropriate primary antibodies diluted in Antibody Diluent (DAKO).  
To determine Hif-1α, sections were stained overnight at 4 °C with 10 µg/ml mouse 
monoclonal anti-mouse Hif-1α (ABCAM) or isotype IgG control antibody (ABCAM) at the 
same concentration.  
After three washing steps in PBS, samples were incubated for 60 min at room temperature 
with 0.5 mg/ml biotinylated goat anti-mouse IgG (ABCAM), washed again three times with 
PBS and coupled to 1 µg/ml streptavidin-alkaline phosphatase (VECTOR LABORATORIES, 
Burlingame, US-CA) for 45 min at room temperature. Alkaline phosphatase activity was 
revealed with the DAKO real detection system (DAKO) following manufacturers’ instructions.  
After coloration for 40 s with Haematoxylin solution (SIGMA), slides were mounted with 
Faramount Mounting Medium (DAKO) and Microscope Cover Slips (THERMO FISHER 
SCIENTIFIC). Sample scanning was performed with the digital slide scanner NanoZoomer-
XR C12000 (HAMAMATSU Photonics, Hamamatsu, Japan). Pictures were analyzed with the 
ImageJ software (open source from national institutes of health). 
To determine HMGB1 and Hif-1α, sections were stained overnight at 4 °C with 1 µg/ml rabbit 
polyclonal anti-mouse HMGB1 (ABCAM) and 10 µg/ml mouse monoclonal anti-mouse Hif-1α 
(ABCAM) antibodies or with isotype IgG control antibodies (ABCAM) at corresponding 
concentrations. To determine IL-10 and CD163, sections were stained overnight at 4 °C with 
160 µg/ml rabbit polyclonal anti-human IL-10 (ABCAM) and 10 µg/ml mouse monoclonal anti-
human CD163 (LEICA BIOSYSTEMS, Wetzlar, Germany) antibodies or with isotype IgG 
control antibodies (ABCAM) at corresponding concentrations.  
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After three washing steps in PBS, samples were incubated for 60 min at room temperature 
with conjugated secondary antibodies to visualize target molecules. For HMGB1 and IL-10, 5 
µg/ml Alexa Fluor® 546 goat anti-rabbit IgG (LIFE TECHNOLOGIES, Carlsbad, US-CA) and 
for Hif-1α and CD163, 1.25 µg/ml DyeLight® 650 goat anti-mouse IgG (ABCAM) were used.  
Slides mounted with Fluorescence Mounting Medium (DAKO) and Microscope Cover Slips 
(THERMO FISHER SCIENTIFIC) were analyzed with a Widefield BX61 multicolor 
fluorescence microscope (OLYMPUS, Tokyo, Japan) at 20- and 40- fold magnification. 
Pictures were acquired and analyzed with the Analysis Pro software (SOFT IMAGING 
SYSTEMS, Münster, Germany). 
All studies were read by the same pathologist using the same subjective grading scale. 
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2.2.4. Microbiological methods 
2.2.4.1. Cultivation and storage of E.coli strains 
E.coli cells were suspended in an appropriate amount of LB - medium and grown at 37 °C on 
a Lab Therm shaker (KUHNER AG, Birsfelden, Switzerland) at 180 – 230 rpm until the 
required OD600 was reached. 
 
LB-Medium  
Tryptone      1 % (w/v) 
Yeast extract     0.5 % (w/v) 
NaCl      1 % (w/v) 
 
If required, 100 µg/ ml Ampicillin (SIGMA) was added to the medium. To cultivate E.coli on 
agar plates, they were spread over the plate and incubated at 37 °C. Agar plates were 
produced by adding 1.5 % (w/ v) agar to the LB – medium before autoclaving. This medium 
was poured into petri dishes. If required, an appropriate amount of antibiotic was added to 
the medium after cooling down to ~55 °C. Plates with E.coli were sealed with parafilm and 
stored at 4 °C. 
 
2.2.4.2. Preparation of transformation-competent E.coli 
A fresh overnight culture of transformation – competent E.coli BL21 (AMERSHAM, Uppsala, 
Sweden) or XL-1 Blue (STRATAGENE, La Jolla, US-CA)  was diluted 1:100 with LB – 
medium and  shaken at 37 °C until the optical density at 600 nm was between 0.4 and 0.5.  
After centrifugation (600 x g, 10 min, 4 °C), the bacterial pellet was carefully resuspended in 
cold, sterile 100 mM MgCl2 solution (FLUKA CHEMIE, Buchs, Switzerland)  (1/ 4 of the 
original volume). The mixture was incubated on ice for 30 min, centrifuged as described 
above and the pellet was resuspended in cold, sterile 100 mM CaCl2 solution (FLUKA 
CHEMIE) (1/ 50 of the original volume). The mixture was incubated 3 – 4 h on ice. Cold, 
sterile glycerol (MERCK) was added to a final concentration of 30 %, the mixture was 
aliquoted and stored at – 80°C. 
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2.2.5. Molecular biological methods 
2.2.5.1. Transformation of competent E.coli with plasmid DNA 
100 µl transformation – competent E.coli cells were mixed with 10 µl plasmid or ligation mix 
(~100ng DNA) and incubated on ice for 30 – 60 min. The mixture was subjected to a heat – 
shock (2 min at 42 °C) and put on ice. 500 µl LB – medium were added to the mix and 
shaken for 30 min at 37 °C. Subsequently, the mix was plated on 2 – 3 LB plates, containing 
the corresponding selection marker, and incubated overnight at 37 °C. 
 
2.2.5.2. Preparation of plasmid DNA from E.coli 
2.2.5.2.1. Small scale plasmid preparation with the Plasmid Midi Kit 
In order to quickly get small amounts of plasmid DNA, solutions from the Plasmid Midi Kit 
(QIAGEN) were used. The principle of this method is an alkaline lysis of the cells with 
subsequent precipitation of proteins, lipids and genomic DNA followed by centrifugation. The 
plasmid DNA in the supernatant was precipitated by ethanol. The obtained purity and amount 
of plasmid DNA is sufficient for a subsequent analysis by restriction enzyme digest or 
sequencing. 
1.5 ml of 2 ml overnight bacterial LB culture with the appropriate antibiotic was transferred to 
a microcentrifuge tube and centrifuged (1’500 x g, 6 min, 4 °C). The pellet was resuspended 
in 150 µl Resuspension buffer I by pipetting up and down. 150 µl of Lysis buffer II were 
added and incubated for 3 min at RT while inverting the tubes. To stop lysis and to 
precipitate proteins and lipids, 150 µl of Neutralization buffer III were added. The tubes were 
inverted several times and centrifuged (16’200 x g, 10 min, 4 °C). The supernatant was 
transferred to a new tube with 800 µl ethanol and mixed. This step precipitates plasmid DNA. 
After incubating the tubes 15 min on ice, they were centrifuged (16’200 x g, 20 min, 4 °C). 
The pellets were washed with 200 µl 70 % ethanol and centrifuged again (16’200 x g, 2 min, 
4 °C). The supernatant was removed by inverting the tubes with subsequent drying of the 
plasmid pellet in a Speed Vac (EPPENDORF) apparatus. The DNA containing pellet was 
resuspended in 20 µl H2O and the nucleic acid concentration was determined. Plasmid 
preparations were stored at -20 °C. 
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Resuspension buffer I 
EDTA       10 mM 
RNAse A     100 µl/ ml 
TRIS/ HCl     50 mM 
Stored at 4 °C after addition of RNAse A 
 
Lysis buffer II 
SDS      1 % (w/v) 
NaOH      200 mM 
 
Neutralization buffer III 
Potassium acetate (3 M, pH 5.5) 
 
2.2.5.2.2. Middle scale plasmid extraction with the Plasmid Midi/ Maxi Kit 
The Plasmid Midi/ Maxi Kit (QIAGEN) were used and plasmid isolation was performed 
according to the manufacturers’ instructions. Plasmids used for transfection of eukaryotic 
cells were isolated with the endofree versions of the isolation kits. Plasmid DNA was stored 
at -20 °C. 
 
2.2.5.3. Determination of the nucleic acid concentration 
In order to determine the concentration of DNA or RNA solutions, the absorption at 260 nm 
was measured. This was done using the UVS-99 Micro-Volume Spectrophotometer 
(ACTGene, Piscataway, US-NJ) according to the manufacturers’ instructions. ddH2O or the 
elution solution from the appropriate isolation kit was used as a blank. Because proteins in 
solution absorb light at 280 nm, the ratio between OD260 and OD280 was taken as an 
indicator for the purity of the nucleic acid. The optimal value is 1.8. 
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2.2.5.4. Agarose gel electrophoresis of DNA 
DNA molecules were separated by agarose gel electrophoresis for analytical and preparative 
purpose. Gels with an agarose content of 0.8 – 2 % (w/ v) in TAE buffer were used. Agarose 
concentration was dependent on the fragment length. Electrophoresis was performed in an 
agarose gel electrophoresis system (BIORAD, Cressier, Switzerland) at 100 – 150 V. To 
visualize DNA bands, 1 mg ethidium bromide (SIGMA) was added per 1 ml gel. The DNA 
samples were mixed with 5 x loading buffer before loading them into the slots. 
 
5x loading buffer  
Orange G      0.2 % (w/v) 
Glycerol     60 % (v/v) 
EDTA       60 mM 
TAE      1x 
 
1x TAE 
TRIS/ HCl     40 mM 
Acetic acid     40 mM 
EDTA      1 mM 
pH 8.0 
 
The bands were visualized under UV light and photographed with a GeneFlash (SYNGENE, 
Cambridge, UK). As size standards pUC Mix DNA marker (MBI FERMENTAS, Nunningen, 
Switzerland) or 1 kb DNA ladder NEW ENGLAND BIOLABS (NEB, Beverly, US-MA) were 
used, depending on the analyzed fragment length. For cloning of fragments, the bands of 
interest were excised with a scalpel under UV light. The UV irradiation was kept as short as 
possible because prolonged exposure to UV damages DNA. 
The DNA was purified from the gel with the Gel Extraction Kit according to the 
manufacturers’ instructions. 
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2.2.5.5. Isolation of total cellular RNA from eukaryotic cells 
For mRNA collection from murine B16 melanoma, minced tumors were transferred to 
Eppendorf tubes filled with 350 µl RLT lysis buffer (QIAGEN), 10 µl 14.3 M β-
Mercaptoethanol (SIGMA) and iron beads. The tubes were incubated for 60 min at 300 rpm 
in a thermomixer (EPPENDORF) and RNA was isolated using the Qiagen RNeasy kit 
(QIAGEN) following manufacturers’ instructions. 
For mRNA collection of in vitro cell cultures, supernatants were removed and cells were 
washed twice with cold PBS. RNA was isolated using the Qiagen RNeasy kit following 
manufacturers’ instructions.  
The RNA concentration of the samples was determined with a UVS-99 Micro-Volume 
Spectrophotometer. Samples were stored at -20 °C. 
 
2.2.5.6. Preparation of cDNA by reverse transcription 
Synthesis of cDNA from total cellular RNA was performed using the RevertAid First Strand 
cDNA Synthesis Kit (THERMO FISHER SCIENTIFIC) according to the manufacturers’ 
instructions: 
 
RNA-Hexamer solution 
RNA      1 µg 
Random Hexamer Primer  1 µl 
H2O      add. 12 µl 
 
The RNA-Hexamer mix was incubated for 5 min at 65 °C in a TProfessional Thermocycler 
(BIOMETRA, Göttingen, Germany) and then placed on ice.  
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Reverse Transcriptase solution 
5x Reaction buffer    4 µl 
RiboLock RNase inhibitor  1 µl 
(40 U/µL) 
10mM dNTP Mix   2 µl 
RevertAid Reverse Transcriptase  1 µl 
(200 U/µL) 
 
RNA-Hexamer solution and Reverse Transcriptase solution were mixed gently by tapping the 
tube. The mixture was briefly spinned down and proceeded in the thermocycler for 5 min at 
25 °C, for 60 min at 42 °C and for 5 min at 70 °C. Samples were stored at -20 °C. 
 
2.2.5.7. Quantitative Real-time PCR (qRT-PCR) 
Relative quantification of gene expression at the RNA level was performed using FastStart 
Universal SYBR Green Master (ROCHE). The real-time PCR was performed with cDNA from 
total cellular RNA or from tissue RNA and a primer pair designed to a fragment of ~150 bp in 
length flanking an intron-exon border of the desired gene. To quantify the relative expression 
level of a certain gene, two reaction mixes were prepared. One contained the primer pair 
targeting the gene of interest, the other contained a primer pair targeting an internal 
reference gene (RPL27). The following mixture was prepared on ice in 0.1 ml MicroAmp® 
Fast Optical 96-Well Reaction Plates (LIFE TECHNOLOGIES): 
 
Real-time PCR reaction mix 
Template cDNA    ~5 – 100 ng 
5`-Primer (3.75 µM)   0.66 µl 
3`-Primer (3.75 µM)   0.66 µl 
SYBR Green Master    5 µl 
ddH2O     add. 10 µl 
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The PCR reaction and detection were performed in the ViiA™ 7 Real-Time PCR System 
(LIFE TECHNOLOGIES) according to the manufacturers’ instructions. The following 
temperature program was applied: 
 
Real-time PCR program 
First denaturation step  10 min  95 °C 
Denaturation step   10 s  95 °C        40 cycles 
Primer annealing and extension 30 s  58 °C         
     15 s  95 °C        dissociation curve 
     20 s  60 °C 
     15 s  95 °C 
 
Specificity of the reaction was ensured by surveying the dissociation curve of a given primer 
pair. Data processing was performed using the ViiA™ 7 Real-Time PCR System software 
(LIFE TECHNOLOGIES) provided by the manufacturers according to the guidelines. 
Expression of mRNA (relative) was normalized to the expression of RPL27 mRNA by the 
change in cycling threshold (ΔCT) method and calculated based on 2−ΔΔCT.  
 
2.2.5.8. MeDIP analysis 
MeDIP analysis of four melanoma cell cultures taken from GSE57971. Acquisition and 
analysis was performed using Nimblescan 2.5 and R package DMR (ROCHE NIMBLEGEN 
INC, Madison, US-WI). A log2 ratio > 1 and FDR adjusted p-value < 0.05 was deemed to be 
significant. 
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2.2.6. General protein methods 
2.2.6.1. Enzyme-linked immunosorbent assay (ELISA) 
Cell culture supernatants were collected at indicated time points and analyzed for presence 
of secreted human IL-1β by ELISA with an ELISA kit from R&D Systems (Minneapolis, US-
MN) according to the manufacturer’s instructions. 
To determine the concentration of HMGB1 in the serum of healthy donors, primary 
melanoma patients and melanoma patients with metastasis, serum samples were analyzed 
using an ELISA kit for HMGB1 (IBL INTERNATIONAL, Hamburg, Germany) according to the 
manufacturers’ instructions.  
To determine the concentration of released HMGB1 from in vitro cell cultures, supernatants 
were centrifuged at 1’500 g for 5 min at 4 °C and analyzed using the HMGB1 ELISA kit 
according to the manufacturers’ instructions.  
Optical densities were measured by the Spectra Max190 plate reader (MOLECULAR 
DEVICES) at a wavelength of 450 nm using the Softmax software. 
 
2.2.6.2. Determination of protein concentration 
Protein concentration of a solution was determined by the BCA protein assay (PIERCE, 
Rockford, US-IL). The assay was performed in duplicates according to the manufacturers’ 
instructions using 96-well plates and a BSA serial dilution in the appropriate buffer for the 
standard curve. Optical densities were measured by the SpectraMax190 plate reader 
(MOLECULAR DEVICES) at a wavelength of 562 nm and protein concentrations were 
calculated using the Softmax software. 
Alternatively, optical density at 280 nm was determined by a UVS-99 Micro-Volume 
Spectrophotometer according to the manufacturers’ instructions. 
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2.2.6.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate proteins according to their size by SDS-PAGE, the buffer system of Laemmli [1] 
was used. This contains glycine as a zwitter ion. The electrophoresis was carried out in 
vertical direction using the SE 250 mini gel system (AMERSHAM) in 1 mm thick 
polyacrylamide gels of appropriate acrylamide concentration depending on the protein size. 
The gel contains a 1 cm long 5 % stacking gel and a 6 cm long 8 – 20 % separating gel. 
Before loading the samples, they were mixed with an equal volume of 2 x sample loading 
buffer and incubated for 5 min at 95 °C. Electrophoresis was performed at 75 V until the 
loading dye reached the separating gel and then at 100 – 140 V until the loading dye 
reached the bottom of the gel. Prestained protein molecular weight marker (MBI 
FERMENTAS) was used in all gels. 
 
Separating gel (5 % Acrylamide)  
 % Acrylamide    8 %   10 %   12.5 %     15 %    18 %    20 % 
Acrylamide/ bisacrylamide 11.4 ml 13.3 ml 16.8 ml 20.0 ml 23.0 ml 24.2 ml 
TRIS/ HCl (1M, pH 8.8) 15.0 ml 15.0 ml  15.0 ml 15.0 ml 15.0 ml 15.0 ml    
ddH2O 13.4 ml 11.5 ml 7.4 ml 4.2 ml 1.2 ml - 
SDS (10 % [w/v]) 400 µl  400 µl  400 µl 400 µl 400 µl 400 µl    
APS (20 % [w/v]) 200 µl  200 µl  200 µl 200 µl 200 µl 200 µl    
TEMED 16 µl  16 µl  16 µl 16 µl 16 µl 16 µl     
 
Stacking gel (5 % Acrylamide) 
Acrylamide/ bisacrylamide (30:0.8)  2.7 ml 
TRIS/ HCl (1 M, pH 6.8)   2.0 ml 
ddH2O      10.8 ml 
SDS (10 % [w/v])    160 µl 
APS (20 % [w/v])    80 µl 
TEMED     16 µl  
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SDS-PAGE running buffer 
TRIS/ HCl (pH 8.0)    25 mM 
Glycine     192 mM 
SDS      10 % (v/v) 
 
2x sample loading buffer 
TRIS/ HCl (pH 8.0)    100 mM 
Glycerol     20 % (v/v) 
SDS      10 % (v/v) 
Bromphenol blue    0.01 % (w/v) 
DTT (1 M)     20 % (v/v) 
 
2.2.6.4. Western blot 
For the detection of specific proteins by western blotting, electrophoretically separated 
proteins were transferred onto a nitrocellulose membrane. After blocking of unspecific 
binding sites, the membrane was incubated with the primary and the corresponding 
secondary antibody. Secondary antibodies are coupled to an enzyme that catalyzes the 
detection reaction. 
 
2.2.6.4.1. Protein transfer by semi-dry blotting 
Three sheets of Whatman 3MM paper (WHATMAN, Maidstone, England) were soaked in 
anode buffer I and placed on the anode side of the blotting apparatus. Two sheets of 
Whatman paper were soaked in anode buffer II and place on top of the first sheets. The 
nitrocellulose membrane (SCHLEICHER & SCHUELL, Dassel, Germany) was equilibrated in 
anode buffer II and subsequently placed onto the Whatman papers, followed by the gel, 
which was carefully pressed onto the membrane to avoid air bubbles in between. Finally, 
three sheets of Whatman paper soaked in cathode buffer were place on top of the gel. 
Blotting was performed in a semi-dry blotter (Z340502, SIGMA) at 75 mAmp per gel for 
30 min. 
 
 
108 Materials and Methods 
 
Anode buffer I 
Methanol     20 % (v/v) 
TRIS/ HCl     300 mM 
 
Anode buffer II 
Methanol     20 % (v/v) 
TRIS/ HCl     25 mM 
 
Cathode buffer  
Methanol     20 % (v/v) 
TRIS/ HCl     25 mM 
ε-Aminocaproic acid    40 mM 
 
2.2.6.4.2. Incubation with antibodies and visualization of protein bands 
Unspecific binding sites were blocked with 3 % milk powder (MIGROS, Zurich, Switzerland) 
in PBST (blocking solution) for at least 30 min. The membranes were then incubated with the 
primary antibody in blocking solution overnight at 4 °C. After washing three times in PBST for 
5 min, the membranes were incubates with the corresponding secondary antibody in 
blocking solution for 30 min at RT. Secondary antibodies were coupled to alkaline 
phosphatase (AP). After incubation, the membranes were washed three times for 5 min. 
AP detection was performed using the NBT/ BCIP substrate kit (PROMEGA). The membrane 
was washed once with AP buffer and incubated in AP buffer containing 33 µl BCIP and 66 µl 
NBT per 10 ml of buffer. Reaction was stopped with H2O when desired band intensities were 
obtained. 
 
AP buffer  
TRIS/ HCl (pH 9.5)    100 mM 
NaCl      100 mM 
MgCl2      5 mM 
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2.2.6.5. Imaging of blots and stained gels 
Blots were scanned using the CanonScan 9950F device (CANON, Tokio, Japan Images 
were acquired with 150 – 300 dpi resolution without filters or other altered acquisition 
settings. Digital image processing was performed using Photoshop software (various 
versions, ADOBE SYSTEMS SOFTWARE, San Jose, US-CA). Processing was restricted to 
cutting. When the observed bands in the original blots were too weak for meaningful digital 
and print reproduction, brightness and contrast adjustments were applied to the whole image 
until the scientific result reflected the one seen on the original blot. 
 
2.2.6.6. Statistical analyses 
Unless otherwise indicated, data are presented as the means ± standard error of the mean 
(SEM) and are representative of three independent experiments. Statistical analysis and 
graphic presentation of the results was performed using the Prism Software (GRAPHPAD 
SOFTWARE, San Diego, US-CA). P-values were calculated with the unpaired Student’s t 
test. Differences were considered significant when: * P≤0.05, ** P≤0.001, *** P≤0.0001 and 
**** P≤0.00001. 
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To the Editor 
 
Tumors secrete pro-inflammatory cytokines, chemokines, and other soluble factors in the 
microenvironment. Interleukin-1β (IL-1β) is a pleiotropic pro-inflammatory cytokine involved in 
cell growth, differentiation, and regulation of immune responses [1]. IL-1β is often detected in 
human cancer tissues including breast cancer, pancreatic cancer, and glioblastoma [2]. It 
has been reported that the expression levels of the IL-1β gene or protein are associated with 
the invasiveness and metastasis of cancers [3]. On the other hand, IL-1β production from 
tumor cells may be considered as a threat by the host's immune system. In this aspect, it has 
been reported that IL-1β-producing melanoma cells induce reduced tumor growth by 
recruiting immune cells [4]. Therefore, melanoma cells must have a precise mechanism of IL-
1β regulation but it remains largely unknown. 
 
IL-1β is first synthesized as a biologically inactive precursor (pro-IL-1β). Pro-IL-1β is then 
cleaved by caspase-1 to biologically active mature IL-1β, resulting in its release into the 
extracellular space [1]. Therefore, we first analyzed IL-1β production from melanoma cell 
lines. THP-1 macrophages and melanoma cells were primed or not with phorbol-12-
myristate-13-acetate (PMA, 500 nM) and exposed to the IL-1β inducer ionomycin (1.5 mM). 
Under these conditions and in contrast to THP-1 monocytic cells, 13 metastatic melanoma 
cell lines were not able to secrete IL-1β (Figure 1a). Inflammasomes are a multi-protein 
complexes whose assembly and activation are responsible for the processing of caspases-1 
and -5 [1]. The NOD-like receptor pyrin domain containing-3 (NLRP3) inflammasome has 
been the most studied inflammasome to date. This high molecular weight complex is 
composed of NLRP3, apoptosis-associated speck-like protein containing a CARD domain 
(ASC) adaptor protein, and the cysteine protease caspase-1 [1]. Assembly of the NLRP3 
inflammasome activates caspase-1, which mediates maturation of proinflammatory cytokines 
such as IL-1β and IL-18. 
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Figure 1. Metastatic melanoma cells are not able to secrete IL-1β 
(a) IL-1β secretion by THP-1 macrophages and A375 and Mamel82 metastatic human melanoma cell lines by 
analyzing supernatants from their culture by ELISA (R&D Systems, Minneapolis, MN). N.D. not detected. 
(b) mRNA expression of ASC, NLRP3, caspase-1, pro-IL-1β, pro-IL-18, and GAPDH in THP-1 and metastatic 
melanoma cell lines. Total RNA from THP-1 cells and metastatic melanoma cell lines (A375, Me191, Me290, and 
MaMel82) was isolated with an RNeasy Mini Kit (QIAGEN, Hilden Germany). RT-PCR was performed with a 
thermal cycler (Biometra, Gottingen, Germany).  
(c) Evaluation of the expression of inflammasome components and IL-1β in primary (n = 6) and metastatic 
(n = 21) melanoma cell lines by RT-PCR.  
(d) MeDIP analysis of four melanoma cell cultures. Two melanoma cell cultures, M010817 and M000921 were 
significantly methylated in the promoter region of ASC having a log 2 ratio >1 of methylated DNA compared to 
input. The other two-melanoma cell cultures, M990115 and M010119, were not significantly methylated in the 
promoter region of ASC.  
(e) A375 human metastatic melanoma cells were treated with 2.5 mM AZA for 24 h and ASC expression was 
assessed by RT-PCR and  
(f) Western blotting. All data are presented as mean ± SD and are representative of two experiments. P-values 
were calculated with Wilcoxon singled-rank test. *p < 0.05. 
 
To address the expression levels of inflammasome components in metastatic melanoma 
cells, we performed reverse transcription polymerase chain reaction (RT-PCR) analyses. In 
contrast to THP-1 cells, one or several inflammasome components were not expressed in 
A375, Me191, and Me290 metastatic melanoma cell lines [5, 6] (Figure 1b). In addition, pro-
IL-1β and pro-IL-18 transcripts were not detected in Me191 and Me290 cells (Figure 1b). To 
further determine the expression pattern of inflammasome components in melanoma cells, 
we used 6 primary and 21 metastatic melanoma cell lines as reported previously 
(Supplemental Tables 1 and 2) [5, 6]. One hundred percent of cell lines derived from primary 
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melanomas expressed ASC. In contrast, only 19 percent of cell lines derived from metastatic 
melanomas expressed ASC (Figure 1c). Also, caspase-1, NLRP3, IL-1β, and AIM2 were 
expressed in a lower proportion of metastatic melanoma cell lines when compared to cell 
lines derived from primary melanoma cell lines (Figure 1c). In tumors, ASC expression is 
inversely correlated with the methylation status of the ASC promoter region [7]. Analysis of 
the methylation profile of ASC by MeDIP [8] revealed that 2 out of 4 tested cell lines had a 
methylated ASC-promoter (Figure 1d). M000921 and M010817 [5, 6] were found to have 
DNA methylation in the promoter region of ASC but not M990115 and M010119 [5, 6]. ASC 
expression was then assessed by qRT-PCR and showed to inversely correlate with ASC 
methylation (data not shown). Consistently with this observation, a treatment with the 
demethylating agent AZA (2.5 μM) induced the restoration of ASC expression as observed 
by RT-PCR (Figure 1e) and western blotting (Figure 1f). These results suggest that most of 
metastatic melanoma cell lines did not secrete IL-1β because of the lack of one or more 
inflammasome components, and DNA methylation is one of the mechanisms that can silence 
the expression of these components. 
 
Macrophages are potent producers of IL-1β and reported to be present in the melanoma skin 
lesion [9]. Necrotic melanoma cells are often found in cutaneous melanomas of patients with 
progressive disease [10] and may be a source of DAMPs sensed by NLRs [1]. Therefore, we 
next analyzed whether necrotic melanoma cells promote IL-1β production from 
macrophages. The soluble fraction and debris from necrotic A2058, and A375 melanoma cell 
lines promoted IL-1β production from human primary monocytes in a dose-dependent 
manner (Figure 2a). We also show that IL-1β production from THP-1 macrophages was 
detected after adding soluble fraction or debris from necrotic melanoma cells (Figure 2b). A 
pre-treatment of THP-1 cells with the caspase inhibitor Z-VAD-fmk (Z-VAD) (5 μM) prior to 
exposure to the soluble fraction or debris from necrotic A375 melanoma cells significantly 
suppressed IL-1β production (Figure 2c), suggesting a caspase-dependent mechanism. To 
further confirm that IL-1β production from THP-1 cells depends on inflammasome activation, 
we generated ASC, caspase-1, and NLRP3 knock-down THP-1 macrophages. All THP-1 
cells transduced with either ASC-shRNA, NLRP3-shRNA or caspase-1-shRNAs showed a 
dramatic decrease of IL-1β production compared to control lamin-shRNA THP-1 (Figure 2d), 
demonstrating that IL-1β release upon exposure to products of necrotic melanoma cells 
depends on the NLRP3 inflammasome. Finally, we examined IL-1β expression in nevi, 
superficially spreading melanomas (SSM), nodular melanomas (NM), and skin metastases of 
melanoma by immunohistochemistry. IL-1β positive cells were not detected in nevi and SSM, 
whilst they were in NM and skin metastasis of melanoma (Figure 2e). Consistent with in vitro 
experiments, these IL-1β positive cells were melanophages but not melanoma cells. 
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Figure 2. Necrotic melanoma cells promote IL-1β secretion from macrophages 
 (a) Human primary monocytes were exposed to different proportions of necrotic cells (A2059/A375 human 
metastatic melanoma) per for 24 h and IL-1β secretion was measured in the supernatant with ELISA. Necrotic 
products of cells were separated between soluble and debris fraction.  
(b) THP-1 macrophages were treated with inflammasome activators (MSU, 150 μg/ml and Nigericin, 5 μM), or 
necrotic (debris or supernatant?) A375 metastatic human melanoma cell line for 6, 12, and 24 h and IL-1β 
secretion was measured in the culture supernatant with ELISA.  
(c) THP-1 cells pre-treated with ZVAD for 30 min were incubated with necrotic A375 for 24 h and IL-1β secretion 
was measured in the supernatant with ELISA.  
(d) NLRP3, ASC and caspase-1 knock down THP-1 were incubated with necrotic soluble of A375 for 24 h and IL-
1β secretion was measured in the supernatants with ELISA and compared to the one of lamin knock down 
exposed to DMSO (vehicle) or ZVAD. All IL-1β ELISA data are presented as mean ± SD and are representative of 
two experiments. P-values were calculated with Wilcoxon singled-rank test. *p < 0.05. 
 
In summary, we demonstrate that the inability of metastatic melanoma cells to secrete IL-1β 
is due to the lack of expression of one or more inflammasome components. On the other 
hand, one or more factors originating from necrotic melanoma cells can promote IL-1β 
production by macrophages. Taken together, metastatic melanoma cells seem to have lost 
the ability for IL-1β production whereas macrophages of the microenvironment secrete high 
amounts of IL-1β in response to putative danger signals released by necrotic tumor cells. It 
has been reported that the expression levels of the IL-1β protein are associated with the 
invasiveness and metastasis of cancers. In this respect, IL-1β is an important factor for the 
expansion of metastatic melanoma. However, the cellular source of IL-1β in tumors is not 
clear. Here, we demonstrate that IL-1β is produced by macrophages upon stimulation with 
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danger signals from necrotic melanoma cells. Although not being able to produce IL-1β 
themselves, tumor cells may benefit from IL-1β release by macrophages present in the 
micro-environment. A better understanding of the mechanisms and consequences of IL-1β 
production by infiltrating macrophages may be of interest for the development of IL-1β 
targeted therapy, such as anti-IL-1β antibody (Canakinumab), of metastatic melanoma. 
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Supplementary figures 
 
Supplemental table 1. Expression of IL-1β and inflammasome components in primary 
melanoma cell cultures as detected by RT-PCR. 
Cell line ASC Caspase-1 NLRP3 IL-1β 
M080729 + + + + 
M971219 + + + + 
M990203 + + + + 
M080326 + + + - 
M070112 + + + + 
M060621 + + + + 
 
 
Supplementary table 2. Expression of IL-1β and inflammasome components in metastatic 
melanoma cell lines as detected by RT-PCR. 
Cell line ASC Caspase-1 NLRP3 IL-1β 
M010817 - + + - 
M82 + - + - 
M000921 - + + + 
MaMel82 + + + + 
M080221 - + + + 
M080228 - + + + 
M010119 - + + + 
M060125 - + + + 
M990115 - + + + 
Me191 + - + - 
WM134.1 - + + + 
A375 - + + + 
Me290 - - - - 
A2058 - + + + 
M080221 - + + - 
M080306 - + + + 
M080423 - - - - 
M080904 + + + + 
M080904B - - + - 
M081021 - + + - 
M081028 - + + - 
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Abstract 
High-mobility group protein B1 (HMGB1) is a highly conserved DNA-binding protein that can 
be released passively by damaged or dead cells or actively by immune cells and stressed 
cancer cells. It then acts as a DAMP or an alarmin, linking tissue damage and stress to 
activation of innate immune responses. Extracellular HMGB1 can then activate cytokine 
release to accelerate inflammatory responses and tumor development. Here, we investigated 
the role of HMGB1 in melanoma. We observed that HMGB1 promotes the accumulation of 
M2 macrophages via CXCR4 and promotes IL-10 production from M2 macrophages, which 
led to melanoma progression. We therefore identified the HMGB1-M2-macrophage axis as a 
key player in melanoma progression and a possible therapeutic target for metastatic 
melanoma. 
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Introduction 
HMGB1 protein is a highly conserved DNA-binding protein with 98.5% sequence homology 
across mammals involved in gene expression and chromatin remodeling [1, 2]. HMGB1 can 
be actively secreted, or passively released upon cell damage, to stimulate immune 
responses either alone or in conjunction with other molecules [3]. The translocation of 
HMGB1 and its subsequent secretion can occur in several situations such as the activation 
of immune cells, including macrophages, cell death (necrosis and apoptosis) and 
ischemia/reperfusion injury. HMGB1 then acts as a DAMP) or an alarmin [4], linking tissue 
damage and stress to activation of innate immune responses. Notably, HMGB1 has been 
reported to be involved in diseases in which chronic inflammation plays a role, such as 
arthritis and cancer [3-6]. 
HMGB1 induces signaling through the binding to the Receptor for Advanced Glycation End 
products (RAGE) and certain Toll-like receptors (TLRs) [7]. The binding of HMGB1 to LPS is 
thought to enhance the production of proinflammatory cytokines via activation of TLR4, the 
signaling receptor for LPS/CD14 [8]. In addition, secreted HMGB1 exerts cytokine-like 
activity through TLR2 and RAGE [7]. Several reports also suggest that the binding of 
immunogenic nucleic acids to HMGB1 is required for subsequent recognition by specific 
pattern-recognition receptors like TLR3, TLR7 and TLR9 and activation of innate immune 
responses [9]. 
Neoplastic transformation, tumor growth, invasion and metastases can be induced by tumor-
infiltrating cells that create an inflammatory tumor microenvironment. Activated 
macrophages, T cells, but also tumor cells themselves secrete HMGB1 under hypoxia, injury 
or inflammatory stimuli [10]. In addition, it has been recently reported that myeloid-derived 
suppressive cells (MDSC) present in tumors secrete HMGB1 [11].  
Extracellular HMGB1 can then activate cytokine release to accelerate inflammatory 
responses and tumor development. HMGB1 has been shown to be released by mesothelial 
cells exposed to asbestos and erionite and is implicated in malignant mesothelioma 
development in an autocrine manner [10, 12, 13]. In a DMBA/TPA-induced skin 
carcinogenesis model, mice deficient for RAGE, a known receptor of HMGB1, are more 
resistant to inflammation and tumor formation [14]. Also, the blockade of HMGB1-TLR4 
interaction impairs the recruitment of inflammatory cells that contribute to tumor development 
in skin and colon cancers [15]. 
Here, we show that HMGB1, when released by tumor cells in hypoxic conditions and binding 
to RAGE, induces the accumulation of M2 macrophages promoting melanoma progression. 
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Results 
HMGB1 is released in metastatic melanoma patients 
We first determined HMGB1 concentration in the serum of patients with primary and 
metastatic melanoma patients and age-matched healthy volunteers as controls. Serum 
HMGB1 levels were significantly increased in the serum of patients with primary melanoma 
when compared to healthy donors and was further increased in patients with metastatic 
melanoma (Fig. 1a). HMGB1 is usually located in the nucleus and a cytoplasmic 
relocalization occurs prior to its release [10]. Therefore, we assessed the intra-cellular 
localization of HMGB1 in nevi, primary melanoma (superficial spreading melanoma) and 
melanoma metastases. While HMGB1 was confined to nuclei in nevi and primary 
melanomas, melanoma metastases exhibited large areas containing tumor cells with 
cytoplasmic HMGB1 which co-localized with Hif-1α-positive tumor areas, indicating that 
HMGB1 is released by cells in hypoxic conditions (Fig. 1b). Hypoxia in tumors is associated 
with advanced malignant progression and resistance to therapies by enhancing genetic 
diversity and exerting a selective pressure [16] and HMGB1 is known to be released in 
hypoxia/ischemia conditions [17]. To assess whether metastatic melanoma cell lines release 
HMGB1 in hypoxia, we cultured them in normal or low oxygen atmosphere and measured 
HMGB1 release in the culture supernatant. When compared to their counterparts kept in 
normoxia, all the tested melanoma cell lines (n=7) secreted increased levels of HMGB1 when 
kept in hypoxic conditions, the latter being confirmed by increased VEGF-A expression [18] 
(Fig. 1c). In hypoxic conditions, no increase in cell mortality was observed as revealed by the 
low LDH release. 
These observations indicate that HMGB1 is released by hypoxic tumor cells in metastatic 
melanoma patients. 
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Figure 1. HMGB1 is released by hypoxic tumor areas 
(a) HMGB1 was measured by ELISA in the serum of healthy individuals (n=10), patients with primary (n=9) and 
metastatic melanoma (n=11). Means +/- SEM are presented. * P<0.05. 
 (b) Immunofluorescence using antibodies to Hif-1α and HMGB1 was performed on healthy skin, nevi, primary 
cutaneous melanoma and metastases as indicated.  
(c) Cells lines derived from metastases were cultured under normoxic or hypoxic conditions. As a hypoxia marker 
VEGF-A qPCR was performed after the culture period (top panels) and the viability of cells cultured in normoxia 
and hypoxia was assessed by LDH release assay (middle panels). HMGB1 release was assessed by ELISA in 
culture supernatants (bottom panels). Means +/- SEM are presented. * P<0.05, **** P<0.0001.  
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Silencing of HMGB1in B16 melanoma cells led to delayed tumor growth  
To assess whether HMGB1 plays a role in melanoma growth, we transduced B16 melanoma 
cells with shRNA to HMGB1 or with shRNA to lamin as an irrelevant control. The HMGB1 
knock-down efficiency was highly stable both in vitro and in vivo (Fig. S1). HMGB1-shRNA-
transduced B16 and lamin-shRNA-transduced B16 were injected sub-cutaneously in 
C57BL/6 mice. Mice having received HMGB1-shRNA-transduced B16 exhibited a 
dramatically delayed tumor growth when compared to mice having received lamin-shRNA-
transduced B16 (Fig. 2a, left panel and Fig. S2). Such a growth delay was not due to intrinsic 
effect of shRNA transduction as revealed by the identical in vitro growth capacity of HMGB1- 
and lamin-shRNA-transduced B16 and the absence of abnormal apoptosis (Fig. S3). To 
assess the effect of extracellular HMGB1 on tumor growth, we next treated mice having 
received lamin-shRNA-transduced B16 with a recombinant HMGB1 inhibitor (BoxA) in an 
independent set of experiments. The treatment of tumor-bearing mice with BoxA also 
resulted in a delayed tumor growth compared to mice treated with vehicle (Fig. 2a, right 
panel). We next evaluated the role of HMGB1 in metastasis by injecting either HMGB1-
shRNA-transduced B16 cells or lamin-shRNA-transduced B16 cells i.v. into wild type mice. 
After 13 days, mice having received HMGB1-shRNA-transduced B16 cells exhibited 
significantly less lung metastases when compared to mice having received the lamin control 
(Fig. 2b).  
Next, we assessed the intra-cellular localization of HMGB1 in B16 tumors using lamin-
shRNA-transduced B16 tumors. In the large hypoxic areas found in the center of the tumors 
(Fig. 2c), cytoplasmic HMGB1 was also observed in Hif-1α positive cells, whereas nuclear 
HMGB1 was restricted to Hif-1α negative cells, which is in line with our observations in 
human melanomas (Fig. 2d).  
Taken together, these results suggest that extracellular HMGB1, released by cells in hypoxic 
conditions promotes B16 melanoma growth. 
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Figure 2. HMGB1 released by hypoxic tumor areas promotes tumor growth and metastasis  
(a) Tumor growth in C57BL/6 mice having received 1x10e5 B16 cells transduced with shRNA to HMGB1 or 
shRNA to lamin (left panel) and tumor growth in C57BL/6 mice having received 1x10e5 B16 cells transduced with 
shRNA to lamin and treated from day 0 with a BoxA recombinant HMGB1 inhibitor (right panel) ** P<0.01, *** 
P<0.001, **** P<0.0001. 
(b) B16 cells transduced with shRNA to HMGB1 or shRNA to lamin were injected i.v. to C57BL/6 mice and lung 
metastases were counted after 10 days. A macroscopic view (left panel) and the numeration of metastases in the 
lungs (n=4) are shown. Results are expressed as means +/- SEM.  
(c) Immunohistochemistry using an antibody to Hif-1α was performed on 1 cm2 tumors. (d) Immunofluorescence 
analysis of Hif-1α and HMGB1 in B16 cells transduced with shRNA to lamin. 
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HMGB1 drives M2 macrophage infiltrates  
We next analyzed tumor-infiltrating immune cells by flow cytometry. The total number of 
infiltrating macrophages was increased in HMGB1-shRNA-transduced B16 tumor whereas 
the total number of neutrophils was decreased in HMGB1-shRNA-transduced B16 tumor 
(Fig. 3a). To assess the phenotype of macrophages infiltrating HMGB1-shRNA- and lamin-
shRNA-transduced B16 tumor, we measured the expression of markers distinguishing M1-
like and M2-like macrophage subpopulations [19]. Quantitative PCR of macrophages 
accumulating at the tumor site revealed that the silencing of HMGB1 in B16 was associated 
with the overexpression of M1 marker (CD80) whereas the expression of HMGB1 was 
associated to the upregulation of M2 markers (YM1, Fizz1, and IL-10) (Fig. 3b). These 
results suggest that HMGB1, when released by tumor cells, promotes M2 infiltrates. 
 
Figure 3. HMGB1 induces the recruitment of macrophages harboring an M2 phonotype  
(a) Macrophage and neutrophil infiltrates in tumors with similar size are shown. Left panel, representative flow 
cytometry pictures (left panels) and numeration of total macrophages and neutrophils in mice having received B16 
cells transduced with shRNA to lamin (n=7) or to HMGB1 (n=7). Means +/- SEM are presented.* P<0.05, ** 
P<0.01.  
(b) Quantification of M1- and M2-specific gene expression by qPCR in primary s.c. tumors form mice having 
received B16 cells transduced with shRNA to HMGB1 (shHMGB1, n=5) or shRNA to lamin (shLamin, n=5). 
Means +/- SEM are presented. * P<0.05. 
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HMGB1 induces CXCR4 expression in M2 macrophages 
TAMs have been reported to be biased towards the M2 phenotype in advanced tumors [20-
22] and the above results suggest that HMGB1 favors the accumulation of M2-like 
macrophages at the tumor site. Therefore, we analyzed the effect of HMGB1 on M2 
macrophages. To this end, we generated M1-like and M2-like macrophages from bone 
marrow (BM) and exposed them to recombinant HMGB1. BM-derived M2 macrophages 
(BMM2) showed an up-regulated CXCR4 expression while CXCR4 expression in BM-derived 
M1 macrophages (BMM1) was not affected by recombinant HMGB1 (Fig. 4A). Interestingly, 
CXCR4 has an essential role in tumor metastasis [23] and it has been recently reported that 
HMGB1 promotes the recruitment of inflammatory cells to damaged tissues by forming a 
complex with CXCL12 and signaling via CXCR4 [24]. 
 
 
 
Figure 4. HMGB1 induces CXCR4 and IL-10 expression in murine M2 macrophages in a RAGE-dependent 
manner.  
(a) CXCR4 mRNA expression in in vitro-differentiated murine M1 and M2 macrophages exposed to recombinant 
HMGB1 or not. Shown is the expression relative to RPL27.  
(b) IL-6, TNF, IL-10 and IL-1β mRNA expression in murine M2 macrophages exposed to recombinant HMGB1 or 
not. Shown is the expression relative to RPL27.  
(c) IL-10 mRNA expression in in vitro-differentiated M2 macrophages from WT, Tlr2-/-, Tlr4-/- and Rage-/- mice. 
Shown is the expression relative to that of WT M2 macrophages not exposed to HMGB1. 
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HMGB1 induces IL-10 in M2 macrophages through RAGE 
The tumor microenvironment, including the cytokine milieu, plays a central role in tumor 
progression [25, 26]. Therefore, we evaluated the effect of HMGB1 on cytokine expression 
by M2 macrophages. IL-10 expression was significantly increased in M2 macrophages when 
incubated with recombinant HMGB1 (Fig. 4B). Such IL-10 upregulation was not observed in 
BMM2 from RAGE-/- mice while it was retained in TLR2-/- and TLR4-/- BMM2 (Fig. 4C). This 
data suggests that HMGB1 induces IL-10 in M2-like macrophages through RAGE signaling. 
To assess the tumor-promoting effect of IL-10-producing M2-like macrophages, mice bearing 
lamin-shRNA transduced B16 tumors were treated with an anti-IL-10 neutralizing antibody. 
Mice receiving anti-IL-10 exhibited a significantly delayed tumor growth when compared to 
vehicle-treated mice (Fig. 5B). Together, these results indicate that IL-10 producing M2 
macrophages infiltrating the tumors are key players in tumor progression. This was further 
supported by the presence of IL-10-producing M2 macrophages in human metastatic 
melanomas as revealed by the presence of CD163+ IL-10+ cells in human metastases 
infiltrates (Fig. 5A). 
To evaluate the relevance of the above observations, we analyzed human melanomas by 
immunohistochemistry using anti-CD163, an M2 marker, and anti-IL-10 antibodies. In 
melanoma metastases, CD163+ IL-10+ cells were found in the infiltrates.   
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Figure 5. IL-10 is present in M2-rich areas of metastases and favors melanoma growth 
(a) Immunofluorescence analysis of nevi and metastases using anti-CD163 and anti-IL-10 antibodies.  
(b) Tumor growth in C57BL/6 mice having received 1 x 105 B16 cells transduced with shRNA to HMGB1 or shRNA 
to lamin treated or not with an anti-IL-10 blocking antibody (N=7/group). 
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Supplementary figures 
 
 
Supplementary figure 1.  
HMGB1 knock-down efficiency is stable over time in vitro and in vivo 
 
 
Figure S1. HMGB1 knock-down efficiency is stable over time in vitro and in vivo 
(a) Cultures of B16 cells transduced with shRNA to lamin or HMGB1 were harvested, lysed and subjected to 
Western-blot analysis using anti-HMGB1 and anti-β-actin antibodies.  
(b) B16 cells transduced with shRNA to lamin or HMGB1 were injected s.c. to C57BL/6 mice and the resulting 
tumors were dissected at day 13 and stained with an anti-HMGB1 antibody. Nuclei were visualized using DAPI. 
Pictures are representative of 7 tumors/group. 
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Supplementary figure 2.  
Two different shRNA sequences to HMGB1 resulted in similar growth inhibition.  
 
 
 
 
Figure S2. Two different shRNA sequences to HMGB1 resulted in similar growth inhibition 
B16 cells were transduced with 2 different shRNA to HMGB1 (seq 1 and seq 2) and with shRNA to lamin and 
injected s.c. into C57BL/6 mice. Tumor growth was monitored every other day. * P < 0.05 
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Supplementary figure 3.  
The in vitro growth properties of B16 cells transduced with shRNA to lamin and HMGB1 are 
identical.  
 
 
 
 
Figure S3. The in vitro growth properties of B16 cells transduced with shRNA to lamin and HMGB1 are 
identical  
(a) B16 cells transduced with shRNA to lamin and HMGB1 were labelled with CFSE and collected 72 and 144 hrs 
later and analyzed in flow cytometry.  
(b) B16 cells transduced with shRNA to lamin and HMGB1 were counted over a 15-day culture period.  
(c) Proliferation of B16 cells transduced with shRNA to lamin (white histograms) and HMGB1 (black histograms) 
was assessed over a 3-day culture period using MTT assay.  
(d) At day 0, 3, 6 and 9, B16 cells transduced with shRNA to lamin (shLamin) and HMGB1 (shHMGB1) were 
harvested, stained with Annexin V and propidium iodide (PI) and analyzed in flow cytometry. Annexin V+/PI+ cells 
were considered as apoptotic. As control, WT B16 cells were treated with staurosporin, a strong apoptosis 
inducer.  
(e) Viability of B16 cells transduced with shRNA to lamin (white histograms) and HMGB1 (black histograms) was 
assessed over a 3-day culture period using LDH release assay. 
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In this work, we have studied two processes that are relevant to tumor-stroma interactions.  
 
First, we have shown that melanoma cell lines are not able to secrete IL-1β, due to a 
dysfunction in the inflammasome, explained in the majority of cell lines tested by methylation 
of the promotor region of the crucial inflammasome component ASC. Given that TAMs are 
present in melanomas and potent producers of IL-1β as judged by immunostaining, we 
further searched for stimuli for TAM IL-1β production and could identify that products 
released by necrotic melanoma cells in vitro are potent activators of the NLRP3 
inflammasome and mature IL-1β production. Thus, metastatic melanoma cells seem to have 
lost the ability for IL-1β production whereas macrophages of the microenvironment secrete 
high amounts of IL-1β in response to putative danger signals released by necrotic tumor 
cells. 
 
Second, and intrigued by the above finding that macrophages of the microenvironment 
secrete high amounts of IL-1β in response to putative danger signals released by necrotic 
tumor cells, we analyzed the functional role of a major DAMP/alarmin known to be released 
upon cell necrosis, namely HMGB1. We could show under hypoxic conditions melanoma 
cells release the DAMP/alarmin HMGB1 and HMGB1 then promotes the subsequent 
recruitment of TAM to the tumor microenvironment and furthermore significantly promotes 
tumor growth. Besides HMGB1, both the recruitment of TAM and the cytokine IL-10 are 
critical for tumor growth in the model studied.  
 
These two above studied events relevant to tumor-stroma interactions might not be exclusive 
and therefore co-exist within the same tumor. Their occurrence may also depend on the 
tumor type and its susceptibility to necrosis and hypoxia. The cancer stage may also 
influence one or both mechanisms. The two latter hypotheses require further investigation. 
 
Inflammation and cancer development appear to be indissociable biological processes. 
However, inflammation-driven carcinogenesis and cancer-induced inflammation should be 
distinguished. Indeed, inflammation appears not only to be a tumor-promoting condition, but 
also a consequence of tumor development. 
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There is evidence that chronic inflammation induced by persistent chemical, bacterial or viral 
insults is a risk factor for cancer [1]. It is also known that dysregulated inflammatory 
processes such as those seen in autoimmune diseases, or persistent repetitive tissue trauma 
may also result in an increased risk of cancer [2]. In established solid tumors, there is a 
reciprocal signaling interaction between cancer cells and stromal cells taking place in the 
tumor microenvironment. This local tumor microenvironment, comprising tumor cells, 
extracellular matrix, immune cells, cytokines and other factors, plays a key role in tumor 
formation, growth, invasion and metastasis. Tumors can secrete pro-inflammatory cytokines, 
chemokines, and other soluble factors into their microenvironment. The pro-inflammatory 
cytokine Interleukin-1β (IL-1β) is one of these cytokines. IL-1β is often detected in human 
cancers including breast cancer, pancreatic cancer, and glioblastoma [3]. It has been 
reported that IL-1β expression levels are associated with the invasiveness and metastasis of 
cancers [4]. In melanoma, IL-1β has been shown to induce chemokines that recruit 
proinflammatory cells [5], promote angiogenesis, and drive metastasis [6]. Interestingly, IL-1β 
has been reported to be expressed at lower levels in nevi when compared to primary and 
metastatic melanomas [5]. Furthermore, selected late stage melanoma cell lines (A375, 
HS294T, and 1205Lu) in vitro have been reported to spontaneously secrete IL-1β via 
constitutive activation of the NLRP3 inflammasome [7]. Alternatively, IL-1β production by 
tumor cells or cells in the tumor environment may be a danger signal for the host's immune 
system and trigger the recruitment immune cells to the tumor [8].  
Here, we showed that human melanomas contain high levels of IL-1β although melanoma 
cells in our hands themselves are not able to secrete IL-1β as observed in 13 cell lines 
tested. Indeed, a great majority (80 %) of the metastatic melanoma cell lines we tested did 
not express the inflammasome adaptor ASC as a result of promoter methylation. Since, IL-1β 
secretion very early during tumorigenesis could be viewed as a danger signal and therefore 
promote host anti-tumor responses, the methylation of ASC may consists an effective 
mechanism developed by tumor cells to protect themselves in a situation where the tumor 
load is still low. Furthermore, we also observed that, when compared to primary 
melanocytes, the expression additional inflammasome components are also lost in 
metastatic melanoma cell lines tested. We thus hypothesized that an important source of IL-
1β in established tumors may be cells within the tumor microenvironment. Macrophages are 
very potent IL-1β producers and known to be an important component of the inflammatory 
infiltrate in melanoma [9]. However, in order to be biologically active and secreted, IL-1β 
requires processing by the inflammasome, and thus TAMs would have to be exposed to 
DAMPs. We hypothesized that necrotic melanoma cells which are often found in advanced 
melanomas [10] may be a source of such DAMPs [11]. Our results show that necrotic 
melanoma cells are very potent IL-1β inducers in macrophages, but the exact DAMP(s) 
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released upon melanoma cell necrosis and responsible for IL-1β processing and release by 
macrophages was not identified.  
 
It appears that there are at least two subclasses of stimulatory immune cells in the tumor 
stroma. One subclass that participates in “normal” immunological/inflammatory activities 
(wound healing, innate and adaptive immune responses), and a second subclass comprising 
TAMs, neutrophils and myeloid progenitor cells that provoke exaggerated wound healing and 
pro-angiogenic responses suggested to promote cancer growth and suppression of anti-
tumor immunity [12]. 
TAMs have emerged as key components of the tumor environment relevant to tumor 
progression [13]. Indeed, the presence of TAMs has been associated with poor prognosis of 
several malignancies [14-17]. It has been proposed that monocytes continuously infiltrate 
tumors and that, once polarized, M2 macrophages preferentially accumulate in hypoxic 
regions of the tumor whereas M1 macrophages are not impacted by hypoxia [18, 19]. By 
promoting angiogenesis and metastasis, M2 polarized macrophages are thought to 
overcome the hostile hypoxic environment within tumors and sustain tumor progression [20, 
21]. However, the factors released by hypoxic cells involved in M2 macrophage recruitment 
remain poorly understood. Here, we show that HMGB1, released from tumor cells in hypoxic 
conditions, promotes the recruitment of M2 macrophages through CXCR4 and RAGE. 
Indeed, our observation that, in B16 tumors, the expression and release of HMGB1 is 
associated with M2 macrophage infiltration and tumor growth and that inversely, reduced 
HMGB1 expression favors tumor predominance of M1 macrophages and a delayed tumor 
growth suggests a crucial role for HMGB1 in M2-dependent tumor progression. 
Nevertheless, we were not able to induce a phenotype switch of macrophages treated with 
HMGB1 in vitro, suggesting that a combination of several factors released by hypoxic cells, 
including HMGB1, is required for M2-macrophage polarization and accumulation. Indeed, a 
recent study showed that lactic acid, produced by tumor cells as a by-product of hypoxic 
glycolysis, has a critical function by inducing VEGF expression and M2-like polarization of 
TAMs in a HIF-1α-dependent manner [22]. Moreover, another recent report shows that 
oncostatin M and eotaxin may promote breast cancer metastasis by favoring M2 polarization 
and infiltration [23]. As recently reported, HMGB1 may also act directly on progenitor cells to 
induce suppressive myeloid-derived cells [24]. Finally, our observation that a treatment of 
tumor-bearing mice with the HMGB1 BoxA inhibitor is not as efficient as the silencing of 
HMGB1 with shRNA also suggest that other factors are involved in the promotion of tumor 
growth.  
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In our experiments, we could show that release of HMGB1 very likely occurs within hypoxic 
areas within human melanoma biopsies, Hypoxia is known to induce the recruitment of 
macrophages to the tumor site [25, 26]. A hypoxic tumor environment, which is seen in up to 
50–60 % solid tumors[27], actively selects for a more aggressive cancer cell phenotype, 
since the mechanisms linked to survival in these conditions are associated with invasion, 
metastasis, and resistance to radiation and chemotherapy [28, 29]. During hypoxia, due to 
fast tumor growth, HMGB1 is released [30]. Extracellular HMGB1 via RAGE has been shown 
to induce the expression of NF-κB dependent pro-angiogenic factors such as VEGF [31] and 
the expression of matrix metalloproteinases such as MMP2 and MMP9 [32]. It has also been 
reported that HMGB1 released from dying cells in prostate cancer induces the accumulation 
of tumor-infiltrating T cells and the expression of Lymphotoxin α1β2 on their surface, which in 
turn recruits macrophages that provide growth factors to the tumor and support angiogenesis 
[33]. Noteworthy, tumor cells or tumor-infiltrating immune cells seem not to be the sole 
possible source of HMGB1. Indeed, UV can induce the release of HMGB1 from epidermal 
keratinocytes which resulting in a neutrophilic inflammatory response stimulating 
angiogenesis and promoting melanoma metastasis [34]. 
The expression of CXCR4 in melanoma is known to play an essential role for tumor 
progression and metastasis [35] and a high expression of CXCR4 and its ligand CXCL12 in 
melanoma patients has been reported to be associated with poor prognosis [36]. A recent 
study showed that HMGB1 promotes the recruitment of inflammatory cells to injured tissues 
by forming a heterocomplex with the chemokine CXCL12 that acts exclusively via CXCR4 
[37]. Our data suggest an additional important role of HMGB1 as we demonstrate that 
HMGB1 can specifically induce CXCR4 upregulation in M2 macrophages in vitro. 
We also observed that HMGB1 induced the production of IL-10 from M2 macrophages in 
vitro, and that the blockade of IL-10 with a neutralizing antibody in vivo led to delayed tumor 
growth. The precise role of IL-10 in our model remains to be investigated however. It has 
been shown that regulatory T cell-mediated/IL-10-dependent suppression of CD8+ T cells can 
be blocked by removal of tumor-derived HMGB1 [38], which is consistent with our 
observation that HMGB1 inhibition leads to delayed tumor growth. Therefore, we hypothesize 
that IL-10, which can also be produced by melanoma cells [39] and tumor-associated MCSC 
[24] may favor immunoregulatory responses by inducing the down regulation of molecules 
involved in antigen presentation to CD8+ T cells [40], by inducing Tregs [41, 42] and/or 
inhibiting the production of pro-inflammatory cytokines including TNF, IFN-γ and IL-2 by T 
cells [43]. Noteworthy, IL-10 production levels by melanoma cells have been shown to be 
associated with a poor prognosis [44].  
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HMGB1 has several receptors, including TLR-2, 4 and -9 and RAGE. In our model, TLRs 
were not involved, as assessed in vitro, in HMGB1-induced CXCR4 and IL-10 expression by 
macrophages. We could demonstrate in vitro that HMGB1 is only able to induce CXCR4 and 
IL-10 expression in the presence of RAGE, as production of these molecules was absent 
when using RAGE-deficient macrophages. An important role of the HMGB1-RAGE 
interaction in promoting tumor progression is supported by a recent report showing that, 
RAGE and HMGB1 are associated with progression of prostate cancer and poor patient 
outcome [45]. It is furthermore likely that HMGB1 when binding to TLRs may exert a distinct 
effect from that induced by RAGE binding. Actually, HMGB1, when released from chemically-
stressed cells, has been shown to induce protective anti-tumor T cell responses by inducing 
the maturation of DCs in a TLR4-dependent manner [46-48]. The reasons for such a dual 
role of HMGB1 in tumor outcome remain unknown. One could hypothesize that the context 
and nature of the cell stress may be associated with the release of different factors which, 
together with HMGB1, trigger different types of antigen-presenting cells expressing different 
HMGB1-receptor patterns and leading to distinct effects.  Overall, we demonstrate in our 
model that HMGB1, derived from hypoxic tumor cells, exerts a key function in melanoma 
progression by promoting the accumulation of IL-10-producing M2 macrophages via CXCR4. 
Therefore, extracellular HMGB1 presents as a possible therapeutic target for the treatment of 
metastatic melanoma. 
  
While being beneficial for the host in many instances, uncontrolled inflammation can be 
detrimental leading to pathologies such as the sterile inflammation of autoinflammatory 
diseases or sterile inflammation associated with tumor development. Such inflammatory 
responses can be triggered by situations that are not favorable for the survival of normal and 
cancer cells such as hypoxia. To overcome such a hostile environment, tumors appear to 
have developed strategies to trigger inflammatory responses in their microenvironment, 
whereby macrophages are important players in this process. As a consequence of this, 
immune cells initially recruited to respond to the danger represented by the presence of a 
tumor become an accomplice of the tumor, helping it to achieve better conditions for its 
survival and growth (angiogenesis and metastasis). It appears that there are several classes 
of immune cells potentially recruited to the tumor site, each of them acting either alone or in 
conjunction with other inflammatory cell types. The emergence of new technologies based on 
multiplex analyses should help researchers to better define and further characterize tumor-
infiltrating cells and understand the complex interplay between tumor cells and the 
inflammatory stroma, as well as between the different inflammatory cell types in the 
microenvironment. In addition to tumor cells themselves, the targeting of such a complex 
inflammatory network involving numerous cell types and mediators presents as an exciting 
challenge for the development of novel therapeutic strategies for cancer.  
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Abbreviations 
 
AICR Association for International Cancer Research 
AIM Absent in melanoma  
AJCC American Joint Committee on Cancer 
ALM Acral lentiginous melanoma 
AML Acute myeloid leukemia 
AP Alkaline phosphatase 
Apaf Apoptotic protease-activating factor 
APC Antigen-presenting cells 
APS Ammonium persulfate 
ARF Alternate reading frame 
ASC Apoptosis-associated speck-like protein 
ATP adenosine triphosphate 
AZA Aza-2′-deoxycytidine 
BAD BCL-2-associated agonist of cell death 
Bcl B-cell lymphoma derived protein 
BIM B-cell lymphoma 2 Interacting Mediator of cell death 
BSA Bovine serum albumin 
Ca Calcium 
CaCl2 Calcium chloride 
cAMP Cyclic adenosine monophosphate 
CAPS Cryopyrin-associated periodic syndromes 
CARD Caspase recruitment domain 
CD Cluster of differentiation 
CDK Cyclin dependent kinase 
CDKN2A Cyclin dependent kinase inhibitor-2A 
CFSE Carboxyfluorescein succinimidyl 
CH Contact hypersensitivity 
CINCA Chronic infantile neurological cutaneous and articular syndrome 
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COX2 Cyclooxygenase-2 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
DAMP Danger-associated molecular patterns 
DC Dendritic cells 
ddH2O  Bidistilled water 
DDT DL-Dithiothreitol 
DIRA Deficiency of interleukin-1 receptor antagonist 
DISC Death-inducing signaling complex 
Diss. Dissertation 
DMEM Dulbecco's Modified Eagle's medium 
DMSO Dimethylsulfoxide 
E.coli  Escherichia coli 
E2F E2F cell cycle regulated transcription factor 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
ER Endoplasmic reticulum 
ERK Extracellular-signal-Regulated Kinase 
FACS Fluorescence-activated cell sorting 
FCAS Familial cold autoinflammatory syndrome 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FOX Forkhead transcription factor 
HBV Hepatitis B virus 
HCC hepatocellular carcinoma 
HCl Hydrogen chloride 
HCV Hepatitis C virus 
hdm Human double minute chromosome-associated protein 
Hif-1α Hypoxia-inducible factor 1α 
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HIV Human immunodeficiency virus 
HMGB1 High-Mobility Group Box 1 
HSP Heat shock protein 
iDC Immature DCs 
IFN Interferon 
IL Interleukin 
IL-1RAcP IL-1 receptor accessory protein 
iNOS NO synthase 
IRAK IL-1 receptor kinase 
JNK c-Jun N-terminal kinase 
K Potassium 
KCl Potassium chloride 
LDH Lactate dehydrogenase 
LMM lentigo maligna melanoma 
LPC Lysophosphatidylcholines 
LPS Lipopolysaccharide 
Lys Lysate 
MAPK Mitogen-activated protein kinase 
MC Mast cell 
MC1R Melanocortin-1 receptor 
M-CSF Macrophage colony-stimulating factor 
mDC Myeloid DCs 
MDM2 Mouse Double Minute 2 homolog 
MDP Muramyl dipeptide 
MDSC Myeloid-derived suppressive cells 
MEK MAPK/Extracellular-signal-regulated Kinase kinase 
MgCl2 Magnesium chloride 
MHC Major histocompatibility complexes 
MIC Modular Incubator Chamber 
MITF Microphthalmia transcription factor 
MMP Matrix metalloproteinase 
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MOMP Mitochondrial outer membrane permeabilization 
mRNA Messenger RNA 
MSH Melanocyte stimulating hormone 
MSU Monosodium urate 
mtDNA Mitochondrial DNA 
mTOR Mammalian target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)- 
  MyD88 Myeloid differentiation primary response gene 88 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NF-kB Nuclear factor ĸB 
NK cells Natural killer cells 
NLRC Nod-like receptor family CARD domain-containing protein 
NLRP Leucine-rich repeat-containing receptor protein 
NLS Nuclear localization signal 
NM Nodular melanoma 
NO Nitric oxide 
O2 Oxygen 
p Probability 
P/S Penicillin/ Streptomycin 
PAMP Pathogen-associated molecular patterns 
PAPA Pyogenic arthritis-pyoderma gangrenosum-acne 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline tween 
PD-1 Programmed death 1 protein 
PDGF Platelet-derived growth factor 
PDK1 Phosphoinositide-dependent kinase 1 
PGE2 Prostaglandin E2 
PI3K phosphatidylinositol-3 kinase 
PMA Phorbol-12-myristate-13-acetate 
PRR Pathogen recognition receptors 
154 Abbreviations and Units 
 
PtdIns(3,4,5)P3 Phosphatidylinositol (3,4,5)-tris-phosphate 
PTEN Phosphatase and Ten sin homolog 
PYD Pyrin domain 
Ra Receptor antagonist 
RAF Rapidly Accelerated Fibrosarcoma 
RAG Recombination-activating genes 
RAGE Receptor for Advanced glycation Endproducts 
RAS Rat sarcoma oncogene 
Rb Retinoblastoma protein 
rec. Recombinant 
RNI Reactive nitrogen intermediates 
ROI Reactive oxygen intermediates 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RSS Recombination signal sequence 
SCF Stem cell factor 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
shRNA Short hairpin RNA 
SN Supernatant 
SSM Superficial spreading melanoma 
Syk Spleen tyrosine kinase 
TAA Tumor-associated antigens 
TAM Tumor-associated macrophages 
TAN Tumor-associated neutrophils 
TBP TATA binding protein 
TCR T cell receptor 
TEMED Tetramethylethylenediamine 
TGF Transforming growth factor 
Th T helper 
TIR Toll/IL-1 receptor 
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TLR Toll-like receptor 
TNF Tumor necrosis factor 
Treg Regulatory T cells 
uPA Urokinase-type plasminogen activator 
uPAR Urokinase receptor 
URPP Zürich University Research Priority Program 
UV Ultraviolet 
UVR Ultraviolet radiation 
VDAC voltage-dependent anion channels 
VEGF Vascular Endothelial Growth Factor 
VLC Vascular leukocytes  
α Alpha 
β Beta 
γ Gamma 
δ Delta 
κ Kappa 
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Units 
 
°C Degree celcius 
µg Microgram 
µl Microliter 
bp Base pairs 
 
 
cm Centimeter 
dpi Dots per inch 
g Gram 
h Hour 
min Minute 
ml Milliliter 
mM Millimolar 
ng Nanogram 
nm Nanometer 
OD  Optical density 
s Second 
U Unit 
V Voltage 
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Abstract 
The incidence of melanoma is increasing worldwide and despite new treatment options 
survival of patients with metastatic melanoma remains poor [1, 2]. The molecular 
mechanisms regulating melanoma metastasis are still poorly characterized. Here we find that 
the pleiotropic pro-inflammatory cytokine interleukin-1β (IL-1β) which has been suspected to 
play a role in metastasis [3, 4] is overexpressed in human melanoma metastases. To 
investigate mechanisms through which IL-1β may promote metastasis, we generated murine 
B16 melanoma cells that overexpress and secrete the active p17 form of IL-1β. 
Overexpressed IL-1β promoted metastasis in tumor-draining lymph nodes and in an 
established model of lung metastasis. Evaluation of cytokine expression during primary 
tumor progression revealed that IL-1β promotes a Th2 biased cytokine environment in 
tumors and tumor infiltration by M2-macrophages. Analysis of fibroblasts revealed that IL-1β 
induces the expression of thymic stromal lymphopoietin (TSLP), a key initiator of Th2 
responses [5], and TSLP is produced by tumor associated fibroblasts isolated from 
melanomas. Ablation of the TSLP-receptor in mice resulted in reduced Th2 cytokine 
expression, macrophage recruitment to tumors, and metastasis, delineating an essential role 
for IL-1β driven TSLP in regulating metastasis. Furthermore, deletion of macrophages by 
clodronate or by diphteria-toxin in LysM diphtheria toxin receptor (DTR) mice likewise 
resulted in a reduction of metastasis. Given that innate lymphoid type 2 cells (ILC2s) can 
sustain M2 macrophage infiltration [6], the presence of ILC2 was analyzed in melanoma. In 
IL-1β-producing B16 tumors and human melanoma metastases increased numbers of ILC2s 
were detected. Depletion of ILCs in Rag1-/- mice using anti-CD25 neutralizing antibodies 
resulted in reduced intratumoral Th2 cytokines, M2-marker expression and lymph-node 
metastases indicating that ILC2 promote tumor enrichment with M2 macrophages and tumor 
metastasis. We demonstrate that the IL-1β-TSLP cytokine signaling axis is essential for 
tumor infiltration by M2 macrophages and ILC2s which promote melanoma metastasis. 
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Main 
The incidence of melanoma has significantly increased over the past few decades [7]. 
Despite new treatment options, the survival rate of patients with metastatic melanoma has 
only marginally improved [1, 2]. One reason for the low survival rate in late stage melanoma 
is due to the difficulty in controlling tumor metastasis. The tumor microenvironment, including 
the cytokine milieu, plays a central role in metastasis [8, 9]. Interleukin (IL)-1β is a pleiotropic 
pro-inflammatory cytokine, which is often detected in human tumors [3, 4]. It has been 
reported that increased expression levels of the IL-1β gene or protein is associated with 
cancer metastasis [10]. However, the precise mechanism of metastasis promotion by IL-1β 
remains largely unknown.  
To assess the effect of IL-1β in melanoma progression, we first evaluated local IL-1β 
expression in benign melanocytic nevi, primary melanomas, and metastatic melanomas. The 
number of IL-1β positive cells was significantly higher in metastatic melanoma compared to 
that in nevi and primary melanomas (Fig.1 A, B). In the BRAF/PTEN autochthonous mouse 
melanoma model [11], IL-1β secretion was also upregulated in late stage tumors that are 
associated with draining lymph node (dLN) metastasis (Fig.1 C). These results indicate that 
the metastatic stage of melanoma is associated with high IL-1β expression at the tumor site. 
To assess the functional role of IL-1β overproduction in metastases, we generated 
melanoma cell lines producing the active (p17) secreted form of IL-1β as previously reported 
[12]. We injected either control B16 cells or IL-1β-producing B16 cells i.v. into wild type mice 
to assess the effect of IL-1β on tumor metastasis. Overexpression of IL-1β by B16 resulted in 
a remarkable increase in lung metastases (Fig.1 D, E). Since i.v. inoculation of tumor cells is 
an artificial model and may have limited relevance to actual mechanisms of metastasis, we 
also analyzed spontaneous metastasis to LNs draining subcutaneously growing B16 tumors. 
Consistent with the lung metastasis model, the number of metastases derived from 
subcutaneous IL-1β-producing B16 melanomas was significantly increased (Fig. 1 F, G). 
Altogether, these results indicate that IL-1β promotes melanoma metastasis. 
To assess the impact of IL-1β on the microenvironment of subcutaneous tumors, we 
evaluated cytokine expression during primary subcutaneous tumor progression by real-time 
PCR. While interferon (IFN)-γ expression in IL-1β-producing B16 tumors was comparable to 
that of control B16 tumors during tumor progression, the expression levels of T helper (Th)2 
cytokines, including IL-4, IL-10, and IL-13 were significantly increased in IL-1β-producing B16 
tumors (Fig. 2A). We next evaluated tumor-infiltrating cells by flow cytometry. The number of 
CD4+ and CD8+ T cells infiltrating control B16 and IL-1β-producing B16 tumors did not differ 
significantly (Fig. 2B, Supplementary Fig S1A). In contrast, the number of tumor-infiltrating 
macrophages, eosinophils, and mast cells were significantly higher in IL-1β-producing B16 
tumors (Fig. 2B, Supplementary Fig S1B, C, D and Supplementary Fig S2). To evaluate Th2 
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T cell numbers, intracellular IL-4 staining was performed on collagenase-digested tumors. 
Consistent with the IL-4 gene expression data, IL-4-producing CD4+ T cells were significantly 
increased in IL-1β-producing B16 tumors (Fig. 2C). To assess the phenotype of 
macrophages that infiltrate IL-1β producing tumors, we examined the expression of markers 
distinguishing M1- and M2- macrophage subpopulations [13]. Quantitative PCR of 
macrophages located at the tumor site revealed that the expression of M2 markers (MR, 
Fizz1, Arg1, and YM1) but not M1 markers (iNOS and Arg2) was significantly upregulated in 
IL-1β-producing B16 tumors (Fig. 2D). To assess the relevance of this observation with 
respect to human melanoma, we stained human melanomas with a specific M2 marker, 
namely CD163. A significant increase in CD163+ cell numbers was also found in human 
metastatic melanomas when compared to primary tumors (Fig.2E). Thymic stromal 
lymphopoietin (TSLP) is a key initiator of Th2 responses [5]. Given a recent study showing 
that TSLP has a negative impact on the survival of pancreatic cancer patients [14], we 
hypothesized that TSLP may play a role in shaping the immunological microenvironment of 
tumors and the subsequent development of metastases. Since it has been reported that the 
interaction of tumors and fibroblasts plays a pivotal role in tumor progression, we first 
exposed mouse embryonic fibroblasts (MEFs) to either recombinant IL-1β or IL-1β-producing 
B16. In both conditions, MEFs produced TSLP in a dose-dependent manner (Fig. 3A). To 
assess the relevance of this observation to human melanoma, we evaluated TSLP mRNA 
levels using healthy donor-derived fibroblasts and melanoma-associated fibroblasts. We 
found that TSLP expression was significantly increased in melanoma-associated fibroblasts 
(Fig. 3B). Functional evaluation of the effect of TSLP on tumor metastasis using TSLP 
receptor (TSLPR)-/- mice revealed that the number of metastases in mice bearing IL-1β-
producing B16 tumors was significantly lower in TSLPR-/- than wild-type mice (Fig. 3C). 
These results demonstrate that TSLP is a key mediator of IL-1β-induced metastasis. 
Interestingly, in the primary tumor (subcutaneous), the expression of Th2 (IL-4 and IL-13) but 
not Th1 (IFN-γ) cytokines was also found to be decreased in TSLPR-/- mice (Fig. 3D). 
Furthermore, both the number of macrophages infiltrating the primary tumors, and the 
expression of M2 markers were decreased in TSLPR-/- mice (Fig. 3D, E), suggesting that 
TSLP is a key regulator of IL-1β-induced recruitment of M2 macrophages to the tumor.  
Tumor associated-macrophages (TAMs) are a major component of the tumor 
microenvironment and they have been reported to be biased towards an M2 phenotype in 
advanced tumors [15-17]. To further address the functional role of TAMs during IL-1β-
induced metastasis, we depleted macrophages using clodronate. Interestingly, the number of 
IL-1β-producing B16 metastases was significantly reduced in clodronate-treated mice (Fig. 
4A). To confirm this observation and exclude a possible role of dendritic cells that are also 
depleted by clodronate, we performed the same experiment in LysM diphtheria toxin receptor 
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(DTR) mice. Consistent with the results obtained with clodronate treatment, the number of 
metastases was also significantly decreased in LysM-DTR mice bearing IL-1β producing B16 
tumors (Fig. 4B). These results identify TAMs as key players in IL-1β-related tumor 
metastasis.  
We next assessed the expression of 84 genes known to be involved in metastasis by PCR 
array analyses of B16 cells exposed or not to IL-1β and/or bone marrow-derived M2 (BMM2) 
macrophages. The expression of 8 genes were significantly modulated in B16 upon 
exposure to BMM2 and IL-1β (> 2-fold change; p<0.05). Notably, 4 genes known to promote 
metastasis Igf1, Mmp13, Mmp9 and Nme2 were significantly upregulated, whereas 4 genes 
known to inhibit metastasis Cd82, Ctbp1, Ephb2 and Ewsr1 were significantly downregulated 
(Fig.4C, Table S1). In line with these data, we also found that CD82 and EPHB2 expression 
levels affect the survival rate of melanoma patients (Fig. S4). 
It has recently been reported that M2 macrophages are sustained by innate lymphoid type 2 
cells (ILC2s) in adipose tissue [6]. Our results showing that IL-1β enhanced the number of 
M2 macrophages in tumors prompted us to analyze the presence of ILC2 in IL-1β-producing 
B16 tumors. At the tumor site, we identified a population of lineage-negative (Lin-) cells that 
lacked the expression of cell surface markers associated with T cells (CD3), B cells (B220), 
DCs (CD11c), macrophages/monocytes (CD11b), or mast cells and basophils (FcγRIα), but 
expressed both Thy1.2 and IL-33R (Fig. 4D, E). This phenotype is consistent with that of 
ILC2s as previously described [18, 19]. Our results demonstrate that significantly increased 
numbers of ILC2 are found in IL-1β-producing B16 tumors (Fig. 4D, E). Interestingly, recent 
in vivo studies have suggested that both murine and human ILC2s are responsive to TSLP 
[20], although the impact of TSLP on ILC2 responses remains unknown. We therefore 
quantified ILC2 in IL-1β-producing B16 tumors implanted in TSLPR-/- mice. In the absence of 
TSLPR, tumor infiltration by ILC2s was dramatically decreased when compared to TSLPR-
expressing mice (Fig. 4F, Fig. S5). To test whether ILC2 affect melanoma metastasis, we 
depleted ILCs in Rag1-/- mice using anti-CD25 neutralizing antibodies as previously reported 
[18]. Depletion of CD25+ ILCs resulted in reduced Th2 cytokine production as well as M2-
marker expression (Fig. S6). In addition, ILC depletion resulted in reduced numbers of 
draining lymph-node metastases (Fig. 4G), indicating that ILC2 promotes tumor enrichment 
with M2 macrophages and tumor metastasis. To determine the relevance of this finding to 
human melanoma, we further examined metastases of melanoma patients for the presence 
of ILC2. Flow cytometry analysis of human melanoma metastases revealed a significantly 
increased frequency of ILC2s in situ in metastatic melanoma samples as compared to 
healthy skin (Fig. 4H, I). 
   It has been reported that systemic Th2-driven chronic inflammation is enhanced in patients 
with metastatic melanoma [21], and the ratio of Th2/Th1 cells is augmented in stage IV 
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melanoma patients [22]. The precise cause and consequences of a Th2 microenvironment in 
late stage melanoma is however unclear to date. We identify IL-1β present in the tumor 
microenvironment as a key promoter of an intratumoral Th2 cytokine milieu and tumor 
metastasis, both of which are critically dependent upon tumor infiltration by M2 
macrophages. Although TAMs are biased towards the M2 phenotype in advanced tumors, 
the factors responsible for the increase of TAMs with a M2 phenotype at site of tumors 
remain largely unknown. In this study, we demonstrate that IL-1β likely derived from the 
microenvironment of primary tumors, induces peritumoral fibroblast-derived TSLP, the latter 
being essential for the recruitment of M2-macrophages to the tumor site. In addition we show 
for the first time, that ILC2 are essential for tumor metastasis likely by promoting sustained 
tumor infiltration by M2-macrophages, and moreover these ILCs are found in large numbers 
both in murine and human metastatic melanoma. Taken together, the IL-1β-TSLP signaling 
axis discovered within the tumor microenvironment here is essential for tumor infiltration by 
M2-macrophages and ILC2s as well as tumor metastasis. Considering the broad diversity of 
tumors, this newly identified signaling pathway in melanoma could be a novel target for the 
treatment of metastatic melanoma (Fig. S7). 
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Methods 
Mice 
Eight- to 12-week-old female C57BL/6 mice were used in this study. C57BL/6 mice were 
purchased from (Harlan, Venray, Netherlands). Rag1-/- mice were purchased from the 
Jackson Laboratory. B6.Cg-Braftm1Mmcm Ptentm1Hwu Tg (Tyr-cre/ERT2) 13Bos/BosJ 
(BRAF/PTEN) mice [11], TSLPR-/- mice and LysM-DTR[23] mice were all described 
previously. All experimental procedures were approved by the Veterinary Office of Zurich and 
the institutional animal care and use committee of Kyoto University Graduate School of 
Medicine. 
 
Generation of IL-1β-producing B16 
IL-1β cDNA encoding for the mature p17 form (i.e. not requiring caspase-1 cleavage) of IL-1β 
was fused to a signal sequence derived from structurally related human IL-1RA in order to 
generate a constitutively mature secreted from of IL-1β as previously reported [12, 24]. 
Transfection was performed using Lipofectamin 2000 (Invitrogen, Carlsbad, California) and 
the transfectants were generated as previous described [25]. Two clones were generated 
and IL-1β production was confirmed by ELISA using the supernatant of IL-1β-producing 
(RnD Systems). 
B16F10 cell line was cultured in RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated fetal calf serum, 2 mM l-glutamine, 25 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid, 1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 100 
units/mL penicillin, and 100 μg/mL streptomycin. 
 
Tumor metastasis experiments 
Control-B16 or IL-1β-producing B16 (2 × 105) were subcutaneously injected into the right 
flank of wild-type mice. Mice were monitored every 2 days and tumor size was measured 
using a caliper. Tumor volume was expressed as the square of the smallest diameter 
multiplied by its largest diameter. Mice that developed tumors with L=10 mm were killed 
according to the Swiss legislation on animal experiments and the number of macroscopically 
visible melanoma metastases in the draining lymph nodes was counted in five fields (× 20 
objective) by the same dermato-pathologist using the same subjective grading scale. Lung 
metastases were generated by intravenous injection of 2 × 105 B16 cells in 100 µl of PBS. 
Mice were killed 14 days after challenge, and the number of macroscopically visible 
melanoma metastases on the surface of the lungs was counted and measured in a masked 
manner by two different experimenters. 
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Cell preparation, antibodies and flow cytometry 
For the preparation of tumor infiltrating cell suspensions, minced tumors were incubated with 
collagenase D (1.5 mg/ml) (Worthington Biochemical) in RPMI for 1 hour at 37°C and 5% 
CO2. Cell suspensions were filtered through a 40-μm cell strainer (BD Bioscience, San 
Diego, CA). The numbers of each cell subset were calculated by flow cytometry and 
presented are the numbers per mm3 of tumor size. 
Anti-mouse CD3, CD4, CD8, CD11b, CD11c, CD45, B220, c-kit, F4/80, FcRI, Gr-1, and 
Thy1.2 antibodies were purchased from eBioscience (San Diego, CA). Anti- mouse CCR3 
was purchased from Bio-Legend (San Diego, CA), SiglecF, IL-4 from BD Biosciences (San 
Jose, CA, USA), CD200R3 from Hycult Biotech (Uden, Netherlands), 7/4 from Abcam, and 
IL-33R from MD bioscience (St. Paul, MN). Anti-human CD25, CD11c, CD45, CD56, IL-33R, 
and TCRαβ antibodies were purchased from BD Pharmingen. Anti-human CD3 and CD16 
were purchased from Bio-Legend, CD19 from Miltenyi Biotech, and FcεRI from 
(eBioscience). Flow cytometry was performed using FACS Canto and Fortessa (BD 
Biosciences) and analyzed with FlowJo (TreeStar, San Carlos, CA).  
For intracellular IL-4 staining of CD4+ T cells, tumor infiltrating cell suspensions were 
collected and incubated with PMA (20 ng/ml), ionomycin (1 µM), and Brefeldin A (5 µM) for 
four hours and as previously reported [26].  
 
Quantitative PCR analysis and qPCR array  
Quantitative PCR analysis was performed as previously reported [27]. Briefly, total RNAs 
were isolated with Trizol (Life Technologies, Gaithersburg, MD) from tissues. cDNA was 
reverse transcribed (RT) using a RevertAid First Strand cDNA kit (Thermo Scientific, MA, 
USA). Quantitative RT-PCR with a Light Cycler real-time PCR apparatus was performed 
(Roche Diagnostics, Foster City, CA) using SYBR Green I (Roche, Basel, Switzerland). 
Expression of mRNA (relative) was normalized to the expression of RPL27 mRNA by the 
change in cycling threshold (ΔCT) method and calculated based on 2−ΔΔCT. 
For PCR array, RNA was analyzed by a RT-PCR array for mouse metastatic genes (PAMM-
028Z, Qiagen). Each condition was performed in triplicate. Fold change and p values were 
calculated by RT2 Profiler PCR Array Analysis 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php, Qiagen). B16 cells as 
control were used as baseline for comparison and significant gene expression changes were 
defined with absolute fold change > 2 and a p value < 0.05. 
Survival data were generated from the melanoma dataset of the TCGA 
(http://cancergenome.nih.gov). The top 30% and bottom 30% patients of CD82 and EPHB2 
normalized RNAseq reads were compared for overall survival by Kaplan Meier survival 
analysis.  
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ELISA 
The amounts of human/mouse IL-1β (R & D) and mouse TSLP (eBioscience) were 
measured by ELISA according to the manufacturer’s instructions. For the measurement of 
mouse IL-1β in the tumor, 5 mm tumor biopsies were collected and homogenized in 300 µl 
PBS. The supernatants were collected for ELISA. 
 
Generation of normal and melanoma-associated fibroblast and co-culture of MEFs 
with B16. 
The normal fibroblast early passage cultures were generated from patients undergoing 
plastic surgery. The tissue was sectioned and put in a flask with RPMI culture medium and 
was trypsinized and split for 1-4 passages until the cells were of similar morphology. The 
same was done from skin that was removed from melanoma biopsies, and the cells were 
confirmed to have fibroblast morphology and to lack known oncogenic mutations from the 
respective patients. 
For co-culture of fibroblasts and control B16 or IL-1β-producing B16, MEFs were obtained 
from embryos at embryonic day 15 by using standard methods in complete DMEM medium. 
MEFs (1 × 105) were co-cultured with control B16 or IL-1β-producing B16 in 96-well plates at 
a B16:MEF ratio of 1: 100, 1:10, and 1:1 for 24 h. 
 
Depletion of macrophages and ILC2 
For macrophage depletion, clodronate and control liposomes (ClrodoronateLiposome.org. 
Amsterdam, Netherlands) were injected intraperitoneally as follows: 300µl on day 3 and 
200µl from on day 3 every 3 days, then 100µl subcutaneously from day 7 every 3 days. As a 
second model of macrophage depletion, LysM-DTR mice, wild-type C57BL/6 mice were 
sublethally-irradiated (9.5 Gy) and received bone marrow cells (5 × 106 - 1 × 107) from LysM-
DTR mice. After reconstitution, chimeric mice were treated with 800 ng DT intraperitoneally. 
For ILC2 depletion, anti-CD25 neutralizing antibody (clone PC-61.5.3, BioXCell) was 
administered to Rag1-/- mice intraperitoneally every 2 days at a dose of 300 µg per mouse 
starting 2 days before IL-1β-B16 injection. 
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In vitro differentiation of M2-macrophages from bone marrow cells 
Bone marrow (BM) cells from tibias and fibulas were plated at 1 × 106 /ml in 10 cm dishes on 
day 0. For macrophages differentiation, BM cells were cultured in cRPMI containing 10 
ng/mL M-CSF (Peprotech). Medium was replaced on days 3 and 6 and cells were harvested 
on day 9. To induce M2 phenotype, cells were stimulated for 48 h with IL-4 (20 ng/mL; 
Peprotech). 
  
Histology and Immunohistochemistry 
For histological examination, tissues were fixed with 10% formalin in PBS, and then 
embedded in paraffin. Sections with a thickness of 5 µm were prepared and subjected to 
staining with hematoxylin and eosin. Immunohistochemistry was performed as previously 
reported [28]. Anti-human CD163 antibody was purchased from Leica Microsystems 
(Wetzler, Germany). The number of immunoreactive cells was counted in five fields (× 20 
objective). All the stainings were quantified by the same pathologist using the same 
subjective grading scale. 
 
Statistical analysis   
Unless otherwise indicated, data are presented as the means ± standard error of the mean 
(SEM) and are representative of three independent experiments. P-values were calculated 
with the Wilcoxon signed-rank test. * p < 0.05.  
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Figure Legends 
 
Figure 1: IL-1β is upregulated in metastatic melanoma and promotes metastasis 
(A) IL-1β positive cell detection by immunohistochemical staining in representative sections 
of human benign melanocytic nevi (n=5), primary melanoma (PM) (n=10), and metastatic 
melanoma (MM) (n=10). Scale bar, 200 µm (upper panel) and 50 µm (lower panel). (B) 
Quantification of IL-1β positive cells within benign melanocytic nevi, PM and MM. (C) Five 
mm skin biopsies from tumors in BRAF/PTEN mice were collected and homogenized in 300 
µl PBS, supernatants collected and IL-β measured by ELISA. (D, E) Lung metastases and 
quantification of tumor colonies in the lungs after i.v. injection with control B16 (n = 5) or IL-
1β-producing B16 (n = 5) (F, G). Melanoma cells in lymph nodes draining subcutaneous 
tumors (delimited within red line) and quantification of metastases 13 days after 
subcutaneous injection of control B16 (n = 10) or IL-1β-producing B16 (n = 10). Scale bar, 
100 µm. Data represent three independent experiments with similar results. 
 
Figure 2: IL-1β promotes Th2 skewing and induces M2-macrophage tumor-infiltration 
(A) Messenger RNA levels of IFN-γ, IL-4, IL-10, and IL-13 at the tumor site on day 0, 3, 7, 
and 13 after subcutaneous injection of control B16 (n = 10) or IL-1β-producing B16 (n = 10). 
(B) Analysis of tumor-infiltrating cells by flow cytometry. The representative FACS plots are 
shown in Supplementary Fig. 1. (C) Intracellular staining of IL-4 in tumor-infiltrating cells from 
control B16 (n = 5) or IL-1β-producing B16 (n = 5) tumors after tumor dissociation, 
stimulation with PMA (20 ng/ml), ionomycin (1 µM), and treatment with Brefeldin A (5 µM) for 
four hours in vitro. (D) Messenger RNA levels of iNOS, Arg2, MR, Fizz, Arg1, and YM1 in 
tumors on day 13. (E) Immunohistochemistry of CD163 in human nevi (n=10), primary 
melanoma (PM) (n=10) and metastatic melanoma (MM) (n=10), and quantification of CD163 
positive cells (right panel). Scale bar, 200 µm (low magnifications) and 50 µm (high 
magnifications). Data for A-D represent three independent experiments with similar results. 
 
Figure 3: IL-1β induced TSLP produced by tumor-associated fibroblasts induces M2 
macrophage infiltration and metastasis. 
(A) TSLP production from MEFs in presence of recombinant mouse IL-1β and control B16 or 
IL-1β-producing B16 was measured by ELISA. (B) TSLP mRNA levels from normal 
fibroblasts (NFs) (n=3) and melanoma-associated fibroblasts (MFs) (n=6). (C) Quantification 
of metastases in draining lymph nodes of IL-1β-producing B16 tumors in WT or TSLPR-/- 
mice. (D) Messenger RNA levels of IL-4, IL-13, IFN-γ, iNOS, Arg2, MR, Fizz, Arg1, and YM1 
at the primary tumor site of WT or TSLPR-/- mice bearing IL-1β-producing B16 tumors on day 
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13. (E) Quantification of macrophages in subcutaneous IL-1β-producing B16 tumors in WT or 
TSLPR-/- mice. Data represent three independent experiments with similar results. 
 
Figure 4: TAMs and ILC2 play a key role in IL-1β-induced metastasis  
(A) Quantification of metastases in dLNs of IL-1β-producing B16 tumor-bearing mice treated 
(n=6) or not with clodronate (n=6). Macrophage depletion efficiency is shown in 
Supplementary Fig. 3. (B) Quantification of metastases in dLNs of IL-1β-producing B16 
tumor-bearing mice with DT-treated WT mice (n=4) or DT-treated LysM DTR mice (n=3). (C) 
Heat map of genes in B16 cell lines co-cultured with/without IL-1β (1ng/ml), BMM2, and 
BMM2 and IL-1β (n = 3) for 24 hours. The color bar represents expression levels of each 
gene normalized to the mean levels of vehicle-treated B16 cells. (D, E) Flow cytometry 
analysis of mouse ILC2 defined as CD45 positive, lineage negative (CD3, B220, CD11c, 
CD11b, FcεRIα) and expressing Thy1.2 and IL-33R in control B16 (n=10) or IL-1β-producing 
B16 tumors (n=10). (F) Flow cytometry analysis and quantification of ILC2 in IL-1β-producing 
B16 tumors implanted in WT (n=10) or TSLPR-/- mice (n=10) (G) Quantification of 
metastases in dLNs of IL-1β-producing B16 tumor-bearing Rag1-/- mice treated with vehicle 
alone (n=10) or anti-CD25 neutralizing antibody (n=10). (H, I) Flow cytometry analysis of 
human ILC2 defined as CD45 positive, lineage negative (CD3, CD11c, CD16, CD19, CD56, 
TCRαβ, FcεRIα) cells expressing CD25 and IL-33R and quantification thereof in normal skin 
(NS) (n=6) or melanoma metastases (MM) (n=6). Presented dot-plots and data are 
representative of three independent experiments with similar results.  
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Supplementary Figure Legends 
 
Figure S1: Flow cytometry of tumor infiltrating cells   
(A) CD45+ CD4+ T cells and CD45+ CD8+ T cells; (B) CD45+ 7/4- CD11b+, F4/80+ 
Macrophages; (C) CD45+ Gr-1- CCR3+ SiglecF+ Eosinophils; and (D) CD45+ FcεRI+ 
CD200R3+ cKit+ Mast cells were quantified by FACS. Presented dot-plots are representative 
of three independent experiments with similar results. 
 
Figure S2: Histological analysis of tumor infiltrating cells   
(A) Immunohistochemistry of macrophages (clone; MAC387, Abcam) in control B16 or IL-1β-
producing B16 tumors. (B) Hematoxylin & Eosin coloration of control B16 or IL-1β-producing 
B16 tumors. Data represent three independent experiments with similar results. 
 
Figure S3: Macrophage depletion after clodronate treatment   
Flow cytometry control of macrophage (7/4- CD11b+ F4/80+) depletion in IL-1β-producing B16 
tumors. Tumor size of tumor after control or clodronate treatment. Presented dot-plots are 
representative of three independent experiments with similar results. 
 
Figure S4: Kaplan Meier curves of CD82 and EPHB2 high vs low patients  
Ninety eight patients were defined with high CD82 expression with a median survival rate of 
8.6 years and 98 patients were defined with low CD82 expression with a median survival rate 
of 5.3 years p = 0.0181. Ninety eight patients were defined with high EPHB2 expression with 
a median survival rate of 11.6 years and 98 patients were defined with low EPHB2 
expression with a median survival rate of 5 years p = 0.0171. 
 
Figure S5: ILC2 analysis in TSLPR-/- mice. 
ILC2, a population of lineage-negative (Lin-) cells that express both Thy1.2 and IL-33R, in IL-
1β-producing B16 tumors implanted in WT (left panel) and TSLPR-/- (right panel) mice. 
Presented dot-plots are representative of three independent experiments with similar results. 
 
Figure S6:  
Messenger RNA levels of IL-4, IL-13, Arg2, MR, Fizz, Arg1, and YM1 at the IL-1β-producing 
B16 tumor site of vehicle- and anti-CD25 neutralizing antibody-treated Rag1-/- mice (n = 10). 
Presented data are representative of two independent experiments with similar results. 
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Figure S7: Illustration depicts how IL-1β promotes melanoma metastases   
(A) IL-1β produced from the site of metastatic melanoma promotes TSLP production from 
melanoma-associated fibroblasts. (B) M2-macrophages and ILC2s are induced in Th2 
microenvironment, which leads to tumor metastasis. 
 
Supplemental Table 1 
 
 +IL-1β +M2 M2+IL-1β 
Symbol Fold p Fold p Fold p 
Apc 1.3412 0.010316 1.084 0.639938 1.4763 0.000648 
Brms1 1.1952 0.108206 -1.1095 0.900877 -1.3342 0.016292 
Ccl7 1.2271 0.309036 26.7483 0.015404 52.3943 0 
Cd44 1.0714 0.202497 -1.0945 0.899628 -1.184 0.017848 
Cd82 1.0621 0.524264 -1.5644 0.136895 -2.8199 0.00131 
Cdh1 1.1534 0.6369 -4.1582 0.024184 -1.4483 0.207373 
Cdh11 1.2271 0.309036 3.3676 0.035687 3.38 0.150492 
Cdh6 -1.4245 0.352949 -1.2587 0.557997 1.2047 0.93624 
Cdh8 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Cdkn2a 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Chd4 1.1676 0.037773 -1.1116 0.761108 -1.4087 0.000664 
Col4a2 -1.1393 0.654254 -2.3386 0.105962 -1.4109 0.013438 
Csf1 1.2293 0.152753 1.0439 0.644729 1.4175 0.004931 
Ctbp1 -1.1338 0.248706 -1.8703 0.106871 -2.0772 0.00124 
Ctnna1 1.0036 0.926323 -1.1292 0.962193 1.2238 0.118803 
Ctsk -1.0768 0.677231 -1.1044 0.953359 -2.8712 0.062699 
Ctsl 1.0962 0.292158 1.2778 0.03826 -1.3698 0.014648 
Cxcl12 1.2271 0.309036 3.5678 0.002396 1.939 0.330781 
Cxcr2 1.2271 0.309036 3.3746 0.332216 -1.2041 0.219783 
Cxcr4 1.2271 0.309036 3.1683 0.323111 1.7626 0.40677 
Denr -1.144 0.081588 1.059 0.296686 -1.1096 0.104632 
Elane 2.8551 0.021072 4.087 0.154713 -1.3189 0.857547 
Ephb2 1.0917 0.536441 1.1712 0.470983 -2.0753 0.000733 
Etv4 1.0073 0.946644 -1.5659 0.037307 -1.5451 0.142811 
Ewsr1 -1.015 0.744821 -1.3685 0.544224 -2.1327 0.000029 
Fat1 -1.1573 0.021433 -1.3161 0.097307 -1.3204 0.002472 
Fgfr4 -2.0356 0.357302 1.0258 0.724825 1.1431 0.754905 
Flt4 1.3246 0.86072 1.4784 0.583022 -1.49 0.569554 
Fn1 1.2677 0.061661 1.0923 0.571852 1.0227 0.774761 
Fxyd5 1.0945 0.281637 1.75 0.027599 1.7901 0.000208 
Gpnmb 1.5086 0.000428 1.0588 0.646999 1.6483 0.018791 
Hgf 1.2271 0.309036 2.0898 0.180318 -1.0752 0.762811 
Hpse 1.0385 0.564399 1.0686 0.597861 -1.71 0.001576 
Hras1 1.0419 0.22569 -1.1758 0.711592 -1.2366 0.000151 
Htatip2 -1.0105 0.89717 1.1058 0.471299 1.0128 0.784851 
Igf1 1.2271 0.309036 15.751 0.12218 19.4451 0.0145 
Il18 1.1974 0.144545 1.0943 0.484805 -1.1815 0.112996 
Il1b 1.2271 0.309036 3.8674 0.346585 -1.2041 0.219783 
Itga7 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Itgb3 1.4421 0.00966 -1.1755 0.545299 -1.4113 0.008337 
Kiss1 1.112 0.784689 2.1695 0.25962 -1.088 0.840452 
Kiss1r 1.2271 0.309036 2.0898 0.180318 1.1024 0.65621 
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Kras 1.1286 0.299661 1.2415 0.304126 -1.3485 0.026844 
Lpar6 -1.2502 0.146661 1.195 0.431696 -1.5185 0.028557 
Mcam -1.1356 0.033098 -1.508 0.155118 -1.5277 0.00133 
Mdm2 1.0115 0.852952 -1.0772 0.888115 -1.4051 0.002357 
Met 1.146 0.076822 -1.4436 0.00285 1.0984 0.236124 
Mmp10 -1.2301 0.507566 2.4386 0.386383 -1.8175 0.220731 
Mmp11 1.2359 0.615628 1.6189 0.277888 1.5703 0.23486 
Mmp13 1.2271 0.309036 2.0898 0.180318 4.3731 0.005313 
Mmp2 1.2718 0.007884 1.021 0.802314 -1.3128 0.052737 
Mmp3 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Mmp7 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Mmp9 1.0426 0.873414 2.7076 0.321542 2.6342 0.035145 
Mta1 1.0616 0.25466 -1.386 0.314831 -1.116 0.083763 
Mtss1 1.1067 0.298133 -1.4879 0.044229 1.284 0.015158 
Myc 1.0929 0.200044 1.0845 0.604489 1.3886 0.005245 
Mycl 2.275 0.034129 4.2204 0.102198 -1.2041 0.219783 
Nf2 1.2288 0.092355 -1.2695 0.72603 -1.6208 0.000582 
Nme1 -1.0537 0.727892 1.4939 0.036814 -1.304 0.055 
Nme2 1.4365 0.012021 1.7093 0.330755 2.0811 0.036304 
Nme4 1.0448 0.284826 1.0666 0.672172 1.2187 0.108366 
Nr4a3 2.3078 0.000283 -1.725 0.012461 1.2882 0.190928 
Plaur 1.0008 0.996657 -1.4399 0.357886 -1.224 0.010044 
Pnn -1.0122 0.928874 1.1642 0.158301 -1.124 0.14695 
Pten 1.0146 0.765932 -1.1714 0.676298 -1.255 0.008715 
Rb1 1.0069 0.940209 -1.2122 0.911737 -1.7847 0.002827 
Rorb 1.5781 0.131893 2.4635 0.084404 -1.2041 0.219783 
Rpsa -1.1343 0.090083 -1.089 0.882637 1.5826 0.028305 
Set 1.0601 0.485228 1.1791 0.524397 1.7967 0.001919 
Smad2 1.1679 0.144327 1.3491 0.145212 1.3296 0.002027 
Smad4 1.1062 0.409828 -1.3161 0.63182 -1.848 0.005104 
Src 1.1491 0.081223 -1.3957 0.423486 -1.6384 0.005651 
Sstr2 1.3587 0.412662 1.2835 0.496637 -1.1452 0.901493 
Syk 1.2271 0.309036 2.0898 0.180318 -1.2041 0.219783 
Tcf20 1.2931 0.000469 -1.388 0.243152 -1.3155 0.002167 
Tgfb1 -1.0045 0.951692 -1.3213 0.448863 -1.6343 0.001818 
Timp2 -1.2129 0.014599 1.1661 0.326182 -1.017 0.751595 
Timp3 -1.1554 0.042166 -1.23 0.821779 -1.3155 0.007756 
Timp4 -3.7049 0.130359 2.5048 0.370105 1.0039 0.879569 
Tnfsf10 -1.1554 0.57972 2.3983 0.383538 -1.6939 0.256885 
Trp53 -1.4285 0.011541 -1.1604 0.4605 -1.5168 0.006379 
Tshr 1.2271 0.309036 3.3381 0.073948 3.8942 0.087118 
Vegfa 1.0796 0.244744 -1.2368 0.694335 -1.635 0.000427 
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